Document:

Prepared by R.R. Donnelley Financial -- EX-10.4

 Exhibit 10.4 
 XENON PHARMACEUTICALS INC. 
 and 

IVAX INTERNATIONAL GMBH 
 COLLABORATIVE DEVELOPMENT AND 
 LICENSE AGREEMENT 

Effective as of December 7, 2012 
 [†] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

 TABLE OF CONTENTS 

 

							
	 ARTICLE 1
	 	DEFINITIONS/INTERPRETATION	  	 	1	  
	 1.1
	 	 Definitions
	  	 	1	  
	 1.2
	 	 Interpretation
	  	 	15	  
			
	 ARTICLE 2
	 	COLLABORATIVE DEVELOPMENT PROGRAM	  	 	16	  
	 2.1
	 	 General
	  	 	16	  
	 2.2
	 	 Collaborative Development Program Costs
	  	 	16	  
	 2.3
	 	 Amendments to the Collaborative Development Plan
	  	 	16	  
	 2.4
	 	 Collaborative Development Term
	  	 	16	  
	 2.5
	 	 Xenon FTE Funding
	  	 	16	  
	 2.6
	 	 FTE Records
	  	 	17	  
	 2.7
	 	 Conduct of Collaborative Development Program
	  	 	17	  
			
	 ARTICLE 3
	 	JOINT DEVELOPMENT COMMITTEE & PRODUCT DEVELOPMENT COMMITTEE	  	 	18	  
	 3.1
	 	 Alliance Managers
	  	 	18	  
	 3.2
	 	 Joint Development Committee and Product Development Committee
	  	 	18	  
	 3.3
	 	 Governance of JDC
	  	 	20	  
	 3.4
	 	 Decision Making
	  	 	21	  
	 3.5
	 	 Responsibilities
	  	 	21	  
	 3.6
	 	 Annual Plan
	  	 	22	  
	 3.7
	 	 Subcontractors
	  	 	22	  
			
	 ARTICLE 4
	 	DISCLOSURE AND REPORTS DURING THE COLLABORATIVE DEVELOPMENT TERM	  	 	22	  
	 4.1
	 	 Technology Transfer
	  	 	22	  
	 4.2
	 	 Quarterly Reports
	  	 	23	  
	 4.3
	 	 Technology Disclosure
	  	 	24	  
	 4.4
	 	 Books and Records
	  	 	24	  
	 4.5
	 	 Copies and Inspection of Records
	  	 	24	  
	 4.6
	 	 Material Transfers
	  	 	24	  
			
	 ARTICLE 5
	 	MANUFACTURE AND SUPPLY	  	 	25	  
	 5.1
	 	 Manufacturing and Supply
	  	 	25	  
			
	 ARTICLE 6
	 	DEVELOPMENT, COMMERCIALIZATION AND CO-PROMOTION	  	 	25	  
	 6.1
	 	 Diligence—Development and Commercialization Activities
	  	 	25	  
	 6.2
	 	 Ivax Reports Following the Collaborative Development Term
	  	 	26	  
	 6.3
	 	 Xenon Co-Promote Option
	  	 	28	  
			
	 ARTICLE 7
	 	CLOSING PAYMENT AND MILESTONE PAYMENTS	  	 	28	  
	 7.1
	 	 Closing Payment
	  	 	28	  
	 7.2
	 	 Development Milestone Event and Payment
	  	 	28	  

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

i 

							
	 7.3
	 	 Sales Milestone Events and Payments
	  	 	28	  
	 7.4
	 	 Time of Payment
	  	 	28	  
	 7.5
	 	 Affiliates and Sublicensees
	  	 	29	  
			
	 ARTICLE 8
	 	ROYALTIES	  	 	29	  
	 8.1
	 	 Full Royalty
	  	 	29	  
	 8.2
	 	 Know-How Royalty
	  	 	29	  
	 8.3
	 	 Generic Products
	  	 	30	  
	 8.4
	 	 Royalty Stacking Offsets
	  	 	30	  
	 8.5
	 	 Combination Products
	  	 	30	  
	 8.6
	 	 Limits on Royalty Reductions
	  	 	31	  
	 8.7
	 	 Non-Monetary Consideration
	  	 	31	  
	 8.8
	 	 Royalty Reports; Payments
	  	 	31	  
	 8.9
	 	 Audits
	  	 	33	  
	 8.10
	 	 Tax Matters
	  	 	34	  
	 8.11
	 	 Currency Exchange
	  	 	34	  
	 8.12
	 	 Late Payments
	  	 	34	  
	 8.13
	 	 Mode of Payment
	  	 	35	  
	 8.14
	 	 Bank Account
	  	 	35	  
	 8.15
	 	 Costs
	  	 	35	  
	 8.16
	 	 Sublicensees
	  	 	35	  
	 8.17
	 	 Post-Royalty Term
	  	 	35	  
	 8.18
	 	 No Set-Off
	  	 	36	  
			
	 ARTICLE 9
	 	LICENSES	  	 	36	  
	 9.1
	 	 Xenon Licenses to Ivax
	  	 	36	  
	 9.2
	 	 Ivax License to Xenon
	  	 	36	  
	 9.3
	 	 Sublicense Rights
	  	 	37	  
	 9.4
	 	 Negative Covenant
	  	 	37	  
	 9.5
	 	 No Implied Licenses
	  	 	37	  
	 9.6
	 	 [†] Considerations respecting XEN403
	  	 	38	  
	 9.7
	 	 [†] Considerations respecting XEN402
	  	 	38	  
			
	 ARTICLE 10
	 	INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION AND ENFORCEMENT	  	 	39	  
	 10.1
	 	 Ownership of Intellectual Property
	  	 	39	  
	 10.2
	 	 Prosecution and Maintenance of Ivax Background IP
	  	 	40	  
	 10.3
	 	 Prosecution and Maintenance of Collaboration IP and Xenon Background IP
	  	 	40	  
	 10.4
	 	 Prosecution and Maintenance of Xenon’s Background IP Patent Rights Covering R1150W
	  	 	43	  
	 10.5
	 	 Infringement by Third Parties
	  	 	43	  
	 10.6
	 	 Third Party Claims
	  	 	45	  
	 10.7
	 	 Cooperation in Intellectual Property Infringement Proceedings
	  	 	46	  
	 10.8
	 	 Settlement
	  	 	46	  
	 10.9
	 	 Data Exclusivity
	  	 	46	  

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

ii 

							
	 10.10
	 	 Trademarks
	  	 	47	  
			
	 ARTICLE 11
	 	CONFIDENTIALITY	  	 	47	  
	 11.1
	 	 Confidential Information
	  	 	47	  
	 11.2
	 	 Exceptions
	  	 	47	  
	 11.3
	 	 Certain Disclosures
	  	 	48	  
	 11.4
	 	 Publications
	  	 	49	  
	 11.5
	 	 Employee and Advisor Obligations
	  	 	49	  
	 11.6
	 	 Term of Confidentiality
	  	 	50	  
			
	 ARTICLE 12
	 	TERM AND TERMINATION	  	 	50	  
	 12.1
	 	 Term
	  	 	50	  
	 12.2
	 	 Bankruptcy, Dissolution and Winding Up
	  	 	50	  
	 12.3
	 	 Termination by the Parties
	  	 	51	  
	 12.4
	 	 Termination for Breach
	  	 	52	  
	 12.5
	 	 Events and Restrictions Following Termination
	  	 	53	  
	 12.6
	 	 Ongoing Obligations
	  	 	54	  
	 12.7
	 	 Dispute Resolution
	  	 	55	  
			
	 ARTICLE 13
	 	DISPUTE RESOLUTION	  	 	55	  
	 13.1
	 	 Mediation
	  	 	55	  
	 13.2
	 	 Audit—Binding Determinations
	  	 	56	  
			
	 ARTICLE 14
	 	REPRESENTATIONS AND WARRANTIES	  	 	56	  
	 14.1
	 	 Representation of Authority; Consents
	  	 	56	  
	 14.2
	 	 Representations and Warranties by Xenon.
	  	 	56	  
	 14.3
	 	 Ivax Covenant
	  	 	58	  
	 14.4
	 	 Employee and Consultant Obligations
	  	 	59	  
	 14.5
	 	 Disclaimer of Warranty
	  	 	59	  
			
	 ARTICLE 15
	 	INDEMNIFICATION	  	 	60	  
	 15.1
	 	 Indemnity By Ivax
	  	 	60	  
	 15.2
	 	 Indemnity by Xenon
	  	 	61	  
	 15.3
	 	 Limitation of Liability
	  	 	61	  
	 15.4
	 	 Method of Asserting Claims
	  	 	62	  
	 15.5
	 	 Notice Period
	  	 	62	  
	 15.6
	 	 Reimbursement
	  	 	62	  
	 15.7
	 	 Settlement
	  	 	62	  
	 15.8
	 	 Grant of Access and Assistance to Indemnifying Party
	  	 	62	  
	 15.9
	 	 Conflict of Interest or Failure to Defend
	  	 	63	  
	 15.10
	 	 Insurance Proceeds
	  	 	63	  
	 15.11
	 	 Insurance
	  	 	63	  
			
	 ARTICLE 16
	 	GENERAL	  	 	63	  
	 16.1
	 	 Assignment
	  	 	63	  

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

iii 

							
	 16.2
	 	 Change of Control Event
	  	 	64	  
	 16.3
	 	 Governing Law
	  	 	65	  
	 16.4
	 	 United Nations Convention
	  	 	65	  
	 16.5
	 	 Business Day
	  	 	65	  
	 16.6
	 	 Notices
	  	 	66	  
	 16.7
	 	 Force Majeure
	  	 	66	  
	 16.8
	 	 Independent Contractors
	  	 	67	  
	 16.9
	 	 No Strict Construction
	  	 	67	  
	 16.10
	 	 No Implied Waivers; Rights Cumulative
	  	 	67	  
	 16.11
	 	 Severability
	  	 	67	  
	 16.12
	 	 Execution in Counterparts
	  	 	68	  
	 16.13
	 	 No Third Party Beneficiaries or Obligors
	  	 	68	  
	 16.14
	 	 Entire Agreement
	  	 	68	  
	 16.15
	 	 Amendment
	  	 	68	  
	 16.16
	 	 Compliance
	  	 	68	  
		
	 Schedule A—XEN402
	  	 	A-1	  
		
	 Schedule B—XEN403
	  	 	B-1	  
		
	 Schedule C—INITIAL SUMMARY COLLABORATIVE DEVELOPMENT PLAN
	  	 	C-1	  
		
	 Schedule D—IVAX BACKGROUND PATENT RIGHTS
	  	 	D-2	  
		
	 Schedule E—XENON BACKGROUND PATENT RIGHTS
	  	 	E-1	  
		
	 Schedule F—XENON CO-PROMOTION RIGHTS
	  	 	F-1	  
		
	Schedule G—PRESS RELEASE	  	 	G-1	  
		
	Schedule H –THIRD PARTY AGREEMENTS	  	 	H-1	  

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

iv 

 COLLABORATIVE DEVELOPMENT AND 

LICENSE AGREEMENT 

This Agreement is made December 7, 2012 (the “Effective Date”) 

BETWEEN: 

XENON PHARMACEUTICALS INC., a Canadian corporation having its principal place of business at 3650 Gilmore Way, Burnaby, British
Columbia, V5G 4W8 (“Xenon”) 
 AND 
 IVAX INTERNATIONAL GMBH a Swiss limited liability company having its principal place of business at Alpenstrasse 2, 8640 Rapperswil, Switzerland (“Ivax”) 

RECITALS 

WHEREAS: 
  

	(A)	Xenon has proprietary technology and scientific expertise relating to research and development of compounds for the treatment of chronic and acute pain in humans;

  

	(B)	Ivax and its Affiliates have expertise in developing, marketing and selling pharmaceutical products; and 

 

	(C)	Xenon and Ivax wish to collaborate on the clinical development of certain compounds, upon the terms set out in this Agreement, and Ivax and its Affiliates shall further
develop, manufacture and sell products containing such compound(s). 

 WITNESSES THAT, in consideration of the premises and
the mutual covenants contained herein, Xenon and Ivax agree as follows: 
 ARTICLE 1 

DEFINITIONS/INTERPRETATION 

1.1 Definitions 
 In this
Agreement: 
 “Active Pharmaceutical Ingredient” means, in a pharmaceutical product, a clinically active material that
provides pharmacological activity (excluding formulation components such as coatings, stabilizers, excipients or solvents, adjuvants or controlled release technologies). 
 “Affected Product” has the meaning set out in Section 8.3(a)(i). 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

1 

 “Affiliate” means, with respect to any Party, any Person, organization or entity
which directly or indirectly controls, is controlled by, or is under common control with such Party. For purposes of this definition only, “control” and, with correlative meanings, the terms “controlled by” and “under
common control with” of another Person, organization or entity will mean the ability, directly or indirectly, to direct the activities of the relevant entity, including: 

 

	 	(i)	ownership or control of more than fifty percent (50%) of the outstanding voting or other ownership interest of the other organization or entity; or

  

	 	(ii)	direct or indirect possession of the power to elect or appoint more than fifty percent (50%) of the members of the governing body of the organization or other
entity; 

 PROVIDED that in the case of jurisdictions in which the maximum percentage ownership permitted by law for a foreign
investor is less than fifty percent (50%), such lower percentage shall be substituted in the preceding sentence if such foreign investor has the power to direct the management and policies of such entity. Neither of the Parties to this Agreement
shall be deemed to be an “Affiliate” of the other solely as a result of their entering into this Agreement. 

“Agreement” means this Agreement, including the Schedules hereto and any written agreement, document or instrument entered into,
made or delivered pursuant to the terms hereof, and as any of them may from time to time be supplemented or amended. 

“Alliance Manager” has the meaning given to that term in Section 3.1. 

“Annual Plan” has the meaning set out in Section 3.6. 
 “Applicable Law” means all applicable laws, rules, regulations, guidelines and policies that apply to the performance of either Party’s obligations relating to this Agreement
that may be in effect from time to time (including disclosure obligations as required by any stock exchange or securities commission having authority over a Party, and any applicable rules, guidelines or other requirements of a Regulatory Authority)
to the extent applicable to such Party. 
 “Arbitration” has the meaning set out in Section 8.5.

 “BIA” means the Bankruptcy and Insolvency Act (Canada). 
 “Books and Records” means, in whatever media, all books and records, documents, reports and accounts in connection with or relating to any research activities pursuant to this Agreement
in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes including to obtain Regulatory Approvals, and which shall be complete and accurate and shall fully and properly reflect all material work done and
results achieved in the performance of the activities hereunder and which shall be retained as may be required by Applicable Law (provided that any such materials that relate to any Patent Rights shall be retained for the life of such rights plus
five (5) years); as well as any other books and records as may be required from time to time by Applicable Law or this Agreement. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

2 

 “Business Day” means any day other than (i) a Friday or Saturday for Ivax,
(ii) a Saturday or Sunday for Xenon or (iii) a commercial holiday in either Vancouver, British Columbia, Toronto, Ontario, New York, NY or Tel Aviv, Israel, or (iv) such other day when the general operations of a Party are closed.

 “Calendar Quarter” means each successive period of three calendar months ending on each of
March 31, June 30, September 30, and December 31. 
 “Ceases Development” or
“Ceased Development” means [†]. 
 “CCAA” means the Companies’ Creditors
Arrangement Act (Canada). 
 “CFR” means the US Code of Federal Regulations. 

“Change of Control Event” has the meaning set out in Section 16.1(b). 

“Clinical Trial” means a Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial or Phase IV Clinical Trial.

 “Collaborative Development Plan” means the written plan setting forth in reasonable detail the Development
activities to be conducted by or on behalf of Ivax and/or Xenon and/or their respective Affiliates pursuant to this Agreement as further described in Section 3.2(a)(i), which plan shall assign responsibility for such Development activities
between the Parties. An Initial Summary Collaborative Development Plan is attached as Schedule C hereto. 
 “Collaborative
Development Program” means the Development activities to be conducted by the Parties over the course of the Collaborative Development Term, as set out in Section 3.2(a)(i) herein and in the Collaborative Development Plan.

 “Collaborative Development Term” means the term of the Collaborative Development Program described in Section
2.4. 
 “Collaboration IP” means any Intellectual Property conceived, identified, or first made by Xenon or Ivax
(each either alone, jointly, or with their Affiliates or Third Parties): (i) [†]; or (ii) [†]. 

“Collaboration Patent Rights” means all Patent Rights under Collaboration IP, including Joint Patent Rights. 

“Combination Product” means a single Product in final form containing (i) one or more of XEN402 or XEN403 as Active
Pharmaceutical Ingredient(s), and (ii) one or more other Active Pharmaceutical Ingredient(s). 
 [†]. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

3 

 “Commercialization” or “Commercialize” means any activities,
including pre-launch activities, directed to preparation for sale of, offering for sale of, or sale of a Product, including activities related to marketing, advertising, promoting, detailing, distributing, importing, exporting such Product,
conducting Phase IV Clinical Trials, and interacting with Regulatory Authorities regarding the foregoing. 
 “Confidential
Information” means all non-public proprietary Intellectual Property or other non-public information (whether or not patentable) regarding a Party’s or its Affiliates’ research, Development, Manufacturing and Commercialization
activities and such Party’s and its Affiliates’ technology, products, business information and objectives, which is designated as confidential by the disclosing Party prior to or at the time any such Intellectual Property or other
information is disclosed by the disclosing Party to the other Party. Notwithstanding the foregoing, Intellectual Property or other non-public information that is orally, electronically or visually disclosed by a Party without a written designation
of confidentiality shall constitute Confidential Information of a Party: (i) if the disclosing Party, within thirty (30) days after such disclosure, delivers to the other Party a written document summarizing the Intellectual Property or
other information, designating the same as confidential, or (ii) if such information is of the type that is customarily considered to be confidential information by Persons engaged in activities that are substantially similar to the activities
being engaged in by the Parties. Confidential Information does not include information that (i) was known or used by the receiving Party prior to its date of disclosure to the receiving Party, as demonstrated by legally admissible evidence
available to the receiving Party; (ii) either before or after the date of the disclosure to the receiving Party is lawfully disclosed to the receiving Party by sources (other than the disclosing Party) rightfully in possession of the
Confidential Information and not bound by confidentiality obligations to the disclosing Party; (iii) either before or after the date of the disclosure to the receiving Party becomes published or generally known to the public through no fault or
omission on the part of the receiving Party; or (iv) is independently developed by or for the receiving Party without access to, reference to or reliance upon the Confidential Information, as demonstrated by competent written records.
Notwithstanding the foregoing, any technical or business information of a Party or its Affiliates disclosed at a meeting of the JDC or PDC shall constitute Confidential Information of a Party unless otherwise specified in writing. 

“Consumer Price Index” means the Consumer Price Index – All-items, applicable to Vancouver, British Columbia, as published
by Statistics Canada, or if such Index is no longer published, then the Index most comparable thereto. 

“Control” or “Controlled” means, with respect to any Intellectual Property, the possession (whether by license,
other than pursuant to this Agreement, or ownership) by a Party or its Affiliates of the right to grant to the other Party access, a license, sublicense, or other right as provided herein (including the right to reference an NDA Filing) without
violating the terms of any agreement or other arrangement, existing before, on, or after the Effective Date with any Third Party. Notwithstanding anything to the contrary under this Agreement, with respect to any Third Party that later becomes an
Affiliate of a Party after the Effective Date (including a Third Party acquirer), no Intellectual Property of such Third Party will be included in the licenses granted hereunder by virtue of such Third Party becoming an Affiliate of such Party.

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

4 

 “Covering”, “Cover”, or “Covered” means, with
respect to a Patent Right, that, [†]. 
 “Decision Point” has the meaning set out in Section
12.3(b). 
 “Development” or “Develop” means the conduct of all research, formulating,
preclinical and other testing, nonclinical activities, Clinical Trials and other studies, and all other activities (including test method development, stability testing, toxicology studies, process development, statistical analysis and report
writing, packaging, labelling and regulatory affairs, product approval and registration activities) necessary, desirable, or reasonably useful or otherwise requested or required by a Regulatory Authority as a condition or in support of obtaining and
maintaining Regulatory Approval. For clarity, Development excludes Phase IV Clinical Trials. 
 “Development Milestone
Event” has the meaning set out in Section 7.2. 
 “Diagnostic Product” means an assay, test, test kit or
service used solely for the purpose of Developing or Commercializing Products that is Covered by a Valid Claim of the Xenon Background Patent Rights in the Territory.  
 “Diligent Efforts” means: 
  

	 	(a)	In respect of Ivax, efforts and resources devoted to [†]. 

  

	 	(b)	In respect of Xenon, efforts and resources devoted to [†]. 

  

	 	(c)	[†]. 

“Disclosure” has the meaning set out in Section 11.4. 
 “Effective Date” has the meaning set out at the beginning of this Agreement. 
 “EMA” means the European Medicines Agency or any successor entity thereto. 
 “EU” means the European Union, or any country within the European Union, as it is constituted as of the Effective Date. 

“FDA” means the US Food and Drug Administration and any successor agency thereto. 

“Field” means all human and non-human indications. 
 “First Commercial Sale” means, with respect to a Product, the first bona fide sale of such Product to a Third Party by or on behalf of Ivax or its Affiliates or Sublicensees for
monetary value, for use or consumption by the end user of such Product, in a country in the Territory after Regulatory Approval has been achieved for such Product in such country. For greater certainty, sales for test marketing, sampling and
promotional uses, Clinical Trial purposes or compassionate or similar use shall not be considered to constitute a First Commercial Sale. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

5 

 “FTE” means the equivalent of one full-time employee’s work time over a twelve
(12) month period (including vacations, sick days and holidays applicable to each Party but in no event less than [†]) related directly to activities under the Collaboration Development Program. The portion of an FTE year devoted by an
employee to the Collaborative Development Program shall be determined by dividing the number of full days during any twelve (12) month period devoted by such employee to the Collaborative Development Program by the total number of working days
during such twelve (12) month period. 
 “FTE Rate” shall mean the amount Ivax will pay to Xenon over a
consecutive twelve (12) month period during the Collaborative Development Term to support one (1) Xenon FTE dedicated to the Collaborative Development Plan. The FTE Rate shall be $[†] per FTE. 

“Full Royalty” has the meaning set out in Section 8.1. 
 “GCP” means, at any time, the then current Good Clinical Practices as such term is defined from time to time by the FDA, or comparable standards or requirements of other relevant
Regulatory Authority within the Territory. 
 “Generic Product” has the meaning set out in Section 8.3(a).

 “IND” means an Investigational New Drug application, as described in 21 CFR § 312.23, filed for purposes of
conducting Clinical Trials on a Product in accordance with the requirements of the United States Food, Drug, and Cosmetic Act of 1938, as amended, and the regulations promulgated thereunder, including all supplements and amendments thereto, and any
analogous application and process required by a Regulatory Authority in a country or regulatory jurisdiction elsewhere in the Territory in order to conduct Clinical Trials on a Product in such country. 

“Indication” means a specific disease for which an NDA Approval has been received. By way of example, the following are each an
Indication: erythromelagia, [†]. For clarity, broad pain states such as neuropathic pain, inflammatory pain or severe pain are each comprised of multiple Indications.  
 “Insolvency Laws” shall mean any of the BIA, the CCAA, the Winding-Up and Restructuring Act (Canada), and any other applicable similar federal, provincial, or foreign law
(including common law or equity) of any jurisdiction (including any law of any jurisdiction permitting a debtor to obtain a stay or a compromise of the claims of its creditors against it) now or hereafter in effect relating to bankruptcy,
insolvency, receivership, liquidation, dissolution, winding-up, restructuring or reorganization of debtors (including any applicable corporations legislation), compromise, arrangement, adjustment, protection, moratorium, relief, stay of proceedings
of creditors generally (or any class of creditors), or composition of any debtor or its indebtedness. 
 “Insolvency
Proceeding” means any of the following, undertaken under Insolvency Laws or otherwise: (a) any case, action, application, petition, or other proceeding before any governmental authority or otherwise (i) relating to bankruptcy,
insolvency, receivership,  

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

6 

 
liquidation, dissolution, winding-up, restructuring or reorganization of debtors (including under any applicable corporations legislation), compromise, arrangement, adjustment, protection,
moratorium, relief, stay of proceedings of creditors generally (or any class of creditors), or composition of any debtor or its indebtedness, or the filing of any notice in respect of the foregoing, or (ii) applying for or seeking the entry of
an order for the appointment of, or the taking of possession by, a receiver, interim receiver, receiver/manager, sequestrator, conservator, custodian, administrator, trustee, liquidator or other similar official for any debtor or any substantial
part of its assets, or (b) any general assignment for the benefit of creditors, scheme of compromise or arrangement, formal or informal moratoria, compositions, extensions, marshaling of assets for creditors, or other similar arrangement in
respect of its creditors generally or any substantial portion of its creditors including the filing of any notice of intent to file a proposal. 

“Intellectual Property” means Patent Rights, Know-How, trade names, trademarks,
copyright, trade dress, industrial and other designs, and all other forms of intellectual property, all whether or not registered, capable of registration, published or unpublished. 
 “Invalidity Claim” has the meaning set out in Section 10.5(f). 

“Ivax Background IP” means: 
  

	 	(i)	Ivax Background Know-How; and 

  

	 	(ii)	Ivax Background Patent Rights. 

“Ivax Background Know-How” means all Know-How that: (i) is Controlled by Ivax or its Affiliates as of the Effective Date;
(ii) is not generally known; and (iii) is necessary for Xenon to conduct Development activities pursuant to the Collaborative Development Program as set forth in the Collaborative Development Plan including any amendments to the
Collaborative Development Plan made by the JDC in accordance with the terms set forth herein. 
 “Ivax Background Patent
Rights” means all Patent Rights Controlled by Ivax or its Affiliates as of the Effective Date that are necessary for Xenon to conduct Development activities pursuant to the Collaborative Development Program as set forth in the Collaborative
Development Plan including any amendments to the Collaborative Development Plan made by the JDC in accordance with the terms set forth herein. All such Ivax Background Patent Rights are set out in Schedule D. 

“Ivax Co-Promotion IP” means (i) all Patent Rights Controlled by Ivax or its Affiliates that are necessary for Xenon
to conduct the activities set out in Schedule F respecting Products to which Xenon has exercised the Xenon Co-Promote Option; and (ii) all Know-How of Ivax or its Affiliates that is necessary for Xenon to perform the activities set out in
Schedule F respecting such Products to which Xenon has exercised the Xenon Co-Promote Option. 
 “Ivax Indemnified
Parties” has the meaning set out in Section 15.2. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

7 

 “Ivax Termination IP” means: 

 

	 	(a)	[†]; and 

  

	 	(b)	[†]. 

 “Joint Collaboration
IP” has the meaning set out in Section 10.1(b)(iii). 
 “JDC” or “Joint Development
Committee” has the meaning set out in Section 3.2(a). 
 “Joint Patent Rights” has the meaning set out
in Section 10.1(b)(iii). 
 “Know-How” means any know-how, inventions,
discoveries, trade secrets, information, data and materials including ideas, concepts, formulas, methods, assays, practices, processes, software, devices, techniques, procedures, designs, compositions, constructs, compounds, plans, applications,
research, preclinical and clinical data, regulatory information, manufacturing process, scale-up and other technical data, reports, documentation and samples, including: biological, chemical, pharmacological, toxicological, pharmaceutical, physical
and analytical, pre-clinical, clinical, safety, manufacturing and quality control data and information, including study designs and protocols; assays and biological methodology. Know-How excludes Patent Right(s). 

“Know-How Royalty” has the meaning set out in Section 8.2(a). 

“Major Market” means each of the United States, the United Kingdom, Germany, France, Spain, and Italy. 

“Manufacture” or “Manufacturing” means all activities associated with the production, manufacture, processing,
filling, finishing, packaging, labeling, shipping and holding, as applicable, for research, Development or Commercialization, as the case may be, including process development, process qualification and validation, manufacturing scale-up,
pre-clinical, clinical and commercial manufacture and analytic development, quality stability testing, impurity characterization, assurance and quality control. 
 “Market Protected Product” means a Product to which, under Applicable Law, data exclusivity protection and/or market exclusivity protection has been afforded and is in effect,
including: 
  

	 	(a)	Market exclusivity respecting introduction of a new chemical entity (NCE) to the market, as provided under the US Hatch-Waxman Act (1984) as amended;

  

	 	(b)	Market exclusivity respecting introduction of an orphan drug to the market, as provided under the US Orphan Drug Act (1983) as amended;

  

	 	(c)	Market exclusivity respecting introduction of a pediatric drug to the market, as provided under the US Best Pharmaceuticals for Children Act (2002) as
amended; 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

8 

	 	(d)	Data exclusivity and/or market exclusivity for a new drug, including any extensions thereto, each pursuant to the EU Data Exclusivity Regulation (EC)
No. 726/2004 as amended; 

  

	 	(e)	Market exclusivity respecting introduction of an orphan drug to the market pursuant to the EU Orphan Drug Regulation (EC) No 141/2000 as amended; and

  

	 	(f)	Market exclusivity respecting introduction of a pediatric drug to the market pursuant to the EU Regulation (EC) No 1901/2006 (Paediatric Regulation), including data
exclusivity and/or marketing exclusivity under the Paediatric Use Marketing Authorization (PUMA), 

 and any other similar
legislation or regulations to the above, and any successor legislation or regulations relating thereto, in any jurisdiction in the Territory. 

“Milestone Event” means a Development Milestone Event or Sales Milestone Event, as the case may be. 

“Milestone Payments” means each of the payments described in Sections 7.2 and 7.3. 

“NDA” or “New Drug Application” means an application submitted to a Regulatory Authority in any jurisdiction
seeking approval to market and sell a Product, including a United States New Drug Application filed with the FDA pursuant to 21 CFR § 314.50 of the US Food, Drug and Cosmetic Act, or any application in any country
corresponding to a United States New Drug Application, and all additions, supplements, extensions and amendments thereto. 

“NDA Approval” means approval by a Regulatory Authority of an NDA. 

“NDA Filing” means the filing with the applicable Regulatory Authority of a New Drug Application for a Product, and all
additions, supplements, extensions, and amendments thereto. 
 “Net Sales” means the gross amount invoiced or
otherwise charged by or on behalf of Ivax or any of its Affiliates or Sublicencees, for the sale of any Products sold to Third Parties, less the following deductions [†], each to the extent actually allowed or incurred based on such sale,
[†]: 
  

	 	(i)	[†]; 

  

	 	(ii)	[†]; 

  

	 	(iii)	[†]; 

  

	 	(iv)	[†]; 

  

	 	(v)	[†]; 

  

	 	(vi)	[†]; 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

9 

	 	(vii)	[†]; 

  

	 	(viii)	[†]; 

  

	 	(ix)	tariffs, duties, excise, sales, value-added and other similar taxes (other than income taxes, franchise taxes or like taxes); and 

 

	 	(x)	all freight, postage and insurance included in the invoice price; 

 PROVIDED that: 
  

	 	(xi)	any of the items set forth above that would otherwise be deducted from the invoice price in the calculation of Net Sales but which are separately charged to Third
Parties shall not be deducted from the invoice price in the calculation of Net Sales. 

 “Party” means
Ivax or Xenon; 
 “Parties” means Ivax and Xenon. 

“Patent Prosecution” has the meaning set out in Section 10.3(a). 
 “Patent Rights” means (i) any national, regional and international patents and patent applications, including provisional patent applications, (ii) any patent
applications filed either from such patents, patent applications or provisional applications or from an application claiming priority from either of these, including divisionals, continuations, continuations-in-part, provisionals, converted
provisionals and continued prosecution applications, (iii) any and all patents that have issued or in the future issue from the foregoing patent applications ((i) and (ii)), including utility models, petty patents and design patents and
certificates of invention), and (iv) any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, extensions, substitutions, re-examinations, renewals, supplemental
protection certificates and the like, pipeline patents, patents of importation, revalidation, confirmation or introduction patents or registration patents or patents of addition to any of the foregoing patents or patent applications ((i), (ii), and
(iii)), and (v) any similar rights, including so-called pipeline protection or any importation, revalidation, confirmation or introduction patent or registration patent or patent of additions to any of such foregoing patent applications and
patents. 
 “PDC” or “Product Development Committee” has the meaning set out in Section
3.2(d). 
 “Person” means any individual, sole proprietorship, partnership, corporation, limited liability
company, joint stock company, unincorporated association, trust or any other entity that has legal capacity to own property in their own name or to sue or be sued, including a government or political subdivision, department or agency of a
government. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

10 

 “Phase I Clinical Trial” means the initial clinical testing of a Product in humans
(first-in-humans study) with the intention of gaining a preliminary assessment of the safety of such Product or any similar clinical testing prescribed by the Regulatory Authorities, including the trials referred to in 21 CFR § 312.21(a), as
amended. 
 “Phase II Clinical Trial” means a human clinical trial of a Product conducted in any country that is
intended to explore a variety of doses, dose response and/or duration of effect to generate evidence of clinical safety and activity in a target patient population, that would satisfy the requirements of 21 CFR § 312.21(b), or an equivalent
clinical trial as required by a Regulatory Authority outside of the United States. 
 “Phase III Clinical
Trial” means a human clinical trial of a Product on a sufficient number of subjects that is designed to establish that the Product is safe and efficacious for its intended use, and to determine warnings, precautions and adverse
reactions that are associated with such Product in the dosage range to be prescribed, which trial is intended to support marketing approval by the FDA under the US Food, Drug, and Cosmetic Act, or a similar Regulatory Authority in a
jurisdiction outside of the United States. 
 “Phase IV Clinical Trial” means a post-marketing human clinical
trial for a Product commenced after receipt of Regulatory Approval in the country for which such trial is being conducted and that is conducted within the parameters of the Regulatory Approval for the Product. Phase IV Clinical Trials may include,
without limitation, epidemiological studies, modeling and pharmacoeconomic studies, investigator-sponsored clinical trials of Product and post-marketing surveillance studies. 
 “Product” means (i) any pharmaceutical product that contains XEN402 as an Active Pharmaceutical Ingredient, or (ii) any pharmaceutical product that contains XEN403 as an
Active Pharmaceutical Ingredient. For clarity, all references to a Product in this Agreement shall include a Combination Product. 

“Project Leader” means the representative designated by each Party pursuant to Section 3.2(b) who will have responsibility
for overseeing the day-to-day activities of such Party with respect to the Collaborative Development Plan and for being the primary point of contact between the Parties with respect to the Collaborative Development Program. 

“Reduced Royalty” has the meaning set out in Section 8.3(a). 
 “Regulations” means regulations, statutes, rules, guidelines and procedures promulgated by a Regulatory Authority pursuant to Applicable Law. 

“Regulatory Approval” means, with respect to any country, any and all approvals (including any applicable governmental price and
reimbursement approvals), licenses, registrations, or authorizations of any Regulatory Authority necessary for the Manufacture, use, storage, import, transport, Commercialization and commercial sale (including packaging and labelling) of a product
for human use in a country, including approvals of biologics license applications, NDA Filings and product license applications (and their respective foreign counterparts). 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

11 

 “Regulatory Authority” means any federal, national, multinational, regional, state,
provincial or local regulatory agency, department, bureau, commission, council or other governmental entity with authority to grant a Regulatory Approval or having jurisdiction over the Manufacture, Development, or Commercialization of a Product in
the Territory. 
 “Regulatory Documents” has the meaning set out in Section 4.1(b). 

“Regulatory Document Transfer Date” has the meaning set out in Section 4.1(b). 

“Royalty” means a Full Royalty, Know-How Royalty or Reduced Royalty, as the case may
be. 
 “Royalty Payment” means a royalty payment required to be paid pursuant to ARTICLE 8. 

“Royalty Reduction Terms” has the meaning set out in Section 12.5(c). 

“Royalty Term” means, in respect of each Product , unless earlier terminated pursuant to the provisions of ARTICLE 12, on a
country-by-country basis within the Territory, the period commencing on the date of the First Commercial Sale of the Product in that country and ending on the later of: 

 

	 	(i)	the expiration of the last to expire of the Valid Claims of the applicable [†] Patent Rights Covering such Product in such country; 

 

	 	(ii)	the date upon which such Product, to the extent previously considered a Market Protected Product, loses the data or market exclusivity that had been afforded it; or

  

	 	(iii)	 the tenth
(10th) anniversary of such First Commercial Sale of a
Product in that country. 

 “Safety Signal” means, in respect to a Product, either of the following events
occurring during a Clinical Trial of such Product: 
  

	 	(i)	[†]; 

  

	 	(ii)	[†]: 

  

	 	(A)	[†] and 

  

	 	(B)	[†], 

 [†];

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

12 

	 	(iii)	[†]; or 

  

	 	(iv)	[†]. 

 By way of example
respecting (ii) above, [†]. 
 “Sales Milestone Event” has the meaning given to that term in Section 7.3.

 “Sublicense” means (i) a sublicense granted pursuant to, and in accordance with, the provisions of Section 9.3,
and (ii) any other agreement between Ivax or its Affiliates and a Third Party, where such agreement does not require a sublicense under Xenon Background IP, but where Xenon is entitled to Milestone Payments or Royalty Payments under this
Agreement. 
 “Sublicensee” means a Person to whom a Sublicense is granted by Ivax or its Affiliates. 

“Substances” has the meaning given to that term in Section 4.6. 
 “Successor Entity” of a Party means such Party’s successor in interest. 
 [†]. 
 [†]. 
 [†]. 
 [†]. 
 [†]. 
 “Term” means the term of this Agreement as set out in Section
12.1. 
 “Territory” means (i) for XEN402 all of the countries of the world, excluding [†];
(ii) [†]; (iii) [†]; or (ii) for Diagnostic Products, all of the countries of the world. 

“Third Party” means any Person other than Ivax, Xenon, and their respective Affiliates. 

“Third Party Claim” has the meaning set out in Section 10.6. 
 “True-Up” has the meaning set out in Section 8.8(c). 

“US” means the United States of America (including all possessions and territories thereof, including Puerto Rico).

 “Valid Claim” means a claim: 

 

	 	(a)	of any issued, unexpired patent whose validity, enforceability, or patentability has not been affected by any of the following: 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

13 

	 	(i)	a holding, finding, or decision of invalidity, unenforceability, or non-patentability by a court, governmental agency, national or regional patent office, or other
appropriate body that has competent jurisdiction, such holding, finding, or decision being final and from which no appeal can be taken, or with respect to which an appeal is not taken within the time allowed for appeal, or 

 

	 	(ii)	disclaimer, irretrievable lapse, abandonment, revocation, dedication to the public, denial or admission of invalidity or unenforceability through reissue, disclaimer or
otherwise, or 

  

	 	(b)	of any patent application which has not been cancelled, abandoned, withdrawn from consideration, finally determined to be unallowable (from which no appeal is or can be
taken), or abandoned or disclaimed; PROVIDED that [†] (i) [†], or (ii) [†]. 

 For avoidance of
doubt, any patent respecting which a supplemental protection certificate has been granted shall be deemed to be a patent for purposes of this definition. 
 “XEN402” means that certain synthetic small molecule chemical compound described in Schedule A and the Xenon PCT Publ. No. [†], and all forms thereof.  

[†] 

“XEN403” means that certain synthetic small molecule chemical compound described in Schedule B and the Xenon PCT Publ. Nos.
[†] and [†], and all forms thereof. 
 “Xenon Background IP” means: 

 

	 	(i)	Xenon Background Know-How; and 

  

	 	(ii)	Xenon Background Patent Rights. 

“Xenon Background Know-How” means all Know-How that: (i) is Controlled by Xenon as of the Effective Date; (ii) is not
generally known; and (iii) is necessary for the work to be undertaken by Ivax pursuant to the Collaborative Development Plan and/or is necessary to research, Develop, Manufacture, have Manufactured, market, make, use, sell, offer for sale,
export and import for sale, or otherwise Commercialize Products or Diagnostic Products in the Territory. 
 “Xenon
Background Patent Rights” means all Patent Rights Controlled by Xenon as of the Effective Date that are necessary to research, Develop, Manufacture, have Manufactured, market, make, use, sell, offer for sale, export and import for sale, or
otherwise Commercialize Products or Diagnostic Products in the Territory.  
 “Xenon Co-Promote Option” has the
meaning set out in Section 6.3. 
 “Xenon Indemnified Parties” has the meaning set out in Section 15.1.

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

14 

 “Xenon Prosecution Notice” has the meaning set out in Section 10.3(c).

 “Year” means a period of one year beginning on January 1 and ending on (and including) December 31 of that
year. 
 1.2 Interpretation 
  

	 	(a)	Headings in this Agreement are solely for the convenience of reference and shall not be used for purposes of interpreting or construing the provisions hereof.

  

	 	(b)	All references in this Agreement to a designated “Article”, “Section”, “Subsection” or other subdivision or to a Schedule are to the
designated Article, Section, Subsection or other subdivision of, or Schedule to, this Agreement. 

  

	 	(c)	The words “herein”, “hereof” and “hereunder” and other words of similar import refer to this Agreement as a whole and not to any
particular Article, Section, Subsection or other subdivision or Schedule. 

  

	 	(d)	The word “including”, when following any general statement, term or matter, is not to be construed to limit such general statement, term or matter to the
specific items or matters set forth immediately following such word or to similar items or matters, whether or not non-limiting language (such as “without limitation” or “but not limited
to” or words of similar import) is used with reference thereto, but rather is to be construed to refer to all other items or matters that could reasonably fall within the broadest possible scope of such general statement, term or matter.

  

	 	(e)	All references to currency, dollar or $ are deemed to mean lawful money of the US. 

 

	 	(f)	Any reference to a statute includes and is a reference to such statute and to the regulations made pursuant thereto, with all amendments made thereto and in force from
time to time, and to any statute or regulations that may be passed which has the effect of supplementing or superseding such statute or such regulations. 

  

	 	(g)	Words imparting the masculine gender include the feminine or neuter gender and words in the singular include the plural and vice versa. 

 

	 	(h)	This Agreement has been prepared jointly by the Parties, each having access to legal counsel of its choice, and shall not be strictly construed or interpreted in favour
of or against either Party. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

15 

 ARTICLE 2 
 COLLABORATIVE DEVELOPMENT PROGRAM 
 2.1 General 

Each Party shall carry out its obligations under the Collaborative Development Program pursuant to the provisions of this Agreement. The Collaborative
Development Program will be conducted as a unified, collaborative effort with the Parties’ activities carried out primarily at each Party’s respective facilities. 
 2.2 Collaborative Development Program Costs 
 Except as otherwise expressly provided in this
Agreement, Ivax shall bear all costs of the Parties’ obligations as set forth under the Collaborative Development Program. For avoidance of doubt, Ivax shall also be responsible for payment of (or reimbursement to Xenon, as applicable), of any
costs and expenses relating to approved subcontractors as set out under Section 3.7. 
 2.3 Amendments to the Collaborative Development
Plan 
 The JDC may amend the Collaborative Development Plan from time to time in accordance with Section 2.4, Section 2.5, and
ARTICLE 3. In the event of a conflict between the terms of this Agreement including the terms of the Initial Summary Collaborative Development Plan attached as Schedule C hereto, and the Collaborative Development Plan, the terms of this Agreement
shall govern. 
 2.4 Collaborative Development Term 
 Except as otherwise provided herein, the term of the Collaborative Development Program shall commence on the Effective Date and continue for [†] years unless the JDC extends such term beyond the
initial [†] years. The JDC may extend the term of the Collaborative Development Program on a year-by-year basis, by notice to Xenon, initially at least ninety (90) days prior to the [†] anniversary of the Effective Date and,
thereafter, at least ninety (90) days prior to each subsequent anniversary of the Effective Date, and the Parties shall, in such case, amend the Collaborative Development Plan as necessary. 

2.5 Xenon FTE Funding 
  

	 	(a)	For the first year of the Collaborative Development Term, and for such further time period (if any) as the JDC may determine, Ivax shall fund, on a Calendar Quarter
basis (pro-rated for any period of less than three (3) months at the beginning or end of the Collaborative Development Term), in advance, as set out in the Initial Summary Collaborative Development Plan attached as Schedule C, a minimum number
of FTEs of Xenon, each at the FTE Rate; 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

16 

	 	(b)	Notwithstanding anything to the contrary herein, (i) such minimum number of Xenon FTEs will remain unchanged for the duration of the first year of the
Collaborative Development Term; and (ii) with regard to the Collaborative Development Plan for the second and/or subsequent years of the Collaborative Development Term, if the JDC desires to decrease such minimum number of Xenon FTEs funded by
Ivax, the JDC will provide Xenon with at least [†] months prior written notice (for clarity, such notice can be provided to Xenon at any time after the Effective Date); and 

 

	 	(c)	In the event that the JDC extends the Collaborative Development Term beyond the initial term of [†] years, if the extended Collaborative Development Plan
contemplates further work by Xenon FTEs, the FTE Rate will be increased by a percentage equal to the percentage increase in the Consumer Price Index from the beginning of the Collaborative Development Term, and for each year thereafter that the
Collaborative Development Term is extended, the FTE Rate will be increased by a percentage equal to the percentage increase in the Consumer Price Index from the commencement of the prior year of the Collaborative Development Term.

 2.6 FTE Records 

Xenon shall keep complete and accurate records of its FTE’s work time (including vacations, sick days and holidays) attributed to the Collaborative
Development Program and Ivax shall be entitled from time to time, but not more than once each Year during the Collaborative Development Term, and only once with respect to records covering any specific period of time, to review such records at its
expense in the location where such records are maintained upon reasonable notice and during regular business hours and under obligations of strict confidence, for the sole purpose of verifying the FTEs work time attributed to the Collaborative
Development Program. 
 2.7 Conduct of Collaborative Development Program 

 

	 	(a)	Each Party shall use Diligent Efforts to perform its obligations pursuant to the Collaborative Development Program. 

 

	 	(b)	Each Party shall conduct the Collaborative Development Program in compliance with all Applicable Law, including GCP. Each Party shall notify the other Party in writing
of any deviations from Applicable Law or Regulations, if applicable. 

  

	 	(c)	Each Party hereby agrees that neither it nor any of its Affiliates shall employ or otherwise use in any capacity, the services of any person debarred under US law,
including 12 U.S.C. 335(a) or (b) or 21 U.S.C. 335a, in performing any portion of the Collaborative Development Program. 

  

	 	(d)	 Each Party shall be entitled to utilize the services of its Affiliates to perform its activities under the Collaborative Development Plan, PROVIDED
that each Party shall remain at all times fully liable for its responsibilities under the Collaborative 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

17 

	 	
Development Program (whether performed by itself or its Affiliates) and shall only use the services of an Affiliate if such Affiliate has entered into an agreement whereunder the Affiliate has
agreed to be bound by terms consistent with the provisions of this Agreement 

  

	 	(e)	While Ivax shall be entitled to utilize the services of Third Parties to perform such Collaborative Development Program activities at its sole discretion provided that
such Third Party has entered into an agreement that contains provisions, as applicable, regarding Intellectual Property, Disclosure, and Confidential Information that comply with the provisions of this Agreement, Xenon shall not be entitled to
utilize the services of Third Parties to perform such Collaborative Development Plan activities except in accordance with Section 3.7 below. 

 ARTICLE 3 
 JOINT DEVELOPMENT COMMITTEE & PRODUCT DEVELOPMENT
COMMITTEE 
 3.1 Alliance Managers 
 Within thirty (30) days following the Effective Date, each Party will appoint (and notify the other Party of the identity of) a senior representative having a general understanding of
pharmaceutical research, Development and Commercialization issues to act as its alliance manager under this Agreement (“Alliance Manager”). The Alliance Managers will serve as the primary business contact point between the Parties
for the purpose of providing Xenon with information on the progress of Ivax’s Development and Commercialization of the Products and will be primarily responsible for facilitating the flow of information and otherwise promoting communication,
coordination and collaboration between the Parties; providing single point communication for seeking consensus both internally within the respective Party’s organization and together regarding key global strategy and planning issues, as
appropriate, including facilitating review of external corporate communications; and raising cross-Party and/or cross-functional disputes in a timely manner. Each Party may replace its Alliance Manager, either with respect to certain matters and/or
for all purposes under this Agreement, by providing prior written advisory (including via e-mail) to the Alliance Manager of the other Party. 
 3.2 Joint Development Committee and Product Development Committee 
  

	 	(a)	Within thirty (30) days following the Effective Date, the Parties shall establish a Joint Development Committee (the “JDC”) which shall have
responsibility to manage, direct and oversee all Development activities relating to the Products, including those activities set out under the Collaborative Development Plan and as set out below: 

 

	 	(i)	As soon as practicable after the establishment of the JDC and no later than [†] following the Effective Date, preparing and finalizing a detailed Collaborative
Development Plan, based upon and consistent with the Initial Summary of such Collaborative Development Plan set out in Schedule C. Such initial detailed Collaborative Development Plan will include: 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

18 

	 	•	 	 A detailed overview and timetable for each Party’s planned activities under the Collaborative Development Program for the 1st year of the Collaborative Development Term;

  

	 	•	 	 A general overview and timetable for each Party’s planned activities under the Collaborative Development Program for the [†] years of the
Collaborative Development Term; 

  

	 	•	 	 Specific activities and timetable goals respecting Ivax’s completion of one or more Phase II Clinical Trials and/or Phase III Clinical Trials in
erythromelalgia. 

  

	 	•	 	 [†] 

  

	 	•	 	 The number of FTEs to be provided by Xenon, subject to Section 2.5; 

 

	 	•	 	 Provisions to deal with Manufacturing of Compounds by Ivax for Development activities; and 

 

	 	•	 	 An allocation of responsibilities of each of the Parties for the activities pursuant to the Collaborative Development Plan.

  

	 	(ii)	Manage, direct and oversee all activities under the Collaborative Development Plan; 

 

	 	(iii)	Select the indication(s) and formulation(s) for each Product in Development; 

 

	 	(iv)	If and as applicable, revising and updating the Collaborative Development Plan in a timely manner and circulating a copy of each revised or updated version to the
Alliance Managers; 

  

	 	(v)	Monitoring progress of the Collaborative Development Plan including monitoring the Parties’ compliance with their respective obligations under same, including the
accomplishment of key objectives, the devotion of the required number of FTEs, and the disclosure of Collaboration IP; 

  

	 	(vi)	Circulate to each representative of the JDC and to each Alliance Manager, at least once per Calendar Quarter, a summary report (in such form and format as determined by
the JDC) of each Party’s Collaborative Development Program activities; and 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

19 

	 	(vii)	Such other activities as set forth in the Collaborative Development Plan or this Agreement, or as agreed by the Parties from time to time. 

 

	 	(b)	The JDC shall be comprised of an equal number of representatives of each Party with expertise appropriate for the function and purpose of the JDC, but in no event will
the membership of the JDC exceed three (3) representatives of each Party. Each Party will designate one of its representatives as its Project Leader, and may replace its representatives on the JDC from time to time in its discretion with prior
written notice to the other Party. 

  

	 	(c)	The Chair of the JDC shall be appointed by Ivax. 

  

	 	(d)	The JDC shall continue and have the responsibilities relating to each Product referenced in the Collaborative Development Plan, up to the date of expiration of the
Collaborative Development Term, at which time the JDC shall be dissolved. 

  

	 	(e)	As of the date of dissolution of the JDC, the Parties will form and convene a Product Development Committee (“PDC”) in a form reasonably analogous to
the JDC, including Section 3.4, to maintain information flow between Xenon and Ivax with respect to any active Development of Products. The PDC shall meet every [†] months, either in person, by audio or by video conference. The PDC shall
continue and have the responsibilities (as applicable) set out under Section 3.6 and Section 6.2(a), up to the date that the first NDA Approval is received for each such Product. The PDC will be dissolved as of the date that all Products
in Development have received a first NDA Approval. 

 3.3 Governance of JDC 

 

	 	(a)	JDC meetings may be held in-person, by audio or by video conference. The JDC shall hold an initial in-person meeting within thirty (30) days of the Effective Date,
at a location to be agreed by the representatives of the JDC. Thereafter, the JDC shall meet at least once per Calendar Quarter, with in-person meetings occurring [†]. 

 

	 	(b)	Unless otherwise agreed by the Parties, the location of in-person meetings shall alternate between the locations of the Parties, with the first meeting to be held at a
location to be agreed by the Parties. 

  

	 	(c)	Each Party shall use all reasonable efforts to cause its JDC representatives to attend the meetings, and if a Party’s representative is unable to attend a meeting,
such Party shall designate an alternate representative to attend in place of the absent representative. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

20 

	 	(d)	Each Party may, in its discretion, invite additional employees (including its Alliance Manager), and, with the consent of the other Party, consultants or scientific
advisors, to attend the meetings of the JDC, provided that such employees, consultants and advisors have entered into agreements that contain provisions, as applicable, regarding Intellectual Property, Disclosure, and Confidential Information that
comply with the provisions of this Agreement. 

  

	 	(e)	Each Party shall be responsible for all of its own expenses of participating in the JDC, including all costs of travel, food and lodging for a Party’s
representatives attending an in-person meeting. 

  

	 	(f)	The Chair of the JDC shall be responsible for providing notice of all meetings to the members of the JDC, leading the meetings and (unless the representatives of the
JDC agree upon a person to act as secretary of the meeting of the JDC), appointing a representative of the JDC to act as secretary of each meeting. Notice of meetings shall be given to all JDC members at least two (2) weeks in advance for
in-person meetings and at least one (1) week in advance for audio or video teleconferences. 

  

	 	(g)	A quorum for a meeting of the JDC shall be two (2) representatives of each Party. 

 

	 	(h)	The secretary of each meeting shall prepare, and the JDC Chair shall distribute to all members of the JDC, minutes of the meeting within fifteen (15) Business Days
following the date of the meeting to allow adequate review and comment. Such minutes shall provide a description in reasonable detail of the discussions held at the meeting and a list of any actions, decisions or determinations approved by the JDC.
Minutes of each meeting shall be approved or revised as necessary at the next meeting. The approved minutes of each meeting shall be distributed to the representatives of the JDC by the Chair of the JDC within thirty (30) days of such approval.

 3.4 Decision Making 
 At all times, the representatives of each Party on the JDC shall take into consideration the view of the representatives of the other Party regarding the matters under consideration by the JDC, and the
objective of the JDC shall be to reach agreement by consensus on matters after reasonable and open discussion. Each Party, but not each representative of a Party, shall have one vote on all matters coming before the JDC. In the event that the JDC
cannot reach agreement on a matter by consensus, [†]. 
 3.5 Responsibilities 

Notwithstanding anything to the contrary in this ARTICLE 3, each Party shall have and retain the rights, powers and discretion granted to it under this
Agreement and the JDC shall not be vested with any right, power or discretion except as expressly provided in this Agreement and shall not have the power to amend or modify this Agreement, including the Collaborative Development Plan, which may only
be amended or modified as provided in Section 16.15. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

21 

 3.6 Annual Plan 
  

	 	(a)	For each Product under Development, Ivax shall prepare, and submit to the PDC within thirty (30) days following the date of formation of the PDC (as set forth
under Section 3.2(e) above), and thereafter not less than thirty (30) days prior to each anniversary of the Effective Date, an annual Development plan (an “Annual Plan”) for the period of one (1) year
commencing on the next succeeding anniversary of the Effective Date, with respect to such year: 

  

	 	(i)	A general overview and timetable for Ivax’s planned Development activities for such Product; and 

 

	 	(ii)	Specific objectives of the Development activities for such Product, including objectives pertaining to: 

 

	 	•	 	 Projected timelines for commencement of Phase I Clinical Trials, Phase II Clinical Trials, and Phase III Clinical Trials (as applicable),

  

	 	•	 	 Projected timelines for NDA Filings and NDA Approvals, and 

 

	 	•	 	 Manufacturing activities. 

3.7 Subcontractors 
 Except with the
prior written consent of Ivax or as specifically provided in the Collaborative Development Plan, Xenon may not subcontract to a Third Party any of its obligations pursuant to the Collaborative Development Plan. In the event that the Collaborative
Development Plan provides for Xenon to subcontract any such obligations and Ivax has provided its consent respecting same, Xenon will ensure that such subcontractor has entered into agreements that contain provisions, as applicable, regarding
Intellectual Property, Disclosure, and Confidential Information that comply with the provisions of this Agreement. 
 ARTICLE
4 
 DISCLOSURE AND REPORTS DURING THE COLLABORATIVE DEVELOPMENT TERM 

4.1 Technology Transfer 
  

	 	(a)	Commencing as soon as reasonably practicable following the Effective Date, Xenon will disclose Xenon Background Know-How to Ivax, and commencing as soon as reasonably
practicable following finalizing the Collaborative Development Plan as set forth in Section 3.2(a)(i), Ivax will disclose Ivax Background Know-How to Xenon, in each case to the extent that the respective Party, in good faith believes is
necessary for the Development activities to be efficiently and effectively undertaken by the other Party pursuant to the Collaborative Development Plan. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

22 

	 	(b)	Within thirty (30) days after the Effective Date, Xenon shall [†] relating to all Products, including all INDs and all related documentation and information
(the “Regulatory Documents”), [†]. 

  

	 	(c)	Within thirty (30) days of a request from Ivax or as otherwise set forth in the Collaborative Development Plan, Xenon shall deliver to Ivax [†] any XEN402
compound, XEN403 compound, or Products in Xenon’s possession, for the Parties’ use in conducting the Development activities under the Collaborative Development Program. 

 

	 	(d)	Xenon shall use commercially reasonable efforts to provide Ivax with a reasonable amount of assistance from its employees, in connection with or related to any or all
of the Development activities being undertaken by Ivax in connection with the Collaborative Development Program, including to the extent requested by Ivax, Ivax’s establishment of manufacturing facilities for Products. 

 

	 	(e)	The Parties shall use reasonable efforts to take such other actions and execute such other instruments, assignments and documents as may be necessary or reasonably
useful to achieve the transfer of rights hereunder to Ivax, or to otherwise effectuate the purposes of this Agreement. 

  

	 	(f)	The consulting services to be provided by Xenon employees under Section 4.1(d) and 4.1(e) are separate and apart and “additional” to those contemplated
under the Collaborative Development Plan. The first [†] hours per Year of such additional consulting services by Xenon employees and/or any further additional consulting services (including those additional consulting services described in
Section 6.1(a) and Section 10.3(a)(iv) below, will be provided by Xenon at no charge to Ivax up until the date of the first NDA Filing. Any consulting services beyond [†] hours per Year or following the date of the first NDA Filing
will be mutually agreed to between Xenon and Ivax, and Ivax will pay Xenon for such further consulting services at an hourly rate cost equivalent to Xenon’s then-current FTE cost rate, such rate which will be agreed to between the Parties at
the relevant time(s). 

 4.2 Quarterly Reports 
 Each Calendar Quarter during the Collaborative Development Term, at or prior to the quarterly JDC meeting referenced in Section 3.3(a), each Party shall provide to the other a written progress report
in accordance with Section 3.2(a)(vi) above, which shall summarize the work performed to date on the Collaborative Development Program, evaluate the work performed in relation to the objectives of the Collaborative Development Program, and
provide such other information required by the Collaborative Development Program or reasonably requested by the JDC. For 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

23 

 
clarity, PROVIDED that such materials are in such form and format and contain such content as requested by the JDC, materials prepared by each Party for presentation at any JDC meeting (e.g.,
slide decks, GANTT charts), shall be deemed to satisfy the requirement to provide a written progress report pursuant to this Section 4.2. 

4.3 Technology Disclosure 
 Within each
quarterly report referred to in Section 4.2, or more frequently if requested by the JDC or either Party, each Party shall disclose to the other Party in writing any Collaboration IP. 
 4.4 Books and Records 
 Each Party shall maintain Books and Records in connection with its
and its Affiliates’ activities pursuant to the Collaborative Development Program. 
 4.5 Copies and Inspection of Records

 Each Party shall have the right, during normal business hours and upon reasonable notice, to inspect and copy all such records of the
other Party referred to in Section 4.4. Each Party shall maintain such records and the information disclosed therein in confidence in accordance with ARTICLE 11. The Party whose records are being inspected may elect, at its sole discretion, to
have the inspection conducted by a Third Party, mutually acceptable to both Parties. Such Third Party shall agree to comply with the applicable Confidential Information provisions of this Agreement, 

4.6 Material Transfers 
 In connection
with the Collaborative Development Program, each of the Parties may from time to time provide to the other Party or its Affiliates materials owned by or licensed to the delivering Party (such materials, “Substances”). Except as
otherwise provided under this Agreement, such Substances may be used for activities pursuant to the terms of this Agreement and no other rights in such Substances shall be conveyed by the delivering Party. All such Substances delivered shall remain
the sole property of the delivering Party. Except as otherwise authorized under this Agreement, such Substances shall not be used for any purpose other than activities pursuant to this Agreement, and shall not be used by, delivered to or used for
the benefit of, any Third Party without the prior written consent of the delivering Party, and shall not be used in research or testing of human subjects unless otherwise specified in the Collaborative Development Program. Because not all of their
characteristics may be known, the Substances supplied under this Section 4.6 must be used with prudence and appropriate caution in any experimental work. THE SUBSTANCES ARE PROVIDED “AS IS” AND WITHOUT ANY REPRESENTATION OR
WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR ANY PARTICULAR PURPOSE OR ANY WARRANTY THAT THE USE OF THE SUBSTANCES WILL NOT INFRINGE OR VIOLATE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF ANY THIRD
PARTY. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

24 

 ARTICLE 5 
 MANUFACTURE AND SUPPLY 
 5.1 Manufacturing and Supply 

Unless otherwise agreed in writing by the Parties, Ivax shall have the sole right and responsibility for, and control over, all Manufacturing of XEN402,
XEN403 and Products, at its sole cost. As of the Effective Date, the Parties agree that the active Third Party agreements related to the Manufacture of the Product for Clinical Trials sponsored by Xenon are identified in Schedule H. Xenon shall
devote all reasonable commercial efforts to obtaining the consent to assign such Third Party agreements to Ivax, and effecting the assignment of the Third Party agreements identified in Schedule H, within thirty (30) days after the Effective
Date. 
 ARTICLE 6 
 DEVELOPMENT, COMMERCIALIZATION AND CO-PROMOTION 
 6.1 Diligence—Development and
Commercialization Activities 
  

	 	(a)	Subject to Xenon’s obligations under the Collaborative Development Program pursuant to the provisions of this Agreement and the Xenon Co-Promote Option as set
forth under Section 6.3 below, as between the Parties, Ivax shall be solely responsible for the Development, Manufacture and Commercialization of Products in the Territory, at its sole cost. Ivax and Xenon, as applicable, shall devote Diligent
Efforts to the Development, Manufacture and Commercialization of Products. In accordance with Section 4.1(f) above, upon the reasonable request of Ivax, Xenon shall provide appropriate personnel to assist and consult with Ivax regarding
Ivax’s activities related to the Development, Manufacture and Commercialization of Products. 

  

	 	(b)	Ivax’s Diligent Efforts referenced in Section 6.1(a) above shall specifically include: 

 

	 	(i)	not having Ceased Development of a Product in any Major Market; provided, for clarity, [†]; and 

 

	 	(ii)	 having Completed [†] Phase II Clinical Trials, [†], each as described in the Initial Summary Collaborative Development Plan and the
Collaborative Development Plan hereunder; PROVIDED that Ivax may, in its sole discretion, cease any Clinical Trial set forth in this Section 6.1(b)(ii) if, in Ivax’s sole discretion, such Clinical Trial triggers a Safety Signal, in which
case Ivax will have no obligation to Complete the Clinical Trial that triggered such Safety Signal, however Ivax’s obligation to Complete [†] other Phase II Clinical Trials in accordance with the terms herein, using any formulation or
dosage in which such Safety Signal has not been observed, shall continue, unless the Parties agree that (A) the Safety 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

25 

	 	
Signal observed is relevant to the other remaining (not yet Completed) Phase II Clinical Trial(s) referenced above, and (B) it is probable that such Safety Signal will also be observed in
such other remaining Phase II Trial(s). 

 For purposes of the aforementioned [†] Phase II Clinical Trials,
each such Phase II Clinical Trial will be considered “Completed” on the date that Ivax completes (1) its first Data Lock for the Phase II Clinical Trial for each Product, and (2) its data analysis respecting the primary
and secondary end points established for such Clinical Trial pursuant to the Collaborative Development Plan. As used herein, “Data Lock” shall mean, [†]. Notwithstanding the foregoing sentence, if primary endpoint or safety
data for such Phase II Clinical Trial is publically disclosed, Data Lock will be deemed to have occurred with respect to such Clinical Trial. 
  

	 	(c)	For avoidance of doubt, at its discretion, Ivax may substitute a Phase III Clinical Trial for [†] the Phase II Clinical Trials referenced above.Ivax’s
responsibilities referenced in Section 6.1(a) above shall specifically include the following: 

  

	 	(i)	Ivax shall have the responsibility for the timely preparation, filing and prosecution of all filings, submissions, authorizations or approvals related to any INDs or
NDAs for the Products with Regulatory Authorities in the applicable countries, and shall own and control all such INDs, NDAs, NDA Filings, submissions, authorizations and NDA Approvals; 

 

	 	(ii)	Ivax shall be the primary contact with each applicable Regulatory Authority and shall be solely responsible for all communications with each applicable Regulatory
Authority that relate to any IND, NDA Filing, NDA, or NDA Approval for the Products; and 

  

	 	(iii)	From and after the Regulatory Document Transfer Date, Ivax shall have exclusive authority and responsibility to submit all reports or amendments necessary to maintain
any IND, NDA Filing, NDA, or NDA Approval for the Products. Without limiting the generality of the foregoing, Ivax shall have sole authority and responsibility to seek and/or obtain any necessary Regulatory Authority approvals of any Product label,
or Regulatory Authority-approved prescribing information, package inserts, monographs and packaging used in connection with a Product, as well as promotional materials and labels used in connection with a Product, and for determining whether the
same requires Regulatory Approval. 

 6.2 Ivax Reports Following the Collaborative Development Term 

Ivax shall submit to Xenon, within thirty (30) days following the expiration of each period of [†] months following the expiration of the
Collaborative Development Term and (with respect to the 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

26 

 
reports referenced in Section 6.2(a) below, in advance of each PDC meeting as referenced in Section 3.2(e) above), a written report for the applicable reporting period describing, in
reasonable detail, Ivax’s efforts, and progress made, with respect to the Development and Commercialization of Products for which Xenon is eligible for or is due Milestone Payments or Royalty Payments under this Agreement, such report(s) which
will include: 
  

	 	(a)	respecting Development activities: 

  

	 	(i)	[†]; 

  

	 	(ii)	[†]; 

  

	 	(iii)	[†]; 

  

	 	(iv)	[†]; 

  

	 	(v)	[†]; 

  

	 	(vi)	such other information that is reasonably requested by Xenon and/or that will assist Xenon in determining if Ivax has complied with its obligations under
Section 6.1 above. 

  

	 	(b)	respecting Commercialization activities: 

  

	 	(i)	[†]; 

  

	 	(ii)	[†]; 

  

	 	(iii)	[†]; 

  

	 	(iv)	[†]; 

  

	 	(v)	[†]; 

  

	 	(vi)	such other information that is reasonably requested by Xenon and/or that will assist Xenon in determining if Ivax has complied with its obligations under
Section 6.1 above. 

 For clarity, PROVIDED that such materials are in such form and format and contain such content as
requested by the PDC, materials prepared by each Party or its Affiliates for presentation at any PDC meeting (e.g., slide decks, GANTT charts) shall be deemed to satisfy the requirement to provide a written report pursuant to Section 6.2(a).
Ivax will reasonably make available to Xenon from time to time, in person at Ivax’s offices, those of its representatives who are capable of discussing and elaborating on such report(s) with Xenon. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

27 

 6.3 Xenon Co-Promote Option 
 Xenon shall have the exclusive right and option, to co-promote Products within the US, subject to the terms and conditions set out in Schedule F. 

ARTICLE 7 

CLOSING PAYMENT AND MILESTONE PAYMENTS 
 7.1 Closing Payment 
 Within two (2) Business Days (as evidenced by wire transfer
confirmation) of the execution of this Agreement by the Parties, Ivax shall pay to Xenon the sum of Forty-One Million Dollars ($41,000,000). 

7.2 Development Milestone Event and Payment 
 On the first occasion of the following events (each, a “Development Milestone Event”) Ivax shall pay to Xenon, at the time set out in Section 7.4(a), the applicable amount set
opposite such event: 
  

					
	 Development Milestone Event
	  	Payment Amount	 
	 [†]
	  	$	[†]	  
	 [†]
	  	$	[†]	  
	 [†]
	  	$	[†]	  
	 [†]
	  	$	[†]	  
	 [†]
	  	$	[†]	  

 7.3 Sales Milestone Events and Payments 
 Upon achievement of the following event (a “Sales Milestone Event”) Ivax shall pay once to Xenon at the time set out in Section 7.4(b), the amount set opposite such event:

  

					
	 Sales Milestone Event
	  	 Payment Amount
	 
	 [†]
	  	$	[†]	  

 7.4 Time of Payment 
  

	 	(a)	The amounts set out in Section 7.2 shall be paid within [†] following achievement of the respective Milestone Event. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

28 

	 	(b)	The amount set out in Section 7.3 in respect of the Sales Milestone Event shall be paid within [†] following the end of the calendar year in which the Sales
Milestone Event is achieved. 

 7.5 Affiliates and Sublicensees 
 The Milestone Payments are payable by Ivax to Xenon regardless of whether the respective Milestone Event is achieved by Ivax or its Affiliate or Sublicensee. 

ARTICLE 8 

ROYALTIES 
 8.1 Full
Royalty 
  

	 	(a)	For Products Covered by a Valid Claim and/or for Market Protected Products, Ivax shall pay to Xenon a royalty (the “Full Royalty”) on annual Net
Sales of such Products in the Territory [†], at the percentage rate set out as follows: 

  

					
	 Annual Net Sales [†]
	  	Royalty Rate	 
	 [†]
	  	 	[†]%	  
	 >[†] but £ [†]
	  	 	[†]%	  
	 >[†] but £ [†]
	  	 	[†]%	  
	 >[†]
	  	 	[†]%	  

  

	 	(b)	In Section 8.1(a) only, for purposes of determining the applicable percentage rate in the table above, (i) [†], and (ii) [†].

 8.2 Know-How Royalty 
  

	 	(a)	For Products other than (i) [†], or (ii) [†], Ivax shall pay Xenon a royalty (the “Know-How Royalty”), on annual Net
Sales of such Products in the Territory [†], at the percentage rate set out as follows: 

  

					
	 Annual Net Sales [†]
	  	Royalty Rate	 
	 [†]
	  	 	[†]%	  
	 >[†] but £ [†]
	  	 	[†]%	  
	 >[†] but £ [†]
	  	 	[†]%	  
	 >[†]
	  	 	[†]%	  

  

	 	(b)	In Section 8.2(a) only, for purposes of determining the applicable percentage rate in the table above, (i) [†], and (ii) [†]; and

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

29 

	 	(c)	[†]: 

  

	 	(i)	[†], and 

  

	 	(ii)	[†], 

 [†]. 

8.3 Generic Products 
  

	 	(a)	If, during any Calendar Quarter in which a Royalty Payment is payable, a Third Party or Third Parties sells a Product (a “Generic Product”) in a
country within the Territory, and: 

  

	 	(i)	with respect to the Product that contains the same Active Pharmaceutical Ingredient as the Generic Product and [†], or 

 

	 	(ii)	[†], 

 then the Royalty that
would otherwise be payable to Xenon by Ivax shall be reduced by [†] (the “Reduced Royalty”) for said Calendar Quarter. Ivax shall pay the Reduced Royalty [†]. For avoidance of doubt, in the event that the circumstances
described in Subsection 8.3(a)(i) and Subsection 8.3(a)(ii) are both applicable, the Royalty payable to Xenon by Ivax shall not be reduced by more than [†] by virtue of the operation of this Section 8.3(a). For purposes of this
Section 8.3, determination of [†]. 
  

	 	(b)	[†]. 

  

	 	(c)	[†]. 

 8.4 Royalty Stacking Offsets

 [†], then, in that event, the Royalty Payments payable to Xenon under this ARTICLE 8 respecting the sale of such Product in such
country to which [†]. 
 8.5 Combination Products 
  

	 	(a)	If a Product is sold in the form of a Combination Product, Net Sales of such Combination Product shall be determined by [†], PROVIDED that such fraction shall not
be a fraction less than [†]. 

  

	 	(b)	[†]. 

  

	 	(c)	[†]. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

30 

	 	(d)	For clarity, Royalty Payments will be paid on Combination Products during the applicable Royalty Term. 

 

	 	(e)	“Arbitration” shall mean arbitration by a single arbitrator pursuant to the provisions of the American Arbitration Association (AAA) expedited
proceeding rules, or any successor rules or legislation then in force. The Parties agree that the arbitrator will have the discretion to access all reasonable expenses of arbitration (including arbitration fees, expert fees, arbitration costs and
attorney’s fees) against the losing Party, and further agree that the Parties will each have the right, but not the obligation, to conduct discovery as part of such arbitration process. The place of arbitration shall be Toronto, Ontario. Any
award rendered in such arbitration may be enforced by either Party in any state, provincial or federal court with jurisdiction over the Party against whom the award is sought to be enforced. 

8.6 Limits on Royalty Reductions 

Notwithstanding the provisions of Section 8.4, the Royalty payable to Xenon shall not be reduced below [†] for Products to which the Full
Royalty is applicable and [†] for Products to which the Know-How Royalty is payable, unless [†] in which case, under no circumstances shall the Royalty payable to Xenon for Products be reduced [†]. 

8.7 Non-Monetary Consideration 
 In the
event that Ivax or any of its Sublicencees, receives any non-monetary consideration in connection with the sale or other disposition for value of Products under which Royalty Payments or Milestone Payments are applicable hereunder, including barter
or counter-trade, the Net Sales of such Product shall be calculated based on the greater of the fair market value of the Product in the country of sale or disposal or the value of such other consideration. Ivax shall disclose to Xenon the terms of
any such non-monetary consideration arrangement promptly on entering into such arrangement and the Parties shall endeavour in good faith to agree on the fair market value in monetary terms as promptly as possible. Where the Parties cannot agree upon
such fair market value within sixty (60) days of the aforementioned disclosure, the matter shall be resolved pursuant to the terms set forth in ARTICLE 13. 
 8.8 Royalty Reports; Payments 
  

	 	(a)	Within [†] days after the end of each Calendar Quarter in which a Royalty Payment is payable hereunder to Xenon, Ivax shall submit to Xenon a report on the basis
of each Product and country, providing in reasonable detail an accounting of all Net Sales made during such Calendar Quarter and the calculation of the applicable Royalty under this ARTICLE 8 including: 

 

	 	(i)	Net Sales (in U.S. dollars) of each Product in each country in the Territory during the Calendar Quarter by Ivax and each of its Affiliates and Sublicensees;

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

31 

	 	(ii)	the exchange rates used to calculate the U.S. dollar amount of such Net Sales from the currencies in which such sales were made, as provided in Section 8.11; and

  

	 	(iii)	the amount of any non-monetary consideration for Net Sales, as determined pursuant to Section 8.7. 

 

	 	(b)	Concurrently with such report, Ivax shall pay to Xenon all Royalty Payments payable by it under this ARTICLE 8 as indicated in the report. 

 

	 	(c)	True-Up: 

  

	 	(i)	Within [†] days after the end of each Year during a Royalty Term, Ivax shall perform a “true-up” reconciliation (and shall provide Xenon with a written
report of such reconciliation) of the deductions outlined in subsections (iii), (iv), and (v) in the definition of “Net Sales.” The reconciliation shall be based on actual cash paid or credits issued plus an estimate for any remaining
liabilities incurred related to the Product, but not yet paid. If the foregoing reconciliation report shows either an underpayment or an overpayment between the Parties, the Party owing payment to the other Party shall pay the amount of the
difference to the other Party within thirty (30) days after the date of delivery of such report. 

  

	 	(ii)	Within [†] months after the termination or expiration of this Agreement, Ivax shall perform a “final true-up” reconciliation (and shall provide Xenon
with a written report of such reconciliation) of the items comprising deductions from Net Sales [†] as outlined in subsection (vi) in the definition of Net Sales. The reconciliation shall be based on actual cash paid or credits issued for
returns, through the [†] period following the termination or expiration of this Agreement. If the foregoing reconciliation report shows either an underpayment or an overpayment between the Parties, the Party owing payment to the other Party
shall pay the amount of the difference to the other Party within thirty (30) days after the date of delivery of such report. 

  

	 	(iii)	In the event that any “true-up” reconciliation performed pursuant to (i) above, shows an underpayment by Ivax for such Year in an amount greater than
[†] percent ([†]%) of the total amount payable to Xenon for such Year, then Ivax shall pay to Xenon any payment owed pursuant to (i) above, together with interest calculated from the first day of the Year to which such payment
applies, in the manner provided in Section 8.12. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

32 

 8.9 Audits 
  

	 	(a)	Ivax shall keep (and shall cause each of its Affiliates and Sublicencees to keep and make available to Xenon pursuant to this Section 8.9) complete and accurate
records of the underlying data relating to the reports and payments required by this ARTICLE 8 for a period of not more than [†] years after delivery of the report setting forth such payment computation. Xenon shall have the right from time to
time (but not more often than once in each Year) at its own expense to have a reputable firm of independent accountants mutually acceptable to the Parties (PROVIDED that such accounting firm shall not be retained or compensated on a contingency
basis) review any such records in the location(s) where such records are maintained upon reasonable notice and during regular business hours and under obligations of strict confidence, for the sole purpose of verifying the basis and accuracy of
payments made under this ARTICLE 8, PROVIDED that the reports for any previous Year may not be audited more than once. Such accountants shall sign a confidentiality agreement in form and substance reasonably satisfactory to Ivax, and shall not
disclose to Xenon or any Third Party any information reasonably labeled by Ivax as being confidential customer information regarding pricing or other competitively sensitive proprietary information. Xenon shall provide Ivax with a copy of the report
or other summary of findings prepared by such accountants promptly following its receipt of same; 

  

	 	(b)	If the review of such records reveals that additional payments were owed by Ivax during such period, and Ivax agrees with such conclusion, then Ivax shall promptly pay
to Xenon any resulting amounts due under this Section 8.9, together with interest calculated in the manner provided in Section 8.12. In the event the review of such records reveals that Ivax overpaid the actual payments required by this
ARTICLE 8 during such period, and Xenon agrees with such conclusion then, Xenon shall promptly repay to Ivax any amounts of such overpayment, together with interest calculated in the manner provided in Section 8.12; PROVIDED that Ivax can
alternatively deduct such overpayment from future payments required by this ARTICLE 8 at Xenon’s option. If any amounts due under this Section 8.9 as a result of such audit are greater than [†] percent ([†]%) of the amounts
actually due for a Year, Ivax shall pay the reasonable costs of such review; and 

  

	 	(c)	If either Party in good faith disputes any conclusion of the accounting firm under this Section 8.9, including that Ivax owes additional amounts, then such Party
shall inform the other Party by written notice within thirty (30) days of receipt of a copy of the audit in question, specifying in detail such dispute. The Parties shall promptly thereafter meet and negotiate in good faith a resolution to such
dispute. In the event that the Parties are unable to resolve such dispute within sixty (60) days after such notice, the matter shall be resolved pursuant to the terms set forth in ARTICLE 13, and interest shall be payable on any disputed
amounts determined to be due in the same manner as provided for in Section 8.12. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

33 

 8.10 Tax Matters 
 Any withholding or other taxes which a paying Party is required by law to pay or withhold from royalties or other payments payable to a receiving Party under this Agreement shall be deducted from
the amount of such royalties or other payments due, and promptly paid or remitted as appropriate, by the paying Party. Any such tax required by law to be paid or withheld shall be an expense of, and borne solely by, the receiving Party. The paying
Party shall furnish the receiving Party with the best available evidence of such payment or amount withheld as soon as practicable after such payment is made or such amount is withheld. The receiving Party shall furnish the paying Party with
appropriate documents supporting application of the most favourable rate of withholding or other tax available under Applicable Law and/or tax treaties. The Parties will each, respectively, devote all reasonable efforts to ensuring that all such
taxes are paid or remitted, as appropriate, at the most favourable rate(s) proposed and adequately supported by the receiving Party. The Parties will reasonably co-operate in completing and filing documents required under the provisions of any
applicable tax laws or any other Applicable Law in connection with the making of any required tax payment or withholding payment, in connection with a claim of exemption from, or entitlement to, a reduced rate of withholding or in connection
with any claim to a refund of or credit for any such payment. 
 8.11 Currency Exchange 

All Net Sales and amounts due to Xenon hereunder shall be expressed and paid in US dollars. With respect to Net Sales invoiced in a currency other than US
dollars, the Net Sales shall be expressed in the domestic currency of the entity making the sale or incurring the expense, together with the US dollar equivalent, calculated using the average exchange rate for the purchase of US dollars over the
course of the Calendar Quarter in which Net Sales were made or the expense was incurred. Such average exchange rates for the conversion of foreign currency into US dollars will be calculated by averaging the daily closing rates published on the
internet by Reuters (or such other organization as the Parties may agree to in writing from time to time) pertaining to the relevant Calendar Quarter. All payments shall be made in US dollars in immediately available funds. 

8.12 Late Payments 
 Any payments that
are not paid on or before the date such payments are due under this Agreement shall be payable on the aggregate amount of such payment at a rate per annum equal to the lesser of the US prime rate of interest plus [†] percent ([†]%), as
reported by THE WALL STREET JOURNAL, or the highest rate of interest permitted by Applicable Law, compounded annually, and calculated on the number of days such payments are paid after the date such payments are due. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

34 

 8.13 Mode of Payment 
 Unless otherwise agreed by Xenon, all payments required to be made to Xenon under this Agreement shall be made via wire transfer to an account designated in writing in advance by Xenon. 

8.14 Bank Account 
 All payments
hereunder shall be made in United States dollars by bank wire transfer in immediately available funds to the account listed below (or such other account as Xenon shall from time to time advise Ivax in writing before such payment is due): 

Bank: 
 Royal Bank of Canada 

Bank Address: 
 Main Branch – Royal Center

 1025 W. Georgia Street 
 Vancouver BC
V5E 3N9 Canada 
 [†] 
 [†]

 8.15 Costs 
 Except as
otherwise provided in this Agreement, each Party shall bear its own costs of performing its obligations under this Agreement PROVIDED that in the event that Xenon is required to incur out-of-pocket costs in connection with providing to Ivax any
assistance that is from time to time requested by Ivax from Xenon pursuant to the terms of this Agreement in connection with the Development and Commercialization of Products in the Territory, Xenon’s obligation to provide such assistance shall
be subject to Xenon and Ivax first agreeing in writing on the amount of such out-of-pocket costs, and Ivax shall thereafter reimburse Xenon for the amount of such agreed costs within thirty (30) days of receipt of an invoice from Xenon for such
costs. 
 8.16 Sublicensees 

The Royalty Payments are payable by Ivax to Xenon regardless of whether the respective Net Sales of Products are made by Ivax or its Affiliate or
Sublicensee. 
 8.17 Post-Royalty Term 
 Following the expiration of the Royalty Term, [†]. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

35 

 8.18 No Set-Off 
 All payments required to be made by each Party to the other pursuant to this Agreement shall be made without any set-off or deduction except as expressly provided herein. 

ARTICLE 9 

LICENSES 
 9.1 Xenon
Licenses to Ivax 
 Xenon hereby grants to Ivax and its Affiliates: 

 

	 	(a)	under the Xenon Background IP an exclusive license in the Field (even as to Xenon), with the right to sublicense, within the Territory subject to Section 9.6(c)
below, to research, Develop, Manufacture, have Manufactured, market, make use, offer for sale, sell, export and import for sale, or otherwise Commercialize Products; and 

 

	 	(b)	under the Patent Rights within Xenon Background IP Covering R1150W, such Patent Rights which are described in Schedule E under the heading “Section II:
[†]”, a non-exclusive license, with the right to sublicense, within the Territory, to research, Develop, Manufacture, have Manufactured, market, make use, offer for sale, sell, export and import for sale, Diagnostic Products.

 The Parties agree that the JDC or PDC, as applicable and pursuant to the Collaboration Development Program, will
direct any Development and/or Commercialization of Diagnostic Products at Ivax’s sole expense, for example as a companion diagnostic for the Products. In the event Ivax or any of its Affiliates or Sublicensees desires to Commercialize such
Diagnostic Products for profit, prior to any such Commercialization, the Parties shall enter into good faith negotiations and agree upon a royalty rate for any such Commercialization of Diagnostic Products by Ivax, under commercially reasonable
terms for diagnostic products in the pharmaceutical industry. 
  

	 	(c)	Pursuant to Section 50(2) of the Canadian Patent Act, as applicable, from and after the Effective Date, Xenon will execute all documents necessary to apply,
register or record Ivax’s right, title and interest in Patent Rights under this Agreement in the Canadian Intellectual Property Office, the content of such document to be agreed upon by the Parties, and Xenon shall provide such cooperation at
Ivax’s cost, as Ivax may reasonably request. 

 9.2 Ivax License to Xenon 

Ivax hereby grants to Xenon and its Affiliates, under the Xenon Background IP, Ivax Background IP, Collaboration IP and Ivax Co-Promotion IP (as
applicable under part (b) herein), a co-exclusive (with Ivax) license: 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

36 

	 	(a)	to conduct Development activities pursuant to the Collaborative Development Program as set forth in the Collaborative Development Plan including any amendments to the
Collaborative Development Plan made by the JDC in accordance with the terms set forth herein; and 

  

	 	(b)	to conduct the activities set out in Schedule F respecting Products to which Xenon has exercised the Xenon Co-Promote Option. 

9.3 Sublicense Rights 
  

	 	(a)	Ivax may grant sublicenses of its licensed rights under Section 9.1 without the prior consent of Xenon, PROVIDED that: 

 

	 	(i)	Such Sublicenses contain an agreement by the Sublicensee to comply with the applicable terms and conditions of this Agreement as set out herein;

  

	 	(ii)	Ivax shall be and remain responsible for failure by its Sublicensees to comply with the terms and conditions of this Agreement, and any action or omission by such
Sublicensee that, if committed by Ivax would be a breach of this Agreement, would be deemed a breach by Ivax of this Agreement for which Ivax is responsible; 

 

	 	(iii)	Each Sublicense shall terminate upon the termination of this Agreement on a country-by-country basis; and 

 

	 	(iv)	Ivax shall give notice in writing and a copy of such Sublicense to Xenon promptly following the grant of any Sublicense, PROVIDED that Ivax may redact from such copy of
any such sublicense any financial or other information that is outside of the scope of and does not relate in any way whatsoever to the license or other rights granted to Ivax under this Agreement, or to the Milestone Payments or Royalty Payments to
which Xenon is entitled under this Agreement. 

 9.4 Negative Covenant 

Each Party covenants that neither it nor any of its Affiliates shall use or practice any of the other Party’s Intellectual Property rights licensed
to it under this Agreement except for the purposes expressly permitted in the applicable license granted under this Agreement. 
 9.5 No
Implied Licenses 
 Ivax acknowledges and agrees that it shall have no right, title or interest in or to the Xenon Background IP except for
the rights expressly set forth in this Agreement. Xenon acknowledges and agrees that it shall have no right, title or interest in or to the Ivax Background IP or Collaboration IP except for the rights expressly set forth in this Agreement. Nothing
in this Agreement shall be construed to grant to either Party or its Affiliates any rights or license to any Intellectual Property of the other Party or the other Party’s Affiliates other than the licenses expressly set forth in this Agreement.

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

37 

 9.6 [†] Considerations respecting XEN403 

 

	 	(a)	[†]: 

  

	 	(i)	[†], and 

  

	 	(ii)	[†] 

 [†]. 

 

	 	(b)	[†]. 

  

	 	(c)	[†]. 

  

	 	(d)	[†]: 

  

	 	(i)	[†]; 

  

	 	(ii)	[†]; 

  

	 	(iii)	[†]; and 

  

	 	(iv)	[†]. 

  

	 	(e)	[†]. 

 9.7 [†] Considerations
respecting XEN402 
 The Parties hereto expressly confirm and agree as follows: 

 

	 	(a)	[†]. 

  

	 	(b)	[†]. 

  

	 	(c)	[†]. 

  

	 	(d)	[†]: 

  

	 	(i)	[†]; 

  

	 	(ii)	[†]. 

  

	 	(iii)	[†]. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

38 

	 	(iv)	[†]. 

  

	 	(v)	[†]. 

  

	 	(vi)	[†]. 

  

	 	(vii)	[†]. 

 ARTICLE 10

 INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION AND ENFORCEMENT 

10.1 Ownership of Intellectual Property 
  

	 	(a)	The determination of whether Intellectual Property is conceived, discovered, developed, or otherwise made by a Party or its Affiliates for the purpose of allocating
proprietary rights therein (including inventorship of Patent Rights), shall, for purposes of this Agreement be determined in accordance with the Applicable Law of [†] as of the Effective Date irrespective of where such conception, discovery,
development or making occurs. 

  

	 	(b)	Subject to the terms and conditions set forth in this Agreement: 

  

	 	(i)	As between the Parties, Ivax shall own and retain all right, title, and interest in and to any and all (1) Ivax Background IP, (2) [†], and
(3) [†]; 

  

	 	(ii)	as between the Parties, Xenon shall own and retain all right, title, and interest in and to any and all (1) Xenon Background IP, and (2) [†]; and

  

	 	(iii)	[†]. As used herein, “Joint Collaboration IP” means any and all Collaboration IP that is conceived, identified, or first made
jointly by or on behalf of Ivax (either alone or with its Affiliates or Sublicensees or Third Parties) on the one hand, and by or on behalf of Xenon (either alone or with its Affiliates or subcontractors) on the other hand and “Joint
Patent Rights” means the Patent Rights under Joint Collaboration IP. Xenon shall promptly disclose to Ivax in writing the development, making, conception or reduction to practice of any Joint Collaboration IP.

  

	 	(c)	Subject to the licenses granted by one Party to the other and/or as otherwise specifically provided under this Agreement, each Party retains full ownership rights
(including as provided under 35 U.S.C. Section 262) in and to such Intellectual Property described in Section 10.1(b)(i) and (b)(ii) above, and including the right to license and sublicense, and to freely exploit, transfer or encumber its
ownership interest without the consent of, or payment or account to the other Party or its Affiliates. Each Party hereby waives any right it may have under the laws of any jurisdiction to request such payment, accounting or consent with respect to
such Intellectual Property. [†]. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

39 

	 	(d)	Each Party shall require all of its employees, contractors, agents, and any other Person including its Affiliates working on its behalf (and their respective employees,
contractors and agents) [†]. 

  

	 	(e)	The Parties shall cooperate with each other to effectuate ownership of any such Intellectual Property as set forth in this Agreement, including, but not limited to,
executing and recording documents associated herewith. 

  

	 	(f)	Ivax shall have the sole right to reference any Intellectual Property with respect to the Products to Regulatory Authorities in the Territory, including Xenon
Background IP, Ivax Background IP, and Collaboration IP, including in connection with NDA Filings or NDA Approvals, and the Approved Drug Products with Therapeutic Equivalence Evaluations (“Orange Book”) or other international
equivalents. Xenon shall cooperate with Ivax’s reasonable requests in connection therewith, including meeting any submission deadlines to the extent required or permitted by Applicable Law or Regulations. 

 

	 	(g)	Upon receiving Regulatory Approval for a Product in any country in the Territory or upon such earlier timeframe as may be applicable under the circumstances, the
Parties shall coordinate the application(s) for any patent term extension or supplementary protection certificates that may be available, and Ivax shall determine for which patent(s) it shall apply for patent term extension for a particular Product
in the Territory. Notwithstanding anything to the contrary in this Section or Section 10.3 below[†]. While Ivax shall have the primary responsibility of applying for any extension or supplementary protection certificate in the Territory,
Xenon shall provide prompt and reasonable assistance, as requested by Ivax, including by taking such action as a patent assignee as is required under any Applicable Law to obtain such patent extension or supplementary protection certificate. Ivax
shall pay all expenses in regard to obtaining the extension or supplementary protection certificate in the Territory. 

 10.2
Prosecution and Maintenance of Ivax Background IP 
 Ivax shall have the sole right but not obligation, in its discretion, to prepare, file,
prosecute and maintain all Ivax Background IP in the Territory, with patent counsel of its choice, including initiating interferences, re-examinations, reissues, oppositions, revocation actions and the like, and gaining patent term restorations,
supplemental protection certificates or their equivalents, and patent term extensions with respect thereto. Ivax shall bear the cost of such prosecution and maintenance. 
 10.3 Prosecution and Maintenance of Collaboration IP and Xenon Background IP 
  

	 	(a)	 During the Term, Ivax shall have the right and final authority, but not the obligation, to prepare, file, prosecute, maintain and control Patent Rights
Covering Xenon Background IP and Collaboration IP in the Territory (except for 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

40 

	 	
the Patent Rights within Xenon Background IP Covering R1150W, that are described in Schedule E, Section II), with patent counsel of its choice, including initiating interferences,
re-examinations, reissues, oppositions, revocation actions and the like, and gaining patent term adjustments or restorations, supplemental protection certificates or their equivalents, and patent term extensions with respect thereto (“Patent
Prosecution”), on the following terms: 

  

	 	(i)	Ivax shall keep Xenon informed of all material matters with regard to Patent Prosecution of such Patents Rights, including its choice of patent counsel and the scope
and progress of Patent Prosecution of the Collaboration Patent Rights and Xenon Background Patent Rights licensed hereunder; 

  

	 	(ii)	Ivax shall provide Xenon with copies of all material correspondence, submissions and documentation to and from any patent authority in the Territory pertaining to such
Patent Rights, and shall provide Xenon drafts of any material filings or responses to be made to such patent authorities in the Territory sufficiently in advance of submitting such filings to allow Xenon to review and comment on such drafts, and
Ivax will, in good faith, consider and not unreasonably reject Xenon’s comments and/or recommendations respecting same; 

  

	 	(iii)	Ivax shall provide to Xenon, so often as reasonably requested, written reports listing the jurisdictions for Patent Prosecution; 

 

	 	(iv)	Xenon shall make its employees (including inventors employed by Xenon), agents, and consultants, reasonably available to Ivax (or to its authorized attorneys, agents or
representatives), to the extent reasonably necessary to enable Ivax to undertake Patent Prosecution and otherwise cooperate with and assist Ivax with respect to Patent Prosecution matters and effectuate the ownership of Intellectual Property as set
forth in this ARTICLE 10, and will also make available to Ivax such copies of material correspondence with patent offices in the Territory that may be requested by Ivax that are in Xenon’s possession respecting applications for Patent Rights
relating to Xenon Background IP. Further, in accordance with Section 4.1(f) Xenon will provide such further information, documents and consultation that may be reasonably requested by Ivax; and 

 

	 	(v)	Except as provided in Section 10.3(c), Ivax shall bear the cost of all matters pertaining to Patent Prosecution of such Patent Rights. 

 

	 	(b)	 Ivax shall have the right to cease Patent Prosecution of any Patent Rights covering any Xenon Background IP or Collaboration IP anywhere in the
Territory, with the exception of any such Patent Rights respecting which[†], without Xenon’s consent, not to be unreasonably withheld. Subject to the foregoing, Ivax shall give

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

41 

	 	
Xenon notice in writing of any determination by Ivax to cease Patent Prosecution of any (other) Patent Rights Covering any Xenon Background IP or Collaboration IP anywhere in the Territory. To
the extent possible, such notice shall be given sixty (60) days, or if not possible, as soon as practicable (but in any event at least ten (10) Business Days) prior to the next deadline of any action required by Applicable Law or by an
officer with authority and jurisdiction in any country where such Patent Right is being prosecuted or maintained. For clarification, a determination by Ivax to (i) abandon a patent application in favour of a continuation or divisional
application or the like, or (ii) to narrow the scope of the claimed subject matter, shall not be deemed a determination to cease such Patent Prosecution, unless such action (i) or (ii) [†], in which case Ivax does not have the
right to take such action(s) without Xenon’s consent, not to be unreasonably withheld. 

  

	 	(c)	Upon receipt of a notice from Ivax pursuant to Section 10.3(b), Xenon shall have the right, exercisable by notice in writing to Ivax within forty-five
(45) days of receipt of such notice, to assume responsibility, at Xenon’s sole cost, for the Patent Prosecution of such Patent Rights (the “Xenon Prosecution Notice”), PROVIDED that Xenon shall not knowingly take any
action with respect to such Patent Rights that Xenon (acting reasonably) should expect could have an adverse effect on Ivax’s rights under this Agreement. Upon receipt of such Xenon Prosecution Notice, Ivax shall forthwith deliver to Xenon all
information and documentation relevant to such Patent Prosecution and shall execute all documents as may be reasonably required by Xenon to assume responsibility for same. With respect to any such Patent Rights for which Xenon assumes responsibility
for Patent Prosecution under such Xenon Prosecution Notice, such Patent Rights shall continue to constitute Xenon Background Patent Rights or Collaboration Patent Rights, as applicable, for all purposes under this Agreement for so long as such
Patent Rights Cover a Product in the applicable jurisdiction; PROVIDED that, without further action by either of the Parties, as of the date that Xenon assumes such responsibility for Patent Prosecution of any such Patent Rights that Cover a
Product, Ivax shall be deemed to have granted to Xenon a non-exclusive fully-paid-up perpetual license or license-back (as applicable) in and to such Patent Rights in the applicable jurisdiction, and FURTHER PROVIDED that in the event that such
Patent Rights do not Cover a Product in the applicable jurisdiction, Ivax shall assign its interest in any such Patent Rights to Xenon. For any such Patent Rights that Xenon elects to file, prosecute and maintain pursuant to this
Section 10.3(c), Xenon agrees to keep Ivax fully informed of all material matters with regard to such Patent Prosecution relating thereto, unless such Patent Rights are assigned to Xenon pursuant to this Section 10.3(c). Xenon shall give
Ivax a reasonable opportunity to provide comments on any and all filings or material responses relating to such Patent Prosecution, and Xenon shall, in good faith, give reasonable consideration to all suggestions and recommendations of Ivax with
respect to such filings or responses. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

42 

 10.4 Prosecution and Maintenance of Xenon’s Background IP Patent Rights Covering
R1150W 
  

	 	(a)	Xenon shall have the right and final authority, but not the obligation, to prepare, file, prosecute, maintain and control Patents Rights in Xenon Background IP Covering
only R1150W in the Territory (such Patent Rights which are identified in Schedule E, Section II), with patent counsel of its choice. Xenon shall bear the cost of such Patent Prosecution. 

 

	 	(b)	Xenon shall not cease Patent Prosecution of any Patent Right Covering any Xenon Background IP Covering R1150W except with Ivax’s prior written consent, such
consent which will not be unreasonably withheld. 

 10.5 Infringement by Third Parties 

 

	 	(a)	If any Collaboration IP or Xenon Background IP is infringed or misappropriated, as the case may be, by a Third Party, the Party to this Agreement first having knowledge
of such infringement or misappropriation, or knowledge of a reasonable probability of such infringement or misappropriation, shall promptly notify the other in writing. The notice shall set forth the facts of such infringement or misappropriation in
reasonable detail. 

  

	 	(b)	Ivax shall have the first right, but not the obligation, to institute, prosecute, and control with its own counsel any action or other proceeding in the Territory with
respect to infringement or misappropriation of Collaboration IP or Xenon Background IP. Xenon shall agree to be named as necessary for Ivax to bring and conduct such action, and Ivax shall provide Xenon with reasonable notice of any such action it
commences, consider all Xenon’s reasonable comments thereto in good faith, seek to accommodate such comments in initiating, conducting and/or prosecuting such action, and keep Xenon reasonably informed of any significant developments in such
action. Xenon shall render, at Ivax’s expense, all reasonable assistance as requested by Ivax in connection with any such action initiated, conducted or prosecuted by Ivax. In any such action, Xenon may, at its election and sole expense, be
represented by counsel of its own choosing, provided, however, that the control of such action, including whether to initiate any legal proceeding, what strategies to pursue or actions to take in prosecution of any such legal proceeding, and/or the
settlement thereof, shall solely be under the control of Ivax. Ivax shall not settle any such action, claim or proceeding brought by Ivax in a manner that Ivax should reasonably expect could have an adverse effect on Xenon’s rights under this
Agreement or any Xenon Background Patent Rights, or could result in a monetary payment greater than that which a biotechnology company of reasonably similar size to Xenon would consider a de minimis monetary payment by or financial loss to
Xenon or which would subject Xenon to any form of injunctive or equitable relief, without Xenon’s prior written consent, which shall not be unreasonably withheld. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

43 

	 	(c)	If Ivax fails to take commercially reasonable efforts to institute, prosecute, and control such action, or proceeding (i) within a period of [†] days after
receiving notice of the infringement or misappropriation under Section 10.5(a), or (ii) within a period of [†] days after an initial commercial sale of an infringing or misappropriated Product by such Third Party; or
(iii) provided such date occurs after the first such notice of infringement or misappropriation is provided, [†] Business Days before the time limit, if any, set forth in appropriate laws and regulations for filing of such action or
proceeding, whichever comes last, Xenon’s sole remedy for such failure shall be to have the right, at its own expense, to bring and control such action or proceeding by counsel of its own choice, and, in such case, Ivax shall have the right, at
its own expense, to join as a party to such action or proceeding and be represented in same by counsel of its own choice. Xenon shall not settle any such claim or proceeding in a manner that Xenon should reasonably expect could have an adverse
effect on Ivax’s rights under this Agreement, or could result in more than a de minimis monetary payment by or financial loss to Ivax or which would subject Ivax to any form of injunctive or equitable relief, without Ivax’s prior
written consent, which shall not be unreasonably withheld 

  

	 	(d)	The Party prosecuting the action or proceeding has the right to join the other Party as plaintiff as necessary for the prosecuting Party to bring and conduct such
action and, in case of joining, the other Party agrees to give the first Party reasonable assistance and authority to file and to prosecute same. 

  

	 	(e)	The proceeds of any award of damages or settlement respecting such actions or proceedings shall be applied as follows: 

 

	 	(i)	the Party that initiated, conducted, prosecuted, defended, maintained and/or controlled the action shall recoup all of its costs and expenses (including reasonable
outside attorneys’ fees) incurred in connection with the action, whether the recovery is by settlement or otherwise; 

  

	 	(ii)	the other Party then shall, to the extent possible, recover its reasonably documented costs and expenses (including reasonable outside attorneys’ fees) incurred in
connection with the action, to the extent not previously reimbursed or paid by the prosecuting Party; 

  

	 	(iii)	[†]; and 

  

	 	(iv)	[†]. 

  

	 	(f)	 If any Third Party alleges invalidity, non-infringement, or unenforceability of any Collaboration IP or Xenon Background IP, including by declaratory
judgment or as a defense or counterclaim, in any action to which either Party or both Parties or their respective Affiliates is a party (an “Invalidity Claim”), then the Party

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

44 

	 	
having knowledge of such Invalidity Claim shall give notice thereof to the other Party, and the Parties shall promptly discuss the matter and seek to agree on the course of action to respond to
such Invalidity Claim. Unless the Parties otherwise agree, Ivax shall have the initial right, in its discretion, to respond to and defend against any such Invalidity Claim, regardless of whether Ivax is initially a Party to such action, PROVIDED
that Ivax will consult reasonably with Xenon as to all such defense against the Invalidity Claim and shall consider in good faith all reasonable comments of Xenon with respect thereto. If Ivax does not respond to or defend against any such
Invalidity Claim, Xenon shall have the right, in its discretion and subject to Ivax’s prior written consent, which shall not be unreasonably withheld, to respond to and defend against any such Invalidity Claim, PROVIDED that Xenon will consult
reasonably with Ivax as to all such defense against the Invalidity Claim and shall consider in good faith all reasonable comments of Ivax with respect thereto. 

 

	 	(g)	The terms of subsections 10.5(a), (b), (c), (d) and (e) above shall not apply to the [†] circumstances set forth in Section 9.7 above.

 10.6 Third Party Claims 
  

	 	(a)	In the event that a Third Party shall make any claim, demand, investigation, suit or bring any other proceeding alleging infringement or misappropriation of any
Intellectual Property against Xenon or Ivax or their respective Affiliates, Sublicensees or customers with respect to the research Development, Manufacture, marketing, using, offering for sale, sale, import or export for sale or any other
Commercialization of Products hereunder (each a “Third Party Claim”), the Party first having notice of a Third Party Claim shall promptly notify the other in writing. The notice shall set forth the facts of the Third
Party Claim in reasonable detail. 

  

	 	(b)	 In the event of a Third Party Claim against Ivax, Xenon, or any of their respective Affiliates, Sublicensees or customers, for infringement or
misappropriation of any Intellectual Property with respect to the research, Development, Manufacture, marketing, using, offering for sale, sale, import or export for sale or any other Commercialization of Products hereunder, Ivax shall have the
right, but not the obligation, to defend and control the defense of such Third Party Claim as well as to initiate and control any counterclaim or other similar action. In the event Xenon is a named defendant in such Third Party Claim or joined as a
party by Ivax, Xenon may, at its election and sole expense, be represented in such Third Party Claim by counsel of its own choosing. Xenon shall fully cooperate with Ivax in defense of such Third Party Claim, including by being joined as a party and
rendering all assistance reasonably requested in connection with any action taken by Ivax, at Ivax’s expense. If Ivax elects (in a written notice delivered to Xenon within a reasonable amount of time after notice of such Third Party Claim) not
to defend or control the defense of, or if Ivax otherwise fails to initiate and 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

45 

	 	
maintain the defense of, any such Third Party Claim, within such time periods so that Xenon is not materially prejudiced by any delays, Xenon may conduct and control the defense of any such Third
Party Claim at its own expense, PROVIDED that Xenon shall obtain the written consent of Ivax prior to ceasing to defend, settling or otherwise compromising such claims in a manner that is adverse to Ivax’s interests under this Agreement, such
consent not to be unreasonably withheld. Each Party shall keep the other Party reasonably informed of all material developments in connection with any such claim, suit, or proceeding, and shall not settle any such claim or proceeding in a manner
that likely will materially adversely affect the other Party’s rights under this Agreement or which results in a monetary payment by or financial loss to the other Party or which would subject the other Party to any form of injunctive or
equitable relief, without the other Party’s written consent, which consent shall not be unreasonably withheld. 

 10.7
Cooperation in Intellectual Property Infringement Proceedings 
 In the event that either Ivax or Xenon takes action pursuant to
Section 10.5 or 10.6 (in such capacity, the “Acting Party”), the other Party shall cooperate to the extent reasonably necessary and at the Acting Party’s sole expense (other than as specifically set forth in Sections 10.5
and 10.6). Such cooperation shall include, without limitation, providing information, documents, witnesses and consultation to the Acting Party, PROVIDED that such cooperation shall not include the obligation to assert any Patent Rights or other
Intellectual Property rights Controlled by the other Party that are not licensed pursuant to this Agreement, or allow the Acting Party to assert any of the same except as otherwise expressly provided in this Agreement. 

10.8 Settlement 
 The Party controlling
any such action or proceeding described in Section 10.5 or 10.6 may not settle or consent to an adverse judgment, including any judgment which affects the scope, validity or enforcement of any Patent Right within the Collaboration IP or Xenon
Background IP, without the express written consent of the non-controlling Party (such consent not to be unreasonably withheld or delayed), except that Ivax or Xenon may each settle or consent to an adverse judgment in any action described in
Section 10.5 or 10.6 without obtaining consent from the other Party unless any such settlement or consent judgment would either (i) impose a financial obligation upon the other Party or its Affiliates, or (ii) admit liability
on behalf of the other Party or its Affiliates, or (iii) limit the scope of or invalidate any Patent Right within the Collaboration IP or Xenon Background IP. 
 10.9 Data Exclusivity 
 Ivax shall devote Diligent Efforts to obtaining and controlling, at
its own expense, applicable data/marketing exclusivity rights with respect to regulatory filings (including clinical, safety and efficacy data) for Market Protected Products, including defense and enforcement of rights against Third Parties seeking
marketing authorization approval from a regulatory agency 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

46 

 
(including the FDA, EMA or equivalent) based on such filings. Such rights shall specifically include the right to take action in connection with Third Party applications for marketing
authorization for Generic Products that reference any Product pursuant to Title VII of the US Patient Protection and Affordable Care Act, the Hatch-Waxman Act, EU Directive 2004/27/EC and any successor legislation or regulations relating thereto,
and all similar foreign legislation with regard to the foregoing. 
 10.10 Trademarks 

Subject to the Xenon Co-Promote Option as set forth under Section 6.3 above, Ivax shall have the right to brand any and all Products owned or
Controlled by Ivax using any words, names, symbols, colors, designations or any combinations thereof that function as source identifiers, including any trademarks, trade dress, brand marks, service marks, trade names, brand names, logos or business
symbols, as Ivax, in its sole discretion, deems appropriate for Products, which may vary by country or within a country (“Product Marks”). As between the Parties, Ivax shall own all rights in the Product Marks and shall register and
maintain Product Marks in the countries and regions it determines reasonably necessary. Xenon shall provide all assistance and documents reasonably requested by Ivax in support of the registration and maintenance of the Product trademarks. Except as
expressly set forth in this Agreement, neither Party or its Affiliates grants the other Party or its Affiliates any rights in such Party’s trademarks, trade dress, brand marks, service marks, trade names, brand names, logos or business
symbols. 
 ARTICLE 11 
 CONFIDENTIALITY 
 11.1 Confidential Information 

Subject to the provisions of Section 11.2, all Confidential Information disclosed by a Party or its Affiliates to the other Party or its Affiliates
during the Term shall not be used by the receiving Party except in connection with the activities contemplated by this Agreement or in order to further the purposes of this Agreement, shall be maintained in confidence by the receiving Party and
shall not otherwise be disclosed by the receiving Party to any Third Party or to any Affiliate of the receiving Party, without the prior written consent of the disclosing Party. 
 11.2 Exceptions 
  

	 	(a)	The provisions of Section 11.1 shall not preclude the receiving Party from disclosing Confidential Information of the other Party: 

 

	 	(i)	To the extent such Confidential Information is required to be disclosed to governmental or other Regulatory Authorities in order to obtain patents pursuant to this
Agreement, or to gain approval to conduct Clinical Trials or to Commercialize Product, but such disclosure may be only to the extent reasonably necessary to obtain such patents or authorizations and in accordance with the terms of this Agreement or
as otherwise requested by the Regulatory Authorities; 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

47 

	 	(ii)	To its agents, consultants, Sublicensees or Affiliates in connection with the Development, Manufacturing or Commercialization of a Product, or to otherwise enable the
Party to fulfill its obligations and responsibilities under this Agreement, on the condition that such entities agree to be bound by confidentiality obligations consistent with this Agreement; or 

 

	 	(iii)	If required to be disclosed by Applicable Law or court order, PROVIDED that notice is promptly delivered to the non-disclosing Party in order to provide an opportunity
to challenge or limit the disclosure obligations. 

  

	 	(b)	Specific information shall not be deemed to be within any of the foregoing exclusions merely because it is embraced by more general information falling within these
exclusions. 

 11.3 Certain Disclosures 
  

	 	(a)	The Parties agree to develop and distribute a joint press release upon execution of this Agreement by the Parties. Except as set forth in this Agreement or as required
by Applicable Law, neither Party shall make any press release or other public announcement or other disclosure to a Third Party concerning the existence of or terms of this Agreement, the subject matter of this Agreement or the activities
contemplated hereunder, without the prior written consent of the other Party, which consent shall include agreement upon the nature and text of such release, announcement or other disclosure and shall not be unreasonably withheld or delayed. Each
Party agrees to provide to the other Party a copy of any such press release or other public announcement or disclosure as soon as reasonably practicable under the circumstances prior to its scheduled release. Each Party shall have the right to
expeditiously (but in any event within [†] review and recommend changes to any such press release or other public announcement or disclosure; PROVIDED that such right of review and recommendation shall only apply for the first time that
specific information is to be disclosed, shall not apply to legally required disclosures (provided that the disclosing Party shall give the other Party reasonable advance notice of same and the other Party shall have the right to provide its
comments), and shall not apply to the subsequent disclosure of substantially similar information that has previously been disclosed unless there have been material developments relating to the Products since the date of the previous disclosure;
PROVIDED, further, that each Party shall provide to the other Party reasonable advance notice of any such subsequent disclosure. 

  

	 	(b)	 Without limiting the generality of Subsection 11.3(a) above, it is understood that the Parties may make disclosure of this Agreement and the terms
hereof in any filings required by the SEC, other governmental authority, or securities exchange, 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

48 

	 	
or as otherwise required by Applicable Law, may file this Agreement as an exhibit to any filing with the SEC, other governmental authority, or securities exchange, and may distribute any such
filing in the ordinary course of its business, PROVIDED, further, that to the maximum extent allowable by the rules and regulations of the SEC, other governmental authority, or securities exchange, and except as required by Applicable Law, Xenon and
Ivax each shall seek to redact any Confidential Information set forth in such filings, and each Party shall provide a draft of the redacted version of this Agreement to the other Party no less than [†] prior to filing with the SEC, other
governmental authority, or securities exchange, and give reasonable consideration to the other Party’s comments regarding any proposed redaction. Further, a Party may disclose this Agreement and the terms hereof in confidence to its existing
directors, officers, employees, investors and service providers, and to bona fide prospective investors, merger partners, strategic partners, or acquirors and their respective professional advisors in connection with the negotiation, entry into
and/or performance of a business transaction between such parties, including the conduct of due diligence involved in such transaction, provided such Persons agree to be bound by (i) written confidentiality agreements typical for such
transactions, or (ii) with respect to attorneys, applicable ethical obligations. 

 11.4 Publications 

If either Party decides that public presentation or publication of certain Confidential Information or other information arising under this
Agreement is desirable, including presentation or publication of the results of Development activities (including initiation of and results from Clinical Trials) and/or receipt of Regulatory Approval pertaining to a Product (such information which
is hereinafter referred to as a “Disclosure”), such Party shall submit a request to make the Disclosure to the JDC or PDC or Ivax following the dissolution of the PDC (as applicable), which shall have the sole authority to authorize
the Disclosure by the Party. 
 11.5 Employee and Advisor Obligations 
 Xenon and Ivax each agree that they shall provide Confidential Information received from the other Party only to their respective employees, consultants, agents and advisors, or to their Affiliates’
employees, consultants, agents and advisors, who have a need to know such Confidential Information to assist such Party in fulfilling its obligations under this Agreement, PROVIDED that such employees, consultants, agents and advisors (i) have
agreed, in writing, to treat such information and materials as confidential, (ii) have existing written agreements with such Party, or (iii) are subject to written corporate rules of the Party, that obligate each of the same to treat such
information and materials as confidential, and copies of such written agreements are promptly provided to the other Party at such other Party’s request. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

49 

 11.6 Term of Confidentiality 
 All obligations of confidentiality imposed under this ARTICLE 11 shall expire [†] years following termination or expiration of this Agreement. 

ARTICLE 12 

TERM AND TERMINATION 

12.1 Term 
 The term of the Agreement
(the “Term”) commences on the Effective Date and, unless earlier terminated pursuant to the provisions of this ARTICLE 12, will continue until the expiration of all payment obligations to Xenon respecting Products hereunder.

 12.2 Bankruptcy, Dissolution and Winding Up 
  

	 	(a)	This Agreement shall terminate forthwith at the election of the Party not involved in the Insolvency Proceeding upon the delivery of notice (in accordance with the
terms of this Agreement) to the Party which is involved in the Insolvency Proceeding 

  

	 	(i)	If an Insolvency Proceeding is commenced by any Party, or if any Party: (1) becomes insolvent, becomes unable to pay its indebtedness or meet its liabilities as
the same become due, admits in writing its inability to pay its indebtedness generally, declares any general moratorium on its indebtedness, proposes a compromise or arrangement between it and any class of its creditors, or commits an act of
bankruptcy under the BIA, (2) threatens to take any of actions described in this Section 12.2(a)(i), (3) takes any action, corporate or otherwise, to approve, effect, consent to, or authorize any of the actions described in this
Section 12.2(a)(i), or (4) otherwise acts in furtherance of, or fails to act in a timely and appropriate manner in defense of, any of the actions described in this Section 12.2(a)(i). 

 

	 	(ii)	If an Insolvency Proceeding is commenced against a Party and any of the following events occur: (a) such Party consents to the commencement of such Insolvency
Proceeding against it, (b) the case, action, application, petition, or other proceeding commencing the Insolvency Proceeding is not timely controverted by the Party, or (c) the case, action, application, petition, or other proceeding
commencing the Insolvency Proceeding continues undismissed, or unstayed and in effect for a period of thirty (30) Business Days after the commencement thereof. 

 

	 	(iii)	If any other event occurs which, under the laws of any applicable jurisdiction, has an effect on any Party equivalent or with similar effect to any of the events
referred to in either Section 12.2(a)(i), or Section 12.2(a)(ii). 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

50 

	 	(b)	All rights and licenses granted under or pursuant to this Agreement by the Parties are, and shall otherwise be deemed to be: (i) the grant of rights to use
Intellectual Property under s. 65.11(7) of the BIA and s. 32(6) of the CCAA, and (ii) for purposes of Section 365(n) of the U.S. Bankruptcy Code, or any analogous provisions in any other country or jurisdiction, licenses of rights to
“intellectual property” as defined under Section 101 of the U.S. Bankruptcy Code. The Parties agree that the Parties, as licensees of such rights under this Agreement, shall retain and may fully exercise all of their rights and
elections under Insolvency Laws, the U.S. Bankruptcy Code, or any analogous provisions in any other country or jurisdiction. The Parties further agree that, in the event of the commencement of any Insolvency Proceeding by or against any Party
under any Insolvency Laws, the U.S. Bankruptcy Code, or any analogous provisions in any other country or jurisdiction, the Party hereto that is not a Party to such proceeding shall be entitled to a complete duplicate of (or complete access to, as
appropriate) any such Intellectual Property and all embodiments of such intellectual property, which, if not already in the non-subject Party’s possession, shall be promptly delivered to it (i) upon any such commencement of such Insolvency
Proceeding upon the non-subject Party’s written request therefor, unless the Party subject to such proceeding elects to continue to perform all of its obligations under this Agreement, or (ii) if not delivered under clause (i) above,
following the rejection of this Agreement by or on behalf of the Party subject to such proceeding upon written request therefor by the non-subject Party. 

 12.3 Termination by the Parties 
  

	 	(a)	By Either Party. This Agreement may be terminated by either Party in its entirety, on a Product-by-Product basis, and/or on a country-by-country basis, in the
event of: 

  

	 	(i)	An unremedied material breach by the other Party or the other Party’s Affiliates, in accordance with the provisions of Section 12.4; or

  

	 	(ii)	A mutual written agreement between the Parties. 

  

	 	(b)	By Ivax. This Agreement may be terminated by Ivax: 

  

	 	(i)	Provided that Ivax, utilizing Diligent Efforts as set out in Section 6.1, has Completed each of the three (3) Phase II Clinical Trials in accordance with
Section 6.1(b) (such date and time which shall hereinafter be referred to as the “Decision Point”), and Ivax in good faith determines that the results of such Development activities do not warrant further Product Development
under the terms and conditions of this Agreement after the Decision Point Ivax may terminate the Agreement in its entirety upon delivery of sixty (60) days advance notice to Xenon; or 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

51 

	 	(ii)	Notwithstanding Section 12.3(b)(i), in the event of any safety or efficacy issues attributable to the Products that are raised during the Development activities
that Ivax in good faith, having devoted Diligent Efforts to resolving such issues, decides to abandon Development of the Products under the terms and conditions of this Agreement, Ivax may terminate the Agreement on a Product-by-Product basis, upon
delivery of sixty (60) days advance notice to Xenon. 

 12.4 Termination for Breach 

 

	 	(a)	Upon a material breach of a representation, warranty or a material obligation of this Agreement by a Party or its Affiliates (in such capacity, the “Breaching
Party”), the other Party (in such capacity, the “Non-Breaching Party”) may provide written notice (a “Breach Notice”) to the Breaching Party specifying the material
breach. For the purposes of this Section 12.4, a material breach includes, but is not limited to, the following: 

  

	 	(i)	Ivax’s failure to pay any amount owing to Xenon pursuant to ARTICLE 7 or ARTICLE 8, PROVIDED that Xenon first provides written notice of such failure to Ivax, and
Ivax does not remedy such failure within thirty (30) Business Days from the delivery of the written notice; or 

  

	 	(ii)	Ivax’s failure to comply with the Product Development obligations specifically set forth in Section 6.1, or 

 

	 	(iii)	Ivax’s failure to comply with the Product Commercialization obligations specifically set forth in Section 6.1, 

(unless with respect to Subsection (ii) above, Ivax is prevented from complying with such obligations as a result of Applicable Law
or Force Majeure (as defined in Section 16.7), in which event(s) the timelines set forth in such provisions shall automatically be extended for a period of time equivalent to the length of time that such events preventing such compliance were
in effect (or such other timeframe as may be agreed to between the Parties under the circumstances)). 
  

	 	(b)	For clarity, for purposes of this Section 12.4, a material breach does not include [†]. 

 

	 	(c)	If: 

  

	 	(i)	the Breaching Party fails to cure such material breach during a ninety (90) day period (or, if such material breach, by its nature, is a curable breach that the
Parties agree is not curable within that ninety (90) day period, then within such longer period as would be reasonably necessary for a diligent party to cure such material breach) following the date on which the Breach Notice is provided; or

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

52 

	 	(ii)	such material breach, by its nature, is incurable; 

 then the Agreement shall terminate, at the option of the Non-Breaching Party, in its entirety, on a Product-by-Product basis and/or on a country-by-country basis, upon written notice to the Breaching
Party with immediate effect and without prejudice to the accrued rights of either Party, PROVIDED that if there is a dispute as to whether a material breach has been cured or is incurable, such matter shall be first referred for resolution pursuant
to ARTICLE 13 and termination shall be stayed pending resolution of such proceedings, and PROVIDED further that in the event of a termination by Xenon under Section 12.4(a)(ii), subject to Ivax’s compliance with Section 12.5 below,
such termination shall be Xenon’s sole remedy. 
  

	 	(d)	Subject to Section 12.5, no payment or agreement to pay under this Agreement shall in any way preclude or limit the rights of either Party to seek the full
recovery of its damages or to seek equitable relief for breach of this Agreement by the other Party. 

 12.5 Events and
Restrictions Following Termination 
  

	 	(a)	In the event of the termination of this Agreement pursuant to Sections 12.3(b) or 12.4 in its entirety, Ivax under Section 12.3(b) and the Breaching Party under
Section 12.4 shall not thereafter: 

  

	 	(i)	research, Develop, Manufacture, have Manufactured, market, use, offer to sell, sell, export or import for sale, or otherwise Commercialize any Product under the Xenon
Background IP or Collaboration IP, 

  

	 	(ii)	assign or otherwise transfer of grant any interest in Xenon Background IP or Collaboration IP to any Third Party, or 

 

	 	(iii)	grant a sublicense under any Xenon Background IP or Collaboration IP to any Third Party. 

 

	 	(b)	In the event of the termination of this Agreement by Ivax pursuant to Section 12.3(b) or by Xenon pursuant to Section 12.4 in its entirety or on a
Product-by-Product basis, and/or on a country-by-country basis (as applicable): 

  

	 	(i)	the license granted to Ivax by Xenon hereunder shall terminate with respect to all such terminated Products, and [†], however, Ivax will retain a non-exclusive
license under such Xenon Background IP and such Collaboration IP for research purposes only; 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

53 

	 	(ii)	at Xenon’s request Ivax shall grant Xenon (at Xenon’s option) (a) a non-exclusive license under the Know-How that falls within the Ivax Termination IP,
and (b) subject to (a), an exclusive license under all other Ivax Termination IP (including all study data, results, regulatory filings and Regulatory Approvals relating to same) utilized by Ivax in the research and Development of all such
terminated Products within the Territory; 

  

	 	(iii)	to the extent permitted by Applicable Law, Ivax shall, at Xenon’s cost, transfer and assign to Xenon all Regulatory Approvals for such terminated Products, and all
materials submitted to a Regulatory Authority for such approvals, in each country in which this Agreement is terminated and in respect of any Products that are terminated on a Product-by-Product basis, and/or on a country-by-country basis (as
applicable), PROVIDED that Ivax may retain a non-exclusive license to such Regulatory Approvals and materials as are applicable to Products in respect of which each paid-up irrevocable license has been granted to Ivax pursuant to Section 8.17
of this Agreement; 

  

	 	(iv)	Ivax will sell to Xenon (at a [†] any Product and API for such Product in its possession that is a terminated Product; and 

 

	 	(v)	Ivax shall immediately, upon and in accordance with Xenon’s written request, either deliver or destroy any Confidential Information relating to each terminated
Product, except for one copy which may be retained in its confidential files for archive purposes only, PROVIDED that Ivax may retain such Confidential Information as is applicable to Products in respect of which each paid-up irrevocable license has
been granted to Ivax pursuant to Section 8.17 of this Agreement. 

  

	 	(c)	In the event of termination of this Agreement by Ivax pursuant to Section 12.3(b) and Xenon subsequently Commercializes the terminated Product, during the period
of time such Product is being sold to Third Parties, [†]. 

 12.6 Ongoing Obligations 

Except where explicitly provided elsewhere within this Agreement, termination of this Agreement for any reason, or expiration of this Agreement, will not
affect: 
  

	 	(i)	obligations of the Parties, including the payment of any amounts payable pursuant to the provisions of ARTICLE 7 and ARTICLE 8; or 

 

	 	(ii)	rights and obligations of the Parties, which, from the context thereof, are intended to survive termination or expiration of this Agreement, including Sections 8.17,
9.4, 9.5, 12.5, 14.5, 16.3-16.16; Articles 11, 13, 15; and Articles 7 and 8 (each in accordance with their terms). 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

54 

 12.7 Dispute Resolution 
 Termination under this ARTICLE 12 for whatever reason will be automatically stayed for the duration of any proceedings initiated under ARTICLE 13, and any applicable cure periods shall commence upon the
resolution of such proceedings. 
 ARTICLE 13 
 DISPUTE RESOLUTION 
 13.1 Mediation 

Except as otherwise provided under Section 13.2 and except for an application for an injunction, and with the exception of any matter properly
considered by a Joint Committee, if any dispute, disagreement, claim or controversy (in each case, a “Disputed Matter”) exists between the Parties arising out of or relating to any provision of this Agreement then such Disputed
Matter shall be submitted to the following mediation process: 
  

	 	(a)	Internal Mediation. The Disputed Matter shall first be referred jointly to two (2) designees, one of each of Ivax and Xenon, who shall be a senior executive
officer of each Party, who shall meet personally and attempt in good faith using their best efforts to resolve the Disputed Matter. If such designees fail to resolve the Disputed Matter within thirty (30) Business Days (or longer if the Parties
mutually agree) after referral of the matter to them, the Parties shall proceed to the next stage of the dispute resolution procedure. 

  

	 	(b)	Outside Mediation. Upon written notice and within fifteen (15) Business Days after the conclusion of the internal mediation described in
Section 13.1(a), either of the Parties may elect to utilize a non-binding resolution procedure whereby the Parties engage a Third Party outside mediator. The mediation shall proceed at such times, and in such place, in such manner and with a
mediator as the Parties, acting in good faith, may agree. If the Parties cannot agree upon a matter pertaining to the mediation, neither Party shall be obliged to proceed with outside mediation, and the mediation will be deemed to have failed. Each
Party may be represented at the mediation by external legal counsel. If the matter cannot be resolved by mediation, within ten (10) Business Days after the failed outside mediation a senior executive officer of each Party shall meet and try
again to resolve the matter. Except as provided under Section 13.2 below, the Parties are then free to pursue legal and equitable remedies available to them and the mediation proceedings will have been without prejudice to the legal position of
any affected Party. Each Party shall bear its respective costs incurred in connection with the mediation procedure, except that they shall share equally the fees and expenses of the mediator and the costs of the facility for the mediation.

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

55 

	 	(c)	The Parties agree not to have the Ontario Commercial Mediation Act, 2010, apply to the mediation proceedings. 

13.2 Audit—Binding Determinations 

In the event that any dispute involving the determination of any amounts due to either Party pursuant to the audit process set out in Section 8.9 has
not been resolved pursuant to the procedures set out in Section 13.1, then the Parties shall agree on the appointment of one (1) internationally-recognized independent accounting firm to determine the matter, which determination shall be
final and binding on the Parties. 
 ARTICLE 14 
 REPRESENTATIONS AND WARRANTIES 
 14.1 Representation of Authority; Consents

 Each Party represents and warrants to the other that: 
  

	 	(i)	It is duly incorporated and organized and validly existing under the laws of its jurisdiction of incorporation; 

 

	 	(ii)	It has full right, power and authority to enter into this Agreement and to perform its obligations under this Agreement; 

 

	 	(iii)	This Agreement has been duly executed by such Party and constitutes a legal, valid and binding obligation of such Party, enforceable in accordance with its terms;

  

	 	(iv)	The execution, delivery and performance of this Agreement by such Party has been duly authorized by all necessary corporate action and does not and will not during the
Term: (A) violate any Applicable Law; nor (B) conflict with or constitute a default under any agreement, instrument or understanding, oral or written, to which it or any of its Affiliates is a party or by which it or such Affiliates may be
bound; nor (C) conflict with or violate such Party’s corporate charter and bylaws; and 

  

	 	(v)	No consents, approvals or authorizations under Applicable Law or from Third Parties are required to be obtained in connection with the execution, delivery and
performance of this Agreement. 

 14.2 Representations and Warranties by Xenon. 

Xenon represents and warrants to Ivax as of the Effective Date: 
  

	 	(a)	all Patent Rights that are included in the Xenon Background Patent Rights existing as of the Effective Date are listed in Schedule E; 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

56 

	 	(b)	to Xenon’s knowledge (i) the Xenon Background IP rights are not being infringed by any Third Party, (ii) no Xenon Background IP rights have been found by
a court or administrative body of competent jurisdiction to be invalid or unenforceable; (iii) the Xenon Background IP rights are not subject to any pending or overtly threatened re-examination, re-issue, opposition, interference, challenge or
litigation proceeding, and Xenon has received no written threat or notice of the initiation of any of the foregoing proceedings; (iv) [†]; and (v) [†]; 

 

	 	(c)	to Xenon’s knowledge, [†]; 

  

	 	(d)	[†]; 

  

	 	(e)	(i) [†]; (ii) [†]; and (iii) [†]; 

  

	 	(f)	[†]; 

  

	 	(g)	[†]; 

  

	 	(h)	[†]; 

  

	 	(i)	[†]; 

  

	 	(j)	[†]; 

  

	 	(k)	[†]; 

  

	 	(l)	Xenon has not received any notice from any Third Party that the Development, Manufacture, or Commercialization of the Products in the Territory infringes or
misappropriates any Intellectual Property rights of any Third Party. 

  

	 	(m)	[†]; 

  

	 	(n)	[†]; 

  

	 	(o)	[†]; 

  

	 	(p)	there are no claims, judgments or settlements against or owed by Xenon; 

  

	 	(q)	[†]; 

  

	 	(r)	[†]; and 

  

	 	(s)	[†]. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

57 

 14.3 Ivax Covenant 
 Ivax covenants to Xenon that at any time on or after the date that Ivax (or any Person acting on behalf of Ivax) Commences a Phase IIb Trial with any Product, upon receipt from Xenon of an IPO Notice:

  

	 	(a)	Ivax will purchase (the “IPO Purchase”) that number of Xenon Stock from Xenon as part of the IPO on the same offering price (the “IPO
Price”) and on economic terms and conditions no less favourable than those provided to any public investors in the IPO that is equal to the lesser of: 

 

	 	(i)	$20,000,000 divided by the IPO Price, if such IPO occurs on a date on or after the Commencement of a Phase III Trial with any Product, or $10,000,000 divided by the IPO
Price, if such IPO occurs on a date prior to the Commencement of a Phase III Trial with any Product; and 

  

	 	(ii)	19% of the issued and outstanding Xenon Stock, on a post-IPO basis; and 

  

	 	(iii)	the number of Xenon Stock specified in the IPO Notice by Xenon; and 

  

	 	(b)	Ivax will take all necessary actions as reasonably requested by Xenon to complete the IPO Purchase, including but not limited to providing all required information,
making all filings and executing all such further documents as may be reasonably requested by the relevant securities commissions, stock exchanges and other regulatory authorities or underwriters or agents for the IPO. 

For the purposes of interpretation of Section 14.3 above: 
 “Commences a Phase IIb Trial” shall mean the first dosing of the first human subject in the particular Phase II Trial that, [†]; 

“IPO” means the initial public offering of the Xenon stock and the commencement of the listing and trading of Xenon Stock; PROVIDED that
(i) such offering is made at a minimum price of $[†] per share of Xenon Stock (subject to adjustment for any share consolidation or subdivision or the grant of any stock dividends subsequent to the date hereof) and for minimum gross
proceeds (before underwriting discounts, commission, expenses of issue and fees of not less than $[†]), or such other minimum price per share or gross proceeds amount that is otherwise approved by Xenon shareholders; and (ii) the shares of
Xenon Stock are listed on a recognized senior stock exchange (including, without limitation, The Toronto Stock Exchange or NASDAQ). 

“IPO Notice” means the written notice that Xenon may at its option (but has no obligation to) send to Ivax informing Ivax that
Xenon is contemplating an IPO and will require Ivax to purchase shares of Xenon Stock pursuant to Section 11.3(a) above. 

“IPO Price” has the meaning set out in Section 11.3(a) above. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

58 

 “IPO Purchase” has the meaning set out in Section 11.3(a) above.

 “Xenon Stock” means the class of shares in the capital of Xenon or its successor offered in the IPO to the public
investors. 
 14.4 Employee and Consultant Obligations 

 

	 	(a)	Each Party represents and warrants to the other that, unless prohibited by, or inconsistent with, Applicable Law all of its employees, officers, consultants and
advisors and all of its Affiliates’ employees, officers, consultants and advisors who are supporting the performance of its obligations under this Agreement shall have executed or will have executed agreements or have existing obligations under
law or such Party’s written corporate rules: 

  

	 	(i)	Requiring assignment to such Party of all Intellectual Property made during the course of and as the result of their association with such Party; and

  

	 	(ii)	Obligating the individual to maintain as confidential such Party’s Confidential Information as well as confidential information of any Person which such Party may
receive, to the extent required to support such Party’s obligations under this Agreement. 

  

	 	(b)	Each Party represents and warrants that, to its knowledge, as of the Effective Date none of its employees and none of its Affiliates’ employees who are involved in
the performance of its obligations hereunder are, as a result of the nature of such obligations to be conducted by such Party set forth herein, in violation of any covenant in any contract with a Third Party relating to non-disclosure of proprietary information, non-competition or non-solicitation. 

14.5 Disclaimer of Warranty 
  

	 	(a)	Except as expressly set forth in this Agreement, nothing in this Agreement shall be construed as a representation made or warranty given by either Party or its
Affiliates: 

  

	 	(i)	that the Intellectual Property of a Party is not infringed by any Third Party, or that the practice of the Intellectual Property rights of a Party does not infringe any
Intellectual Property rights of any Third Party; or 

  

	 	(ii)	that any patents will issue based on pending applications or that any such pending applications or patents issued thereon will be valid. 

 

	 	(b)	 EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, EACH PARTY EXPRESSLY DISCLAIMS, WAIVES, RELEASES, AND RENOUNCES ANY WARRANTY, EXPRESS OR IMPLIED,
STATUTORY 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

59 

	 	
OR OTHERWISE, INCLUDING ANY WARRANTY OF MERCHANTABILITY, DURABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND WARRANTIES ARISING FROM USAGE OF TRADE OR COURSE OF DEALING, RELATING TO PRODUCT OR
OTHER PRODUCT OR SERVICE PROVIDED BY EITHER PARTY TO THE OTHER HEREUNDER. 

 ARTICLE 15 

INDEMNIFICATION 
 15.1
Indemnity By Ivax 
 Ivax agrees to defend Xenon at Ivax’s cost and expense, and will indemnify and hold Xenon and its directors,
officers, employees and agents (the “Xenon Indemnified Parties”) harmless from and against any action, suit, liabilities, losses, costs, damages, claims, demands, encumbrances, fees or expenses (including reasonable legal fees and
disbursements) (collectively, a “Loss”) arising out of any Third Party claim relating to: 
  

	 	(a)	Any breach by Ivax of any of its representations, warranties or obligations pursuant to this Agreement; 

 

	 	(b)	The negligence or wilful misconduct of Ivax; or 

  

	 	(c)	Any injury, damage or loss resulting from any Product Commercialized by Ivax or its Sublicencees, except to the extent that Xenon is obliged to indemnify Ivax pursuant
to the provisions of Section 15.2. 

 In the event of any such claim against the Xenon Indemnified Parties by any Third
Party, Xenon shall promptly notify Ivax in writing of the claim and Ivax shall manage and control, at its sole expense, the defense of the claim and its settlement, keeping Xenon reasonably advised of the status of the defense and/or settlement. No
settlement shall be finalized without obtaining Xenon’s prior written consent, which shall not be unreasonably withheld, except that, in the case of a settlement that does not require an admission or action on the part of Xenon, subject to
compliance with Section 10.8, Xenon’s consent shall not be required so long as Xenon is unconditionally released from all liability in such settlement. The Xenon Indemnified Parties shall cooperate with Ivax and may, at their option and
expense, be represented in any such action or proceeding. Ivax shall not be liable for any litigation costs or expenses incurred by the Xenon Indemnified Parties without Ivax’s prior written authorization, unless Ivax is in breach of any of its
obligations pursuant to this Section 15.1. In addition, Ivax shall not be responsible for the indemnification or defense of any Xenon Indemnified Party to the extent any Third Party claims arises from any negligent or intentional acts or
omissions by any Xenon Indemnified Party, or the breach by Xenon of any obligation, representation or warranty under this Agreement, or any claims compromised or settled without Ivax’s prior written consent. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

60 

 15.2 Indemnity by Xenon 
 Xenon agrees to defend Ivax at Xenon’s cost and expense, and will indemnify and hold Ivax and their respective directors, officers, employees and agents (the “Ivax Indemnified
Parties”) harmless from and against any action, suit, liabilities, losses, costs, damages, claims, demands, encumbrances, fees or expenses (including reasonable legal fees and disbursements) arising out of any Third Party claim relating
to: 
  

	 	(a)	Any breach by Xenon of any of its representations, warranties or obligations pursuant to this Agreement; 

 

	 	(b)	The negligence or wilful misconduct of Xenon; or 

  

	 	(c)	In the event Xenon exercises its option to co-promote pursuant to Section 6.3, any of Xenon’s detailing activities under such co-promote.

 In the event of any such claim against the Ivax Indemnified Parties by any Third Party, Ivax shall promptly notify Xenon in
writing of the claim and Xenon shall manage and control, at its sole expense, the defense of the claim and its settlement, keeping Ivax reasonably advised of the status of the defense and/or settlement. No settlement shall be finalized without
obtaining Ivax’s prior written consent, which consent shall not be unreasonably withheld, except that, in the case of a settlement that does not require an admission or action on the part of Ivax, subject to compliance with Section 10.8,
Ivax’s consent shall not be required so long as Ivax is unconditionally released from all liability in such settlement. The Ivax Indemnified Parties shall cooperate with Xenon and may, at their option and expense, be represented in any such
action or proceeding. Xenon shall not be liable for any litigation costs or expenses incurred by the Ivax Indemnified Parties without Xenon’s prior written authorization, unless Xenon is in breach of any of its obligations pursuant to this
Section 15.2. In addition, Xenon shall not be responsible for the indemnification or defense of any Ivax Indemnified Party to the extent any Third Party Claim arises from any negligent or intentional acts or omissions by any Ivax Indemnified
Party, or the breach by Ivax of any obligation, representation or warranty under this Agreement, or any claims compromised or settled without Xenon’s prior written consent. 
 15.3 Limitation of Liability 
 EXCEPT FOR FRAUD, GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT,
IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER OR ANY OF ITS AFFILIATES FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE, AGGRAVATED OR EXEMPLARY DAMAGES (INCLUDING LOST PROFITS, BUSINESS OR GOODWILL) SUFFERED OR INCURRED BY
SUCH OTHER PARTY OR ITS AFFILIATES, WHETHER BASED UPON A CLAIM OR ACTION OF CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHER TORT, OR OTHERWISE, ARISING OUT OF THIS AGREEMENT. THE FOREGOING SENTENCE SHALL NOT LIMIT THE OBLIGATIONS OF EITHER
PARTY TO INDEMNIFY AN INDEMNIFIED PARTY FROM AND AGAINST THIRD PARTY CLAIMS UNDER THIS ARTICLE 15. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

61 

 15.4 Method of Asserting Claims 
 In the event that any written claim or demand for which a Party (the “Indemnifying Party”) would be liable to the other Party (the “Indemnified Party”) hereunder
is asserted against or sought to be collected from any Indemnified Party by a Third Party, such Indemnified Party shall promptly, but in no event more than [†] Business Days following such Indemnified Party’s receipt of such claim or
demand, notify the Indemnifying Party of such claim or demand and the amount or the estimated amount thereof to the extent then feasible (the “Claim Notice”). The failure to provide such notice will not affect any rights under this
Agreement except to the extent that the Indemnifying Party is materially prejudiced by such failure. 
 15.5 Notice Period

 The Indemnifying Party shall have [†] days from the delivery or mailing of the Claim Notice (the “Notice
Period”) to notify the Indemnified Party whether or not it desires to defend the Indemnified Party against such claim or demand. An election to assume the defense of such claim or demand shall not be deemed to be an admission that the
Indemnifying Party is liable to the Indemnified Party in respect of such claim or demand. All costs and expenses incurred by the Indemnifying Party in defending such claim or demand shall be a liability of, and shall be paid by, the Indemnifying
Party; PROVIDED, however, that the amount of such expenses shall be a liability of the Indemnifying Party hereunder, subject to the limitations set forth in this ARTICLE 15. 
 15.6 Reimbursement 
 In the event that it is ultimately determined that the Indemnifying
Party is not obligated to indemnify, defend or hold the Indemnified Party harmless from and against any Third Party claim, the Indemnified Party shall reimburse the Indemnifying Party for any and all costs and expenses (including reasonable
attorney’s fees and court costs) incurred by the Indemnifying Party in its defense of the Third Party claim. 
 15.7 Settlement

 The Indemnified Party shall not settle a Third Party claim or demand without the consent of the Indemnifying Party, which shall not be
unreasonably withheld. The Indemnifying Party may settle any claim or demand for monetary damages without obtaining consent from the Indemnified Party; it being understood that the Indemnifying Party shall not, without the prior written consent of
the Indemnified Party, which shall not be unreasonably withheld, settle, compromise or offer to settle or compromise any such claim or demand on a basis which would result in the imposition of a consent order, injunction or decree that would
restrict the future activity or conduct of the Indemnified Party thereof. 
 15.8 Grant of Access and Assistance to Indemnifying Party

 To the extent the Indemnifying Party shall control or participate in the defense or settlement of any Third Party claim or demand, the
Indemnified Party will give the Indemnifying Party and its 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

62 

 
counsel access to, during normal business hours, the relevant business records and other documents, and shall permit them to consult with the employees and counsel of the Indemnified Party. The
Indemnified Party shall use its reasonable efforts to assist in the defense of all such claims. 
 15.9 Conflict of Interest or Failure to
Defend 
 If the Indemnifying Party shall fail to undertake in a timely manner the defense of any Third Party claim or it is determined that
representation by the Indemnifying Party’s counsel of both the Indemnifying Party and the Indemnified Party may present a conflict of interest, the Indemnified Party shall have the right to undertake the defense or settlement thereof at the
Indemnifying Party’s expense, subject to counsel for Indemnified Party being reasonably acceptable to Indemnifying Party. If the Indemnified Party assumes the defense of any such claim or proceeding and proposes to settle such claim or
proceeding prior to a final judgment thereon or to forgo any appeal with respect thereto, then the Indemnified Party shall give the Indemnifying Party timely written notice and the Indemnifying Party shall have the right to participate in the
settlement or assume or reassume the defense of such claim or proceeding. 
 15.10 Insurance Proceeds 

Any indemnification hereunder shall be made net of any insurance proceeds recovered by the Indemnified Party; PROVIDED that if, following the payment to
such Indemnified Party of any amount under this ARTICLE 15, such Indemnified Party recovers any insurance proceeds in respect of the claim for which such indemnification payment was made, the Indemnified Party shall promptly pay an amount equal to
the amount of such proceeds (but not exceeding the amount of such indemnification payment) to the Indemnifying Party. 
 15.11 Insurance

 Prior to its first use of a Product in a human, Ivax shall obtain[†] insurance (including product liability insurance) or self-insure
with respect to its activities hereunder[†] in such amount as is consistent with the standards in the pharmaceutical industry. All such insurance shall be maintained at Ivax’s cost and Ivax shall from time to time provide to the Xenon
certificates of insurance or such other evidence of insurance as Xenon may reasonably request. 
 ARTICLE 16 

GENERAL 
 16.1
Assignment 
 Except as hereinafter provided in this Section 16.1, this Agreement shall not be assigned in whole or in part by either
Party without the prior written consent of the other Party. Any attempt by either Party to assign this Agreement without such consent shall be null and void and of no effect PROVIDED that either Party may assign this Agreement without the consent of
the other Party: 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

63 

	 	(a)	in whole or in part to any Affiliate of a Party, PROVIDED that the assigning Party notifies the other Party in writing within twenty (20) Business Days of such
assignment and the assignee promptly enters into a written agreement with the other Party wherein the assignee agrees to assume responsibility for and be bound by all of the terms of this Agreement in addition to the assigning Party, which shall
continue to be bound by such terms; or 

  

	 	(b)	in whole in connection with a transfer or sale of all or substantially all of the assets or business of a Party or in the event of such Party’s merger or
amalgamation with another Person or other business combination (a “Change of Control Event”) provided that such Party or its successor (as applicable) gives notice in writing to the other Party within ten (10) Business Days
following such Change of Control Event; 

  

	 	(c)	No assignment shall release any Party from responsibility for the performance of any accrued obligation of such Party hereunder; and 

 

	 	(d)	This Agreement shall be binding upon and enforceable against the successor to or any permitted assignees from either of the Parties hereto. 

16.2 Change of Control Event 
  

	 	(a)	Notwithstanding anything in this Agreement to the contrary, in the event of a Change of Control of Xenon, Ivax will not be obligated to disclose any Confidential
Information to the Successor Entity during the remainder of the Agreement Term (but notwithstanding the foregoing shall continue to provide the royalty reports required under ARTICLE 8 of this Agreement and shall provide reasonable summaries of
Development and Commercialization status and efforts as contemplated under Section 6.2 of this Agreement), and Ivax may request the immediate return or destruction of Confidential Information previously disclosed to Xenon by Ivax. Further,
notwithstanding anything in this Agreement to the contrary, within ninety (90) days of the date of any Change of Control of Xenon, Ivax may: (i) terminate the JDC or PDC, as applicable, in its sole discretion, and (ii) terminate the
obligation under Section 14.3 to participate in Xenon’s IPO if not then exercised by Xenon, in Ivax’s sole discretion. 

  

	 	(b)	Notwithstanding anything to the contrary in Section 6.3, in the event of a Change of Control Event of Xenon in which the surviving entity is an Unacceptable Person
(as defined below), then [†]. Accordingly, the Parties further agree as follows: 

 In the event of an
Anticipated Change of Control (as defined below): 
  

	 	(i)	Xenon will in confidence provide notice to Ivax of an Anticipated Change of Control, and in such notice will request that Ivax deliver to Xenon a list of the names of
Persons that as of the date of such notice, Ivax has determined are Unacceptable Persons; and 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

64 

	 	(ii)	Ivax shall deliver to Xenon within [†] Business Days following the date that Xenon delivers such notice and request to Ivax the list of Unacceptable Person.

 “Unacceptable Person” or “Unacceptable Persons” means (1) [†]; or (2)
[†]: 
  

	 	(i)	[†]; or 

  

	 	(ii)	[†]. 

 “Anticipated
Change of Control” means (i) an offer submitted to Xenon by a Third Party whereunder such Third Party has indicated that it desires to enter into discussions with Xenon that, if such discussions successfully conclude, would result in a
Change of Control of Xenon; or (ii) a good faith determination by the Board of Directors of Xenon, as evidenced by the minutes of such meeting of the Board of Directors or a resolution consented to in writing by all of the Directors of Xenon,
that Xenon Management is to initiate discussions with one or more Third Parties in furtherance of a Change of Control of Xenon. 
 16.3
Governing Law 
 This Agreement shall be construed and the respective rights of the Parties determined according to the substantive
laws of [†] notwithstanding any provisions governing conflict of laws under such law to the contrary. Subject to ARTICLE 13, any Disputed Matter shall be brought exclusively in a court of competent jurisdiction located in [†]. Each Party
irrevocably waives any right to, and will not oppose any such [†] action or proceeding on any jurisdictional basis, including forum non conveniens, and will not oppose the enforcement of any judgment or other duly obtained
order from [†]. Each Party irrevocably and unconditionally attains and submits to the jurisdiction of [†], and agrees to service of process issued or authorized by, such court. EACH PARTY HEREBY IRREVOCABLY WAIVES ITS RIGHT TO A JURY
TRIAL. 
 16.4 United Nations Convention 
 THE PARTIES EXPRESSLY DISCLAIM AND EXCLUDE THE APPLICATION OF THE UNITED NATIONS CONVENTION ON CONTRACTS FOR THE INTERNATIONAL SALE OF GOODS. 
 16.5 Business Day 
 In the event that an obligation to be performed under this Agreement
falls due on a day that is not a Business Day, the obligation shall be deemed due on the next Business Day thereafter. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

65 

 16.6 Notices 
 Notices, invoices, communications, and payments hereunder shall be deemed made and given three (3) days after sending if sent by registered or certified envelope, postage prepaid, and one
(1) day after sending if sent by courier or by facsimile transmission, and addressed to the Party to receive such notice, invoice, or communication at the address given below, or such other address as may hereafter be designated by notice in
writing by one Party to the other from time to time: 
  

			
	To Xenon:	  	Xenon Pharmaceuticals Inc.
		  	3650 Gilmore Way
		  	Burnaby, BC
		  	CANADA
		  	V5G 4W8
		  	 Attention: President and Chief Executive Officer

		  	 Facsimile: 604-484-3450

		
	With a copy (which	  	Xenon Pharmaceuticals Inc.
	shall not constitute	  	3650 Gilmore Way
	notice) to:	  	Burnaby, BC
		  	V5G 4W8
		  	 Attention: General Counsel and Corporate Secretary

		  	 Facsimile: 604-484-3450

		
	To Ivax:	  	Ivax International GmbH
		  	Alpenstrasse 2
		  	8640 Rapperswil
		  	SWITZERLAND
		  	 Attention: Managing Director

		  	 Facsimile: 41-55-220-1049

		
	 With a copy (which
 shall not
constitute
 notice) to:
	  	
		  	Teva Pharmaceuticals
		  	1090 Horsham Road
		  	North Wales, PA 19454
		  	USA
		  	 Attention: Chief Legal Officer

		  	 Facsmile: 215-293-6499

 16.7 Force Majeure 
 No failure or omission by either Party in the performance of any obligation of this Agreement shall be deemed a breach of this Agreement or create any liability if the same shall arise from

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

66 

 any cause or causes beyond the reasonable control of such Party, including the following: acts of God; acts
or omissions of any government; any inordinate or unanticipated delays in the regulatory review or governmental approval processes that are within the sole control of such government or governmental agency; any rules, regulations or orders issued by
any governmental authority or by any officer, department, agency or instrumentality thereof; fire; storm; flood; earthquake; accident; war; rebellion; insurrection; riot; and invasion; PROVIDED that such failure or omission resulting from one of the
above causes is corrected as soon as is practicable after the occurrence of one or more of the above mentioned causes by the Party claiming force majeure taking all reasonable steps within its power to resume compliance with its obligations with the
least possible delay. The Party claiming force majeure shall notify the other Party with notice of the force majeure event as soon as practicable, but in no event longer than ten (10) Business Days after its occurrence, which notice shall
reasonably identify such obligations under this Agreement and the extent to which performance thereof will be affected. In such event, the Parties shall meet promptly to determine an equitable solution to the effects of any such event. 

16.8 Independent Contractors 
 It is
understood and agreed that the relationship between the Parties is that of independent contractors and that nothing in this Agreement shall be construed as authorization for either Xenon or Ivax to act as agent for the other. 

16.9 No Strict Construction 
 This
Agreement has been prepared jointly and shall not be strictly construed against either Party. 
 16.10 No Implied Waivers; Rights Cumulative

 No failure on the part of Xenon or Ivax to exercise, and no delay in exercising, any right, power, remedy or privilege under this
Agreement, or provided by statute or at law or in equity or otherwise, shall impair, prejudice or constitute a waiver of any such right, power, remedy or privilege or be construed as a waiver of any breach of this Agreement or as an acquiescence
therein, nor shall any single or partial exercise of any such right, power, remedy or privilege preclude any other or further exercise thereof or the exercise of any other right, power, remedy or privilege. 

16.11 Severability 
 If any provision
hereof should be held invalid, illegal or unenforceable in any respect in any jurisdiction, the Parties hereto shall substitute, by mutual consent, valid provisions for such invalid, illegal or unenforceable provisions which valid provisions in
their economic effect are sufficiently similar to the invalid, illegal or unenforceable provisions that it can be reasonably assumed that the Parties would have entered into this Agreement with such valid provisions. In case such valid provisions
cannot be agreed upon, the invalid, illegal or unenforceable of one or several provisions of this Agreement shall not affect the validity of this Agreement as a whole. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

67 

 16.12 Execution in Counterparts 
 This Agreement may be executed in counterparts, each of which counterparts, when so executed and delivered, shall be deemed to be an original, and all of which counterparts, taken together, shall
constitute one and the same instrument. For purposes of execution, a copy of this Agreement or any amendment hereto will be deemed an original (including a printed copy of a PDF file delivered via email or a facsimile transmitted telephonically via
a fax machine). Notwithstanding the foregoing, the Parties shall deliver original execution copies of this Agreement to one another as soon as practicable following such execution. 
 16.13 No Third Party Beneficiaries or Obligors 
 No Person other than Ivax, Xenon and their
respective permitted successors and assigns hereunder shall be deemed an intended beneficiary hereunder, nor have any right to enforce any obligation of any Party to this Agreement, nor shall any Person other than Ivax and Xenon and their respective
permitted successors and assigns have any obligations to any Party under this Agreement. 
 16.14 Entire Agreement 

This Agreement contains the entire agreement of the Parties with respect to the matters referred to herein. 

16.15 Amendment 
 This Agreement,
including the Schedules hereto (with the exception of Schedule C, which may be amended pursuant to Section 2.3), may only be amended by a written document duly executed by authorized signatories of each of the Parties. 

16.16 Compliance 
 The Parties shall
comply fully with all Applicable Law in connection with their respective activities under this Agreement. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

68 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date.

  

			
	XENON PHARMACEUTICALS INC.
		
	By:	 	 /s/ Simon Pimstone

		 	Name: Simon Pimstone
		 	Title: President and Chief Executive Officer
	
	IVAX INTERNATIONAL GMBH
		
	By:	 	 /s/ Naama Baram

		 	Name: Naama Baram
		 	Title: General Manager
		
	By:	 	 /s/ R. David Koch

		 	Name: R. David Koch
		 	Title: Managing Officer

 Signature Page 
 to 
 COLLABORATIVE DEVELOPMENT AND 

LICENSE AGREEMENT 

 SCHEDULE A - XEN402 

[†] 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

A-1 

 SCHEDULE B - XEN403 

[†] 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

B-1 

 SCHEDULE C - INITIAL SUMMARY COLLABORATIVE DEVELOPMENT PLAN 

[†]: 
  

	 	(1)	[†], 

  

	 	(2)	[†], and 

  

	 	(3)	[†]. 

 [†]. 

[†]. 
 [†].

 The Phase II Clinical Trials and/or Phase III Clinical Trials may include the Indications and subject genotypes as set out in the table below.

  

					
	 XEN402
 Formulation
	  	 Indication
	  	Genotype
	 Topical
	  	Primary erythromelalgia	  	[†]
	  	[†]	  	[†]
	  	[†]	  	[†]
			
	 Oral
	  	[†]	  	[†]
	  	[†]	  	[†]
	  	[†]	  	[†]

 Selection of Clinical Trials and protocols will be set out in the Collaborative Development Plan. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

C-1 

 SCHEDULE D - IVAX BACKGROUND PATENT RIGHTS 

There are no Ivax Background Patent Rights as of the Effective Date. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

D-2 

 SCHEDULE E - XENON BACKGROUND PATENT RIGHTS 

 

											
	 Entry
	  	 Xenon
File No.
	  	PCT Application
Publication No. / Filing Date	  	Title	  	Priority Application/
Priority Date	  	Active Jurisdictions
(via PCT National/Regional Phase)
	 Section I: XEN402 and XEN403 Product Patent Applications

	 [†]
	  	[†]	  	[†]	  	[†]	  	[†]	  	[†]
	 [†]
	  	[†]	  	[†]	  	[†]	  	[†]	  	[†]
	 [†]
	  	[†]	  	[†]	  	[†]	  	[†]	  	[†]
	 [†]
	  	[†]	  	[†]	  	[†]	  	[†]	  	[†]
	 [†]
	  	[†]	  	[†]	  	[†]	  	[†]	  	[†]
	 [†]
	  	[†]	  	[†]	  	[†]	  	[†]	  	[†]
	 [†]
	  	[†]	  	[†]	  	[†]	  	[†]	  	[†]
	 [†]
	  	[†]	  	[†]	  	[†]	  	[†]	  	[†]
	 Section II: Diagnostics for SCN9A Variants

	 [†]
	  	[†]	  	[†]	  	[†]	  	[†]	  	[†]

  

	*	Denotes non-PCT (direct) national filing (conducted simultaneously with the corresponding PCT application, as applicable). 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

E-1 

 SCHEDULE F - XENON CO-PROMOTION RIGHTS 

Xenon Co-Promotion Right 
 Subject to the
following provisions, Xenon shall have the exclusive right and option, at its election, to co-Promote the Products within and throughout the Co-Promotion Territory (as defined below) (the “Co-Promotion
Right”): 
  

	1.	Definitions. Unless otherwise specifically defined in this Schedule F, capitalized terms herein shall have the meaning set forth in the Agreement. For
purposes of this Schedule F: 

 “Arbitration” shall have the meaning set forth in paragraph
3(c) below. 
 “Co-Promotion Agreement” shall have the meaning set forth in paragraph 12 below. 

“Co-Promotion Expenses” shall mean [†]. 
 “Co-Promotion Territory” shall mean the US and its territories (including Puerto Rico). 
 “Detail” or “Detailing” shall mean an interactive personal visit and discussion by a sales representative with a Target Prescriber during which a full presentation
emphasizing the features and functions of the Product is undertaken. 
 “Promotion” shall mean those activities
necessary to implement and carry out the Promotional Plan. When used as a verb, “Promote” or “Promoting” means to engage in Promotion. 
 “Promotional Plan” shall mean the annual promotional plan that will be developed by the Promotional Committee for the Product in the Co-Promotion
Territory that is the subject of Xenon’s Co-Promotion Right, such plan to take into consideration the elements set forth in Annex A attached hereto. 

“Target Prescriber” shall mean the physicians or other healthcare provider identified in the Promotion Plan. 

 

	2.	Co-Promotion Interest. Xenon’s co-promotion interest shall be at least [†] percent ([†]%) and up to [†] percent ([†]%) (the
“Co-Promotion Interest”) with respect to the total Promotion for each Product sold within the Co-Promotion Territory. 

  

	3.	[†] Notice. [†] following the [†], Ivax will provide notice in writing to Xenon respecting the conditions that, in accordance with standard
practices in the pharmaceutical industry for Promoting products of a comparable commercial potential, in Ivax’s reasonable opinion, will indicate that Xenon is able to exercise its right to co-Promote Products in the Co-Promotion Territory (“Ivax Conditions”).  

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

F-1 

	 	(a)	Ivax’s Objective Criteria. The Ivax Conditions will be reasonable and objective criteria that, provided they are met by Xenon, will satisfy Ivax in its
reasonable opinion that Xenon is able to co-Promote with Ivax in the Co-Promotion Territory those Products that (as of the date of the notice to Xenon referenced in this paragraph 3 above) Ivax anticipates will be the subject matter of the
anticipated NDA Filing referenced in paragraph 4 below. While the details of the Ivax Conditions will be fully set forth at the time set forth above, and such details are solely within Ivax’s discretion to determine at that time, the subject
matter of the Ivax Conditions will be the following: 

  

	 	(i)	Xenon’s financial position at the time of the anticipated US Product launch date of such Products; 

 

	 	(ii)	Xenon’s number and qualifications of managers for co-promotion activities that must be employed or otherwise retained by Xenon no fewer than a pre-determined
number of days prior to the anticipated US Product launch date; 

  

	 	(iii)	Xenon’s number and qualifications of sales representatives for co-promotion activities that must be employed or otherwise retained by Xenon no fewer than a
pre-determined number of days prior to the anticipated US Product launch date; and 

  

	 	(iv)	Any such other reasonable and objective criteria consistent with standard practices in the pharmaceutical industry for Promoting products in the Co-Promotion Territory,
including the existence of a compliance program. 

  

	 	(b)	Xenon’s Right to Protest. Xenon will provide a response to Ivax, within [†] following receipt of the Ivax Conditions, as to whether Xenon agrees
that the Ivax Conditions are reasonable and objective criteria as provided above, and an appropriate prerequisite for Xenon to exercise its right to co-Promote the relevant Products in the Co-Promotion
Territory as set forth in paragraph 6 below. In the event Xenon does not agree that the Ivax Conditions are such reasonable and objective criteria, Xenon will provide written notice of its position to Ivax (“Xenon Notice”), and the
Parties shall endeavour in good faith to agree on the Ivax Conditions as promptly as possible. Where the Parties cannot agree upon such Ivax Conditions within [†] of the Xenon Notice, Xenon shall have the right to submit this matter to
Arbitration as defined in paragraph 3(c), for a final and binding determination. 

  

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

F-2 

	 	(c)	Matters referred pursuant to paragraph 3(b) and paragraph 12 shall be resolved through binding arbitration in accordance with this paragraph 3(c) and under [†].
The proceedings and decisions of the arbitrator shall be confidential, final and binding on the Parties. The arbitration shall take place in [†] and will be conducted by one (1) arbitrator who shall be reasonably acceptable to the Parties
and who shall be appointed in accordance with [†] rules. If the Parties are unable to select an arbitrator within ten (10) Business Days of the submission of the relevant matter to arbitration, then the arbitrator shall be appointed in
accordance with [†] rules. The arbitration shall be conducted at a pace to render a decision by the arbitrator as soon as practicable, and in the event of arbitration pursuant to paragraph 12, no later than ninety (90) days after the
selection of the arbitrator. Any arbitrator chosen hereunder shall have educational training and industry experience sufficient to demonstrate a reasonable level of scientific, financial, medical and industry knowledge relevant to the particular
dispute. The Parties agree that the arbitrator will have the discretion to assess all reasonable expenses of arbitration (including arbitration fees, expert fees, arbitration costs and attorney’s fees) against the losing Party. Any decision
rendered in such arbitration may be enforced by either Party in any state, provincial, or federal court with jurisdiction over the Party against whom the decision is sought to be enforced. 

 

	4.	Ivax Anticipated Filing Notice. Not less than [†] and not longer than [†] prior to Ivax, its Affiliates or Sublicensees anticipated filing of the first
Product NDA Filing with the applicable Regulatory Authority in the US, Ivax shall give notice in writing to Xenon of such anticipated filing (the “Anticipated Filing Notice”). Such Anticipated Filing Notice shall specify:

 (a) the Product, and 
 (b) the anticipated date of the NDA Filing for such Product. 
 Upon delivery of an
Anticipated Filing Notice, Ivax and Xenon shall forthwith enter into good faith discussions and endeavor to finalize and execute a Co-Promotion Agreement as set forth in paragraph 12 below. 

 

	5.	Ivax Co-Promotion Notice. Not less than [†] following the date of the US NDA Filing set forth in paragraph 4 by Ivax, its Affiliates or Sublicensees, Ivax
shall give notice in writing to Xenon (a “Co-Promotion Notice”). Such Co-Promotion Notice shall specify: 

 (a) the Product, 
 (b) the date of the NDA Filing, and 

(c) the anticipated US Product launch date. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

F-3 

	6.	Xenon Exercise Notice. Subject to paragraph 7 below, Xenon may, at its election, exercise its Co-Promotion Right in
respect of the Product by giving notice in writing to Ivax within [†] after receipt of a Co-Promotion Notice that Xenon will fulfill all of the Ivax Conditions prior to NDA Approval of the Product (an “Exercise Notice”). For
clarity, the Parties confirm that, for purposes of such Exercise Notice, any Exercise Notice shall be considered an Exercise Notice respecting all Products containing XEN402 or all Products containing XEN403, as applicable. Any such Exercise Notice
shall specify the specific percentage Co-Promotion Interest of Xenon applicable to such Products. 

  

	 	(a)	The Exercise Notice shall set forth the Ivax Conditions met by Xenon at the time of the Exercise Notice, and the Ivax Conditions that are not yet met by Xenon at the
time of the Exercise Notice. To the extent required by the Ivax Conditions, such Exercise Notice shall also provide relevant Xenon financial statements and other relevant financial information (including a financing plan, if applicable) relating to
Xenon’s ability to co-Promote the applicable Products. 

  

	 	(b)	To the extent any Ivax Conditions are not yet met by Xenon at the time of the Exercise Notice, Xenon shall set forth in the Exercise Notice a detailed plan for meeting
all such Ivax Conditions by the applicable deadlines. Thereafter, Xenon shall submit to Ivax by the applicable deadline for each such Ivax Condition a report setting forth information verifying to Ivax that Xenon has fulfilled such Ivax Condition.

  

	 	(c)	In the event Xenon fails to meet any reasonable and objective criteria of an Ivax Condition by the applicable deadline, Ivax has the right, at its sole discretion, to
determine that such failure is a material breach of Xenon’s Co-Promotion Right. In the event of any such determination by Ivax of such material breach, within [†] following date of the applicable deadline, Ivax shall provide written notice
(a “Co-Promotion Breach Notice”) to Xenon specifying the material breach. If Xenon fails to cure such material breach within [†] following the date on which the Co-Promotion Breach Notice is delivered to Xenon, Xenon’s
Co-Promotion Right shall, without further act by either Party, terminate. 

  

	7.	Failure to Deliver an Exercise Notice. If Xenon does not give an Exercise Notice within [†] after the latter of (i) the date that Xenon receives a
Co-Promotion Notice or (ii) the date of the final determination of the Arbitration referenced in Section 3(b) above, the Xenon Co-Promotion Right shall, without further act by either Party, terminate. 

 

	8.	Failure to Receive Regulatory Approval. If Ivax does not receive Regulatory Approval for the particular Product described in the NDA Filing referenced in the
Co-Promotion Notice, if and as applicable, for the next Product that Ivax seeks Regulatory Approval in the US, Ivax shall give to Xenon a new Anticipated Filing Notice and new Co-Promotion Notice for such Product pursuant to the provisions of
paragraph 4 and paragraph 5 above, and Xenon may thereafter exercise its Co-Promotion Right respecting such Products pursuant to paragraph 6, subject to paragraph 7. 

 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

F-4 

	9.	Royalty Payments if Not Co-Promoting. If Xenon does not exercise its Co-Promote Right under paragraph 6 above, or upon Xenon exercising its right to cease
co-promotion activity for Products as set forth under paragraph 12(f) below, then, notwithstanding any term of the Agreement to the contrary, Ivax shall pay to Xenon Royalty Payments applicable to such Products in the
Co-Promotion Territory, in the manner and at the times provided in the Agreement. 

  

	10.	No Royalty Payments if Co-Promoting. If Xenon exercises its Co-Promotion Right under paragraph 6 above, subject to paragraph 12(f) of this Schedule F and for
such time that Xenon continues such co-promotion activity, no Royalty Payments respecting Products shall be payable by Ivax to Xenon within the Co-Promotion Territory. 

 

	11.	Co-Promotion Fee. If Xenon exercises its Co-Promotion Right under paragraph 6 above, Xenon shall pay to Ivax the sum of an Initial Co-Promotion Fee and a
Development Compensation Fee (such sum which shall hereinafter be referred to as the “Co-Promotion Fee”): 

 

	 	(a)	Initial Co-Promotion Fee payable by Xenon. Xenon shall pay to Ivax a one-time only “Initial Co-Promotion Fee”. Such Initial Co-Promotion Fee
shall be calculated according to the formula set forth below: 

  

					
		  	Initial Co-Promotion Fee =	  	(Xenon Co-Promotion Interest)
			
		  		  	 x

			
		  		  	(Amount equivalent to the total Milestone Payments paid or payable by Ivax relating to (i) the Commencement of Phase III Trial Milestone Event ($[†]), and (ii) the
First NDA Filing with FDA Milestone Event in the Co-Promotion Territory (e.g., $[†]))
			
		  	By way of example, [†]	  	

  

	 	(b)	 Development Compensation Fee payable by Xenon. In addition to the Initial Co-Promotion Fee payable by Xenon set forth in paragraph 11(a), Xenon
shall also pay to Ivax, a one-time only “Development Compensation Fee”. Such 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

F-5 

 
Development Compensation Fee shall be calculated according to the formula set forth in below: 
  

					
		  	Development Compensation Fee =	  	(Xenon Co-Promotion Interest)
			
		  		  	 x

			
		  		  	(Ivax US Product Development Costs)
		
		  	 By way of example, [†]

 “Ivax US Product Development Costs” shall [†]. 

 

	 	(c)	Payment Dates. The Co-Promotion Fee payable to Ivax shall be paid by Xenon in [†], and on the dates, as follows: 

 

	 	(i)	[†]% of the Co-Promotion Fee amount payable shall be paid in the form of a credit to Ivax against the NDA Approval Development Milestone Payment payable by Ivax to
Xenon respecting the NDA Approval in the US for the Products to which Xenon has exercised its Co-Promotion Right. 

In the event that, as of the date of the NDA Approval in the US for which Xenon has exercised its Co-Promotion Right, both the First NDA
Approval Development Milestone Payment and the Second NDA Approval Development Milestone Payment (each of the foregoing Milestone Payments as set forth in Section 7.2 of the Agreement) have already been paid by Ivax to Xenon in consideration
for other NDA Approvals in other jurisdictions in the Territory, Xenon shall pay [†]% of the Co-Promotion Fee to Ivax within thirty (30) days following receipt of notice from Ivax that it has obtained the NDA Approval in the US for the
Product to which Xenon has exercised its Co-Promotion Right; and 
  

	 	(ii)	the remaining [†]% of the Co-Promotion Fee amount payable shall thereafter be paid in the form of a credit to Ivax against one or more of the following future
amounts payable by Ivax to Xenon (ie, payments payable to Xenon under this Agreement after the date of the NDA Approval in the US referenced in subparagraph 11(d)(i) above): the Second NDA Approval Milestone Payment, or the Sales Milestone Event, or
the Operating Profits. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

F-6 

 In the event that Xenon does not pay the entire Co-Promotion Fee as set forth under
subparagraphs 11(c)(i) and 11(c)(ii) above, Xenon shall be obligated to pay the balance of the Co-Promotion Fee to Ivax upon termination of the Agreement, provided, however, that in the event of termination of this Agreement as the result of a
breach by Ivax or any of its Affiliates, Ivax shall have the right to set off such balance against the damages attributable to such breach. 
  

	 	(d)	NDA Approval Milestone Payment. If Xenon exercises its Co-Promotion Right under paragraph 6 above, subject to paragraph 12(f) of this Schedule F and for such
time that Xenon continues such co-Promote activity, the Milestone Payment paid or payable by Ivax relating to the First NDA Approval with FDA Milestone Event in the Co-Promotion Territory (e.g., $[†]) shall be reduced by the Co-Promotion
Interest percentage multiplied times [†] percent ([†]%). 

 By way of example, [†] 

 

	 	(e)	Sales Milestone Payment. If Xenon exercises its Co-Promotion Right under paragraph 6 above, subject to paragraph 12(f) of this Schedule F and for such time that
Xenon continues such co-Promotion activity, the Sales Milestone Payment set forth in Section 7.3 of the Agreement ($[†]M) shall only be paid in Ivax’s first fiscal year for which aggregate annual gross sales (sold by Ivax or any of
its Affiliates or Sublicensees, as applicable) of Products outside the Co-Promotion Territory are equal to or greater than [†] Dollars ($[†]), and shall also be reduced to [†] Dollars ($[†]) in such event.

  

	12.	Co-Promotion Agreement. Upon Ivax’s delivery of an Anticipated Filing Notice pursuant to paragraph 4 above, Xenon and Ivax shall forthwith enter into good
faith discussions and devote sufficient resources to finalize and execute within one (1) month after Xenon’s delivery of an Exercise Notice to Ivax, a definitive co-promotion agreement with respect to the co-promotion of such Products,
which agreement will include among other provisions for planning and overseeing the Promotion of the Product in the Co-Promotion Territory (a “Co-Promotion Agreement”). Each Party shall agree to devote appropriate resources and use
commercially reasonable efforts to perform the functions necessary to Promote the Product throughout the Co-Promotion Territory 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

F-7 

	 	
consistent with the manner in which it would market and promote products of comparable commercial and medical significance in the Co-Promotion Territory, which are developed and controlled by
such Party. If the Parties cannot reach agreement on the terms of the Co-Promotion Agreement by the end of such one-month period, then any remaining issues in such negotiations shall be resolved using the accelerated Arbitration process as provided
in paragraph 3(c), and, at Xenon’s election, the Parties then shall complete such negotiations based on such resolution and enter into the Co-Promotion Agreement as soon as practicable thereafter or,
alternatively, Xenon shall have the right not to enter into the Co-Promotion Agreement, which right must be exercised within thirty (30) days of the arbitration decision. The Co-Promotion Agreement shall contain commercially reasonable terms,
including terms encapsulating the following principles: 

  

	 	(a)	Ivax shall book and invoice each sale of Products within the Co-Promotion Territory. Ivax shall pay to Xenon, not less than once each Calendar Quarter, a share of the
Operating Profit from sales of Products within the Co-Promotion Territory for the immediately preceding Calendar Quarter, which percentage share (and payment to Xenon subject to any reconciliation under paragraph 12(c) below), shall be equal to the
Co-Promotion Interest. 

 “Operating Profit” shall mean the Net Sales (as that term is defined in
Section 1.1 of the Agreement) for Products in the Co-Promotion Territory less the following additional amounts, all determined in accordance with Ivax’s standard practices, consistently applied: 

 

	 	(i)	[†]; and 

  

	 	(ii)	Co-Promotion Expenses (other than capital costs and taxes) incurred by both Parties and their respective Affiliates and Sublicensees. 

The amounts referred to in subparagraphs 12(a)(i) and 12(a)(ii) of this Schedule F will be itemized and listed in the Co-Promotion
Agreement by mutual agreement of the Parties each acting reasonably, and in accordance with standard practices in the industry. 
  

	 	(b)	Xenon shall maintain appropriate conditions in accordance with standard practices in the pharmaceutical industry to co-Promote all subsequent Products approved in the Co-Promotion Territory during the term of the Co-Promotion Agreement. 

  

	 	(c)	 Each Party shall keep (and shall cause each of its Affiliates and Sublicensees to keep) and make available to the other Party pursuant to this
paragraph 12(a) complete and accurate records of the underlying data relating to the amounts referred to in paragraphs 12(a)(i) and 12(a)(ii) of this Schedule F for a period of no more than [†] years. Each Party (the “Auditing
Party”) shall have the right 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

F-8 

	 	
from time to time (but not more often than once in each Year) at its own expense to have the independent, certified public accountant of the other Party (the “Audited Party”),
during the Audited Party’s annual audit period, review any such records of the Audited Party upon reasonable notice and during regular business hours and under obligations of confidence, for the sole purpose of verifying the basis and accuracy
of the Audited Party’s records relating to the amounts referred to in subparagraphs 12(a)(i) and 12(a)(ii) of this Schedule F. If the Auditing Party reasonably believes, after reviewing information received from the Audited Party’s
independent, certified public accountant, that an additional audit is appropriate to address an apparent discrepancy with respect to the Audited Party’s calculations, then the Auditing Party shall have the right to audit using a major
independent, certified public accounting firm reasonably acceptable to the Audited Party in accordance with Section 8.9 of the Agreement. If the review of such records reveals that the Audited Party has failed to accurately report amounts
referred to in subparagraphs 12(a)(i) and 12(a)(ii) of this Schedule F, then the Parties shall promptly make the necessary payments and adjustments between themselves to rectify the failure, together with interest on any amounts owing by the Audited
Party to the Auditing Party from the date of the failure that gave rise to the owing amount at a rate per annum equal to the lesser of (i) one month London Inter-Bank Offered Rate (LIBOR) fixed by the British Bankers’ Association (BBA),
plus [†] percent ([†]%), or (ii) the highest rate permitted by applicable law, compounded annually, and calculated on the number of days such payments are paid after the date such amounts became owing. If any amounts due under this
paragraph 12(a) as a result of an audit are greater than [†] percent ([†]%) of the Operating Profits for a Year, the Audited Party shall pay the reasonable costs of such audit. Draft and final audit results and findings shall be shared by
the Audited Party and the Auditing Party. If the Audited Party in good faith disputes any conclusion of the accounting firm under this paragraph 12(a), including that the Audited Party owes additional amounts, the Audited Party shall so inform the
Auditing Party by written notice within thirty (30) days after receipt of a copy of the audit in question, specifying in detail such dispute. The Parties shall promptly thereafter meet and negotiate in good faith a resolution to such dispute.
If the Parties are unable to resolve such dispute within sixty (60) days after notice by the Audited Party, then the matter shall be resolved pursuant to the terms set forth in Article 13 of the Agreement, and interest shall be payable on any
disputed amounts determined to be due in the same manner as provided for in this paragraph 12(a). 

  

	 	(d)	 Each Party shall contribute its proportional percentage share of the collective Co-Promotion Expenses, in
accordance with the Co-Promotion Interest. The Co-Promotion Expenses will be itemized and listed in the Co-Promotion Agreement by mutual agreement of the Parties, each
acting reasonably in accordance with reasonable industry standards. Each Party will bear its proportional share of all such Co-Promotion Expenses, in accordance with the Co-Promotion Interest percentage. As
referenced in paragraph 12(a) above, in the 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

F-9 

	 	
event that the amounts of such costs incurred by each Party are not in fact equal to their respective share having regard to the Co-Promotion Interest, a reconciliation shall take place each
Calendar Quarter respecting these cost amounts, to ensure that each Party bears (only) its proportional share of all such costs, in accordance with the Co-Promotion Interest percentage, and (if applicable) each Calendar Quarter payment by Ivax to
Xenon of its share of the Operating Profits (as set forth under paragraph 12(a) above) shall be adjusted (up or down) accordingly. 

  

	 	(e)	Xenon will contribute its percentage share of the total full time equivalent number of sales representatives dedicated to the Detailing and sale of Products within the
Co-Promotion Territory, which percentage share shall be equal to the Co-Promotion Interest. Across the Co-Promotion Territory, having regard to the Co-Promotion Interest, Ivax shall have the sole right to assign accounts to both Ivax and Xenon sales
representatives, and such Xenon sales representatives shall be responsible for the same proportion of high and low volume accounts and same proportion of primary and secondary Details as are the Ivax sales representatives, and shall pro rata perform
as well as the Ivax sales representatives. Each Party will be subject to agreed upon penalties for any non-compliance or shortfalls (eg: minimum call shortfalls). Ivax will have the right, upon reasonable notice to Xenon, to have Ivax management
periodically accompany Xenon’s sales representatives in the course of Detailing the Products. If requested by Xenon[†]. For the avoidance of doubt, and notwithstanding anything to the contrary under Article 15 of the Agreement, under no
circumstances shall either Party be obliged to indemnify or hold harmless the other Party for negligent or intentional acts or omissions relating to Detailing conducted by the other Party’s sales representatives. The annual incentive
compensation (excluding contests and special incentives) of the sales force of Xenon for Detailing the Products as a percentage of base salary shall be [†]; provided, that such incentive compensation is consistent with the financial
targets applicable to both Xenon and Ivax as set forth in the Promotion Plan in proportion to the Co-Promotion Interest. 

  

	 	(f)	Xenon shall be permitted, on a Product-by-Product basis, at any time, to cease co-promotion activity within the Co-Promotion
Territory, at its sole discretion, after providing Ivax with [†] prior written notice of its intent to cease such co-promotion activity in the Co-Promotion Territory. At the time of cessation, Xenon shall no longer receive a share of the
Operating Profit within the Co-Promotion Territory and Ivax shall, as of and following the date of any such cessation, pay to Xenon the Royalty Payments respecting Products, in the manner and at the times provided in the Agreement.

  

	 	(g)	 Ivax and Xenon agree that Xenon shall share with Ivax, proportionately in accordance with its Co-Promotion Interest, up to the next $[†] of any
expenditures made by Ivax after the date of the first NDA Approval in the US, related to Development and Phase IV Clinical Trials of the Product to which Xenon has exercised its Co-Promotion Right in the Co-Promotion Territory. Xenon’s

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

F-10 

	 	
proportional share of any such additional expenditures, on a Calendar Quarter by Calendar Quarter basis, may be credited to Ivax against Xenon’s share of Operating Profits payable by Ivax to
Xenon as set forth under paragraph 12(a) above. Ivax shall be solely responsible for any further expenditures. 

  

	 	(h)	Ivax shall form a “Promotional Committee” that shall be responsible for planning and overseeing the Promotion of the Product within the Co-Promotion
Territory. The Promotional Committee shall create an annual Promotional Plan for the Product in the Co-Promotion Territory, which shall contain elements as set forth in Annex A attached hereto, with a budget
for Co-Promotion Expenses, and an allocation of responsibility between Ivax and Xenon of all Promotion activities. 

  

	 	(i)	Xenon shall be entitled to have at least one Xenon representative on any Promotional Committee formed by Ivax respecting the Co-Promotion Territory, and on any other
related committees formed by Ivax that are specific to the Promotion of the Product in Co-Promotion Territory. The chair of the committee(s) referred to in this paragraph 12(i) shall be a representative from
Ivax. If the Parties’ representatives on any committee(s) referred to in this paragraph 12(i) are unable to agree on any matter, then the chair will have the casting and deciding vote. In addition to the foregoing, Xenon shall also be entitled
to attend and participate in any other meetings (and receive copies of materials and presentations relevant to such meetings) in which matters are discussed that may be material to the Promotion or further Commercialization of the Product in the
Co-Promotion Territory, including but not limited to meetings with key opinion leaders or external advisory boards, but not including any routine internal reporting meetings between Ivax personnel and Ivax’s executive management.

  

	 	(j)	Each of Xenon and Ivax shall report to the other in writing, not less than once each Calendar Quarter, with respect to their respective Promotion efforts and, in the
case of Ivax, providing sales figures, in such detail as Xenon shall reasonably require. All relevant sales representatives performing Detailing calls on behalf of Ivax and Xenon with respect to the Products will maintain written (including
electronic) records of all such Detailing calls made to Target Prescribers. The quarterly report of each Party respecting Promotion efforts will be accompanied by summary Detail reports for the period. Each Party on an annual basis may, upon
reasonable prior notice to the other Party, audit the other Party’s records to verify that the information disclosed in the quarterly reports is accurate and consistent with the other Party’s obligations herein. If the information
disclosed in the quarterly reports is found not to be consistent with the other Party’s obligations herein, the non-complying Party shall pay the reasonable costs of such audit, and shall pay penalties for any such non-compliance or shortfalls
as agreed to pursuant to paragraph 12(c). 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

F-11 

	 	(k)	Ivax shall Manufacture, or have Manufactured, each Product in accordance with all Applicable Law and the specifications for such Product as approved by the relevant
Regulatory Authority within the Co-Promotion Territory, and shall be responsible for all quality assurance issues arising therefrom. Ivax shall be responsible for all Manufacture, labeling, packaging and distribution of Products in the Co-Promotion
Territory, and shall comply with Applicable Law regarding the same. 

  

	 	(l)	Each Party, including its sales representatives, shall Promote the Product in the Co-Promotion Territory in strict adherence
with regulatory and professional requirements and all Applicable Law, including the U.S. Federal Food, Drug, and Cosmetic Act of 1938, as amended from time to time, and all rules, regulations and guidance promulgated thereunder; the American
Medical Association Gifts to Physicians from Industry Guidelines, as revised from time to time; the Prescription Drug Marketing Act of 1987, as amended, and the regulations promulgated thereunder; and the PhRMA Code on Interactions with Healthcare
Professionals promulgated and adopted by the Pharmaceutical Research and Manufacturers of America, which became effective July 1, 2002, as amended from time to time. To the extent a Party has knowledge or becomes aware that the Applicable Law
related to Promoting the Product in the Co-Promotion Territory has changed, it will promptly notify the other in writing, and both Parties will as soon as practicable adhere to the updated obligations to
Promote the Product under Applicable Law. Pursuant to this paragraph 12(l): 

  

	 	(i)	Each Party shall ensure that it and its respective sales representatives’ statements and claims regarding the Product, including those as to safety and efficacy,
are consistent with the applicable product labeling and Marketing Materials. As used herein, “Marketing Materials” shall mean all written, printed, electronic or graphic materials developed by Ivax or its Affiliates and/or on behalf
of Ivax and/or its Affiliates by any Third Party, in connection with the Promotion of the Product pursuant to the Promotional Plan in the Co-Promotional Territory, including scientific education materials, professional education materials, any and
all patient lists, physician references, Detailing reports, Detailing pieces (such as visual aids and file cards), premium articles, reprints, market surveys, training materials and other reports and related data or programs.

  

	 	(ii)	Each Party and its sales representatives may only utilize the Marketing Materials that have been approved by the Promotional Committee to Promote the Product in the
Co-Promotional Territory. All Marketing Materials shall be owned exclusively by Ivax. Neither Party nor its sales representatives may make any changes in the Marketing Materials, and may not add, delete or modify claims of safety or efficacy stated
in the Marketing Materials, without the prior written approval of the Promotional Committee. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

F-12 

	 	(m)	In accordance with Ivax’s standard practices for its own marketing, Detailing and sales teams, Ivax/or and its Affliates will provide training to and consult with
Xenon with respect to the Detailing of the Products in the Co-Promotion Territory, including without limitation, training sessions for purposes of remedial training, education on current developments, new uses or indications, and new Ivax Marketing
Materials or programs. If such training and consultation is in addition to the Ivax or Ivax Affiliate’s standard program, Xenon shall bear all Xenon out-of-pocket costs and all Ivax costs (at Ivax’s cost rates, including all out-of-pocket
costs of Ivax respecting Ivax employees employed in such training and consultation) respecting such training. If such Xenon participation is in training undertaken by Ivax or an Ivax Afflicate as part of their respective standard marketing,
Detailing, or other sales training program(s), Xenon shall be responsible only for its own out-of-pocket costs. 

  

	 	(n)	Ivax shall continue to be solely responsible for the formulation, indications, and packaging for the Products. Ivax may change any packaging at its own discretion with
thirty (30) days prior written notice to Xenon. Unless required by Applicable Law, Ivax shall be responsible for the cost of such changes and the cost to change any and all Marketing and promotional materials. If required by Applicable Law,
Xenon shall share such costs according to its Co-Promotion Interest. Should Xenon elect to do so, and subject to Applicable Law, product packaging of Products in the Co-Promotion Territory shall include, at
Xenon’s sole discretion, the name of Xenon, Xenon trademarks or tradenames, or other Xenon identifying material (collectively, the “Xenon Identifying Material”). Such Xenon Identifying Material shall be in a form and format
that is reasonably acceptable to each of Xenon and Ivax, having regard to standard industry practices and Ivax’s previous practices with other companies in this regard. 

 

	 	(o)	As provided under Article 10 of the Agreement (unless the Agreement is terminated earlier), Ivax shall have responsibility for prosecuting and maintaining all patent
applications and patents relating to the Products. Ivax shall also have responsibility for all trademark applications and trademarks relating to any trademark, service marks, copyrights and other Intellectual Property rights (if any) relating to the
Products within the Co-Promotion Territory. Ivax shall use Diligent Efforts to maintain in the Co-Promotion Territory its trademarks relating to the Products. 

 

	 	(p)	Ivax and Xenon shall each notify each other within two (2) Business Days of receiving any Product complaints. As between Xenon and Ivax, Ivax shall be responsible
for addressing all manufacturing defects in the Products. In addition, Ivax shall be responsible for addressing all customer complaints regarding any alleged manufacturing defects of any Product. Ivax shall be responsible for handling and covering
the cost of all recalls and returns of Products and replacement of defective Products. Xenon, its Affiliates, Sublicensees, officers, directors, employees or agents shall in no way be responsible for any defects or damages with respect to Products,
or their shipment or delivery. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

F-13 

	 	(q)	Ivax shall use Diligent Efforts to supply sufficient quantities of the Product to meet the requirements of purchasers in the Territory (including in the Co-Promotion
Territory). 

  

	 	(r)	[†]. 

  

	 	(s)	Ivax shall produce all samples for use in the Promotion of the Product. Ivax shall establish the guidelines for sampling, and shall consult with Xenon with respect
thereto. Ivax shall supply such quantities of samples to Xenon as Ivax and Xenon mutually agree is appropriate in connection with Promotion efforts. 

  

	 	(t)	If any Product is recalled by Ivax or Regulatory Authorities in the Co-Promotion Territory, Ivax shall be responsible for all expenses relating to such recall and for
all activities to be performed relating to such recall, and Xenon shall repay to Ivax its proportional percentage share of the expenses relating to such recall in accordance with the Co-promotion Interest, except to the extent that such recall is a
direct result of activities under the sole control of Ivax. Prior to any such recall, Ivax shall advise Xenon of the situation. Ivax shall provide Xenon with a prepared statement for use in response to inquiries regarding the Product recall which
Xenon shall provide to Xenon sales representatives Promoting the Product. 

  

	 	(u)	Each Party shall promptly, and in any event within any time periods required by Applicable Law, give notice in writing to the other of any adverse drug experience
associated with the Product. Prior to the first Regulatory Approval for Commercialization of the first Product in the Co-Promotion Territory, and pursuant to the delivery of the Co-Promotion Notice, the
Parties shall agree and implement a procedure for the mutual exchange of adverse event reports and safety information associated with the Product. Details of the operating procedure respecting such adverse event reports and safety information
exchange shall be the subject of a mutually-agreed-to pharmacovigilance agreement between the Parties which shall at that time be made an addendum to the Co-Promotion Agreement. 

 13. No Conflict 
 The provisions of this Schedule F are in addition to, and not in
substitution for, the other provisions of the Agreement. If there is any conflict between the provisions of this Schedule and any other provisions of the Agreement, the provisions of the Agreement shall prevail. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

F-14 

 SCHEDULE G - PRESS RELEASE 

Teva and Xenon Announce Teva’s World Wide License of Xenon’s Pain Drug XEN402 

XEN402 is a Strategic Fit for Teva’s Commercial, R&D and Technology focus in CNS and Pain 

Jerusalem, and Burnaby, British Columbia DATE — Teva Pharmaceutical Industries Ltd (NYSE: TEVA) and Xenon Pharmaceuticals Inc. (Xenon) announced
today that they have entered into a collaborative development and exclusive worldwide license for XEN402. XEN402 is currently in clinical development for a variety of painful disorders. This product specifically targets sodium channels which are
abundantly found in sensory nerve endings that can increase in chronic painful conditions. Under the Agreement, Teva will pay Xenon an upfront fee of $41 million. In addition Teva shall pay development, regulatory, and sales-based milestones
totaling up to $335M. Xenon is entitled to royalties payable on sales and an option to participate in commercialization in the U.S. 

“Teva is building a focused pipeline of novel medicines in select areas of medical need,” stated Dr. Jeremy Levin, President and CEO of
Teva Pharmaceutical Industries Ltd. “XEN402 fits this strategy. It holds the potential to address the significant unmet medical need for the many patients who suffer from chronic pain. In addition, XEN402 has the potential for broader
therapeutic use across other pain conditions.” 
 “We are delighted to be collaborating with Teva” said Simon Pimstone, M.D.,
Ph.D., President and CEO of Xenon. “Teva is among the world’s leading pharmaceutical companies and is building a significant global presence in innovative drug development and commercialization. This partnership with Teva is Xenon’s
seventh major pharmaceutical alliance, once again highlighting the value of Xenon’s unique genetics approach and translational R&D capabilities.” 
 About XEN402 
 XEN402 treats pain locally at its source through blocking of Nav1.7 and
Nav1.8 sodium channels. XEN402 has been studied in human subjects as both oral and topical forms. In a published study, oral XEN402 was shown to be effective at relieving the pain associated with the rare neuropathic pain condition, erythromelalgia
(Pain 2012 Jan;153(1):80-5). Topical XEN402 was studied in a phase 2 trial to evaluate for effectiveness in alleviating the pain of post herpetic neuralgia. In this study the proportion of patients reporting clinically meaningful reductions in pain
was significantly greater for topical XEN402 than for placebo (p=0.049 for >30% response and p=0.0078 for >50% response). 
 About Teva

 Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to
high-quality healthcare by developing, producing and marketing affordable generic drugs as well as specialty pharmaceuticals and active 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

G-1 

 
pharmaceutical ingredients. Headquartered in Israel, Teva is a world leading generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60
countries. Teva’s branded businesses focus on CNS, oncology, pain, respiratory and women’s health therapeutic areas. Teva currently employs approximately 46,000 people around the world and reached $18.3 billion in net revenues in 2011.

 About Xenon Pharmaceuticals Inc. 
 Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing novel therapies based on the genetic causes of select metabolic, neurological and
cardiovascular diseases. For more information, visit the Company’s website at http://www.xenon-pharma.com. 
 Teva Safe Harbor

 The following discussion and analysis contains forward-looking statements, which express the current beliefs and
expectations of management. Such statements involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialize additional pharmaceutical products, competition from
the introduction of competing generic equivalents and due to increased governmental pricing pressures, the effects of competition on sales of our innovative medicines, especially Copaxone® (including competition from innovative orally-administered alternatives as well as from potential generic equivalents), potential liability for sales of generic
medicines prior to a final resolution of outstanding patent litigation, including that relating to our generic version of
Protonix®, the extent to which we may obtain U.S. market exclusivity for certain of our new generic medicines,
the extent to which any manufacturing or quality control problems damage our reputation for high quality production and require costly remediation, our ability to identify, consummate and successfully integrate acquisitions (including the
acquisition of Cephalon), our ability to achieve expected results through our innovative R&D efforts, dependence on the effectiveness of our patents and other protections for innovative medicines, intense competition in our specialty
pharmaceutical businesses, uncertainties surrounding the legislative and regulatory pathway for the registration and approval of biotechnology-based medicines, our potential exposure to product liability claims to the extent not covered by
insurance, any failures to comply with the complex Medicare and Medicaid reporting and payment obligations, our exposure to currency fluctuations and restrictions as well as credit risks, the effects of reforms in healthcare regulation and
pharmaceutical pricing and reimbursement, adverse effects of political instability and adverse economic conditions, major hostilities or acts of terrorism on our significant worldwide operations, increased government scrutiny in both the U.S. and
Europe of our agreements with brand companies, interruptions in our supply chain or problems with our information technology systems that adversely affect our complex manufacturing processes, the impact of continuing consolidation of our
distributors and customers, the difficulty of complying with U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority requirements, potentially significant 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

G-2 

 
impairments of intangible assets and goodwill, potential increases in tax liabilities resulting from challenges to our intercompany arrangements, the termination or expiration of governmental
programs or tax benefits, any failure to retain key personnel or to attract additional executive and managerial talent, environmental risks, and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31,
2011 and in our other filings with the U.S. Securities and Exchange Commission (“SEC”). Forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to update any forward-looking statements or
other information contained in this report, whether as a result of new information, future events or otherwise. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

G-3 

 SCHEDULE H – THIRD PARTY AGREEMENTS 

1. Master Services Agreement dated June 3, 2010 between Xenon Pharmaceuticals Inc. and [†]. 

2. Master Services Agreement dated July 25, 2007 between [†] and Xenon Pharmaceuticals Inc. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

H-1 

 GUARANTEE OF PERFORMANCE 
 THIS GUARANTEE is made effective as of December 7, 2012.  
 BETWEEN:

 TEVA PHARMACEUTICAL INDUSTRIES LTD., an Israeli limited liability corporation having its principal place of
business at 5 Basel Street, Petach, Tikva, 49131, Israel 
 (“Teva”) 

AND: 
 XENON
PHARMACEUTICALS INC., a Canadian corporation having its principal place of business at 3650 Gilmore Way, Burnaby, British Columbia, V5G 4W8 
 (“Xenon”) 
 WHEREAS: 

 

	A.	Xenon has entered into a Collaborative Development and License Agreement (the “Agreement”) with Ivax International GMBH (“Ivax”), a
wholly-owned subsidiary of Teva, upon the condition that Teva guarantee the performance of the financial obligations of Ivax under the Agreement; 

  

	B.	Teva is prepared to guarantee the performance of the financial obligations of Ivax under the Agreement upon the terms set out herein; 

IN CONSIDERATION of Xenon entering into the Agreement with Ivax, and for other good and valuable consideration, the receipt and sufficiency of
which is hereby acknowledged, Teva hereby unconditionally guarantees to Xenon the due and punctual performance by Ivax of all obligations of Ivax (financial or otherwise) under the Agreement. The following terms apply to this Guarantee: 

 

	 	(a)	Teva hereby unconditionally, absolutely and irrevocably guarantees and covenants to Xenon the full performance, observance and satisfaction of, any and all obligations
as and when due by Ivax to Xenon under the Agreement (the “Guaranteed Obligations”), 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

	 	(b)	The liability of Teva pursuant to this Guarantee shall not be discharged, limited or released by any extensions of time for any Guaranteed Obligations granted by Xenon
to Ivax. 

  

	 	(c)	If any default shall be made in the performance, observance and satisfaction of any of the Guaranteed Obligations, Teva covenants and agrees with Xenon that following
receipt from Xenon of notice of such default , it shall perform, observe and satisfy for the benefit of Xenon forthwith any and all of the Guaranteed Obligations in respect of which such default will have occurred, on the same terms and conditions
and subject to the same rights, benefits and limitations as are applicable under the Agreement respecting the carrying out of such Guaranteed Obligations by Ivax under the Agreement. 

 

	 	(d)	Until there has been full performance, observance, satisfaction and payment of all of the Guaranteed Obligations, the rights of Xenon and the obligations of Teva under
this Guarantee shall remain in full force and effect without regard to, and shall not be released, discharged or in any way affected or impaired, terminated or prejudiced by, the dissolution, winding-up or other cessation of existence of Ivax, the
amalgamation of Ivax with another corporation, the appointment of a custodian, liquidator, receiver or trustee in respect of the assets or undertaking, in whole or in part, of Ivax, any arrangement, bankruptcy, composition, insolvency, liquidation,
readjustment, receivership, reorganization or other similar proceeding or occurrence relating to Ivax, or any assignment by Ivax for the benefit of creditors. 

 

	 	(e)	In any action commenced by Xenon to enforce this Guarantee against Teva, Teva shall be entitled, in relation to the Guaranteed Obligations, to any and all of the
rights, defenses and equities to which Ivax would be entitled in respect of such Guaranteed Obligations. 

  

	 	(f)	The foregoing guarantee shall be fully enforceable against Teva without Xenon first bringing legal process against or exhausting any remedy against Ivax.

  

	 	(g)	Xenon may assign, grant, pledge or transfer its interest in this Guarantee or any of the guaranteed liabilities or any power, remedy or right of Xenon hereunder on the
same terms upon which Xenon may assign its interest in the Agreement. 

  

	 	(h)	No waiver on the part of Xenon to exercise, and no delay in exercising, any right hereunder will operate as a waiver of this Guarantee, nor will any single or partial
exercise of any right hereunder preclude the other or further exercise thereof of the exercise of any other right. The remedies provided hereunder are not exclusive of any remedies provided at law. 

 

	 	(i)	This Agreement shall be governed by and construed in accordance with the laws of the Province of Ontario and the laws of Canada in force therein without reference to
any rules of conflict of laws. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

2 

 IN WITNESS WHEREOF, the parties hereto have executed this Guarantee on the dates stated below:

  

			
	XENON PHARMACEUTICALS INC.
		
	Per:	 	 /s/ Simon Pimstone

		 	Name: Simon Pimstone
		 	Title: President and Chief Executive Officer
		
	Date:	 	December 7, 2012

  

			
	TEVA PHARMACEUTICAL INDUSTRIES LTD.
		
	Per:	 	 /s/ Gyal Desheh

		 	Name: Gyal Desheh
		 	Title: EVP and CFO
		
	Date:	 	December 7, 2012

  

			
	TEVA PHARMACEUTICAL INDUSTRIES LTD.
		
	Per:	 	 /s/ Judith Vardi

		 	Name: Judith Vardi
		 	Title: President & CEO of EMIA and APAC
		
	Date:	 	December 7, 2012

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
  

  
 

 
 March 27, 2013 
 Xenon Pharmaceuticals Inc. 
 200 - 3650 Gilmore Way 

Burnaby, BC 
 Canada 

Facsimile: 604-484-3450 

(“Xenon”) 
  

	Re:	Letter of agreement (the “Letter Agreement”) regarding the assignment of manufacture and supply agreements as described in the Collaborative Development
and License Agreement and regarding certain third party services under such agreements. 

 Dear President and Chief
Executive Officer, 
 We refer to the Collaborative Development and License Agreement dated December 7th, 2012 by and between Ivax International GmbH
(“Ivax”) and Xenon, pursuant to which Xenon and Ivax collaborate on the clinical development of certain compounds, and Ivax and its Affiliates shall further develop, manufacture and sell products containing such compound(s) (the
“Agreement”). 
 Pursuant to section 5.1 of the Agreement, Ivax has the sole right and responsibility for, and control
over, all Manufacturing of XEN402, XEN403 and Products, at its sole cost. In order to comply with such right and responsibility, the Parties agreed that Xenon shall devote all reasonable commercial efforts to assign the Third Party agreements
identified in Schedule H (“Third Party Agreements”) to Ivax, and effecting the assignment of the Third Party Agreements within thirty (30) days after the Effective Date of the Agreement. 

Without derogating from section 5.1, the Parties hereby agree: 
  

	 	1.	To amend and expand Schedule H to include the Master Services Agreement dated [†] between Xenon and [†], as amended pursuant to the Amendment #1 dated for
reference [†] and the letter agreement dated [†] (hereinafter collectively referred to as the “[†] MSA”), and further agree that the term “Third Party Agreements” is and shall hereafter be deemed to include
the [†] MSA. 

  

	 	2.	That Xenon is to withhold from contacting the relevant Third Parties to obtain their consent (as applicable) to assign such Third Party Agreements and to otherwise
withhold from effecting such assignments as described in Section 5.1 of the Agreement, in order to allow the smooth transaction of the Manufacture by said Third Parties, until such time(s) that: 

  
 Teva Pharmaceutical
Industries Ltd. 
 Tel: +972.3.9267267     Fax. +972.3.9267425.     5 Basel Street, Petach Tikva,
Israel. 49131 www.tevapharm.com 
 [†] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
 Page 1 of 3 

 

 
  

	 	a.	with respect to the [†] MSA (as defined below), that the (4) Work Orders described in paragraph 4(a) below have been executed; and 

 

	 	b.	with respect to the [†] MSA, that the (1) Task Order described in paragraph 4(b) below has been executed; and 

 

	 	c.	with respect to the Master Services Agreement dated [†] between Xenon and [†], as amended pursuant to the Amending Agreement made and dated as of [†]
(hereinafter collectively referred to as the “[†] MSA”), within [†] days following the date of this Letter Agreement; and/or 

  

	 	d.	such other date or time that may hereafter be agreed upon by and between duly authorized signatories of the Parties in writing. 

 

	 	3.	As of the dates referenced in paragraph 2 above, Xenon shall resume reasonable commercial efforts to obtaining the consent(s) to assign the relevant Third Party
Agreement(s) to Ivax and effecting such assignment(s). 

  

	 	4.	Until the assignment of each Third Party Agreement takes place, the Parties hereby agree that Xenon shall proceed doing business under the Third Party Agreement(s) on
behalf of and in cooperation with Ivax, in order to facilitate the conduct of certain services by said Third Parties as described below, and Ivax shall reimburse Xenon, through its affiliate Teva Pharmaceutical Industries Ltd
(“Teva”), within [†] after the last day of the month of which the invoice was received by Teva, for payments made by Xenon to such Third Parties relating to such services, further details of which are set forth below:

  

	 	a.	Pursuant to the Master Services Agreement made as [†] between Xenon Pharmaceuticals Inc. and [†], as amended February 20, 2013 (hereinafter collectively
referred to as the “[†] MSA”), [†] shall proceed providing the services, and on behalf of Ivax Xenon shall make payments to [†], each as described in: 

 

	 	i.	Work Order #[†]; 

  

	 	ii.	Work Order #[†]; 

  

	 	iii.	Work Order #[†]; and 

  

	 	iv.	Work Order #[†]. 

  

	 	b.	Pursuant to the [†] MSA, [†] shall proceed providing the services, and on behalf of Ivax Xenon shall make payments to[†], each as described in:

  

	 	i.	Task Order #[†], relating to [†] (such services which the Parties currently anticipate will commence in [†]). 

 

	 	5.	As of the date of assignment of the [†] MSA, Xenon shall also assign to Ivax, the (4) Work Orders referenced in paragraph 4(a) above.

  

	 	6.	As of the date of assignment of the [†] MSA, Xenon shall also assign to Ivax, the Task Order referenced in paragraph 4(b) above. 

  
 Teva Pharmaceutical
Industries Ltd. 
 Tel: +972.3.9267267     Fax. +972.3.9267425.     5 Basel Street, Petach Tikva,
Israel. 49131 www.tevapharm.com 
 [†] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
 Page 2 of 3 

 

 
  

	 	7.	The Agreement shall be construed in conjunction with this Letter Agreement as an integral part thereof and shall remain of full force and effect, save as specifically
amended herein. The remaining terms and conditions of the Agreement shall continue in full force and effect. However, if there are any inconsistencies between the terms of this Letter Agreement and the provisions of Agreement, then this Letter
Agreement shall prevail. 

  

	 	8.	All capitalized terms used in this Letter Agreement, which are not otherwise defined herein, shall have the same meaning as ascribed to such terms in the Agreement.

 We would like to take this opportunity to thank you for your cooperation on this project. 

Please confirm your agreement to the above by signing both copies of this Letter Agreement, returning one copy to me at the address above and retaining a
copy for your records. 
 Yours sincerely, 
  

					
	Ivax International GmbH,
		
	 By:
	 	 /s/ Naam Baram

		 	 Name:
	 	 Naama Baram

		 	 Title:
	 	 General Manager

		
	 By:
	 	 /s/ David Koch

		 	 Name:
	 	 David Koch

		 	 Title:
	 	 Managing Officer

 Countersigned for and on behalf of Xenon Pharmaceuticals Inc., 

 

					
	 By:
	 	 /s/ Simon Pimstone

		 	 Name:
	 	 Simon Pimstone

		 	 Title:
	 	 President and CEO

  

	Cc:	Xenon Pharmaceuticals Inc., 200 - 3650 Gilmore Way, Burnaby, BC, Canada 

 Attention: General Counsel and Corporate Secretary. Facsimile: 604-484-3450 

  
 Teva Pharmaceutical
Industries Ltd. 
 Tel: +972.3.9267267     Fax. +972.3.9267425.     5 Basel Street, Petach Tikva,
Israel. 49131 www.tevapharm.com 
 [†] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 
 Page 3 of 3 

					
	 

	  	  	  	IVAX International GmbH
	  	  	  
 Alpenstrasse
2

	  	  	 8640 Rapperswil

	  	  	 Switzerland

	  	  	  
 Tel: +41 (0)55 220
1040

	  	  	 Fax: +41 (0)55 220 1049

			
		  		  	 April 4, 2013

 Xenon Pharmaceuticals Inc. 
 200 - 3650 Gilmore Way 
 Burnaby, BC 
 Canada 
 Facsimile: 604-484-3450 
 (“Xenon”) 
  

	 	Re:	Letter of agreement (the “Letter Agreement #2”) regarding certain third party services to be conducted in furtherance of clinical development activities
under the Collaborative Development and License Agreement. 

 Dear President and Chief Executive Officer, 

We refer to the Collaborative Development and License Agreement dated December 7th, 2012, as amended by a Letter of Agreement dated March 27,
2013, by and between Ivax International GmbH (“Ivax”) and Xenon, pursuant to which Xenon and Ivax collaborate on the clinical development of certain compounds, and Ivax and its Affiliates shall further develop, manufacture and sell
products containing such compound(s) (the “Agreement”). 
 The Parties hereby agree: 

 

	 	1.	Provided that Xenon has first received a written request to engage such Third Party consultants and/or service providers from one or more persons designated in writing
from time to time by a duly authorized signatory of Teva as having the authority to provide such request (such designated persons which shall include its Project Leader under the Agreement (currently Dr. Shoshi Tessler) and/or Dr. Michaela
Vardi), such written request which may be in the form of an email or otherwise, in cooperation with Ivax, Xenon may and shall proceed doing business under its consulting agreements and/or services agreements with such Third Parties in order to
facilitate the conduct of certain services by these consultants/service providers which are and/or shall be contemplated under the Collaborative Development Plan of the Agreement, and Ivax shall reimburse Xenon, through its affiliate Teva
Pharmaceutical Industries Ltd (“Teva”), within 60 days after the last day of the month of which the invoice was received by Teva, for payments made by Xenon to such consultants/service providers relating to such services.

  

	 	2.	The Agreement shall be construed in conjunction with this Letter Agreement #2 as an integral part thereof and shall remain of full force and effect, save as
specifically amended herein. The remaining terms and conditions of the Agreement shall continue in full force and effect. However, if there are any inconsistencies between the terms of this Letter Agreement #2 and the provisions of Agreement, then
this Letter Agreement #2 shall prevail. 

  
 Teva Pharmaceutical
Industries Ltd. 
 Tel: +972.3.9267267     Fax. +972.3.9267425.     5 Basel Street, Petach Tikva,
Israel. 49131 
 [†] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED
SEPARATELY WITH THE COMMISSION 
 Page 1 of 2 

					
	

	 		  	 IVAX International GmbH
  

Alpenstrasse 2
 8640 Rapperswil

Switzerland
  
 Tel: +41 (0)55 220 1040
 Fax: +41 (0)55 220 1049

 

	3.	All capitalized terms used in this Letter Agreement #2, which are not otherwise defined herein, shall have the same meaning as ascribed to such terms in the Agreement.

 We would like to take this opportunity to thank you for your cooperation on this project. 

Please confirm your agreement to the above by signing both copies of this Letter Agreement #2, returning one copy to me at the address above and
retaining a copy for your records. 
  

					
	Yours sincerely,
	
	Ivax International GmbH,
		
	By:	 	 /s/ Naama Baram

		 	Name:	 	Naama Baram
		 	Title:	 	General Manager
		
	By:	 	 /s/ David Koch

		 	Name:	 	David Koch
		 	Title:	 	Managing Officer

 Countersigned for and on behalf of Xenon Pharmaceuticals Inc., 

 

			
	By:	 	 /s/ Karen G. Corraini

		 	Name: Karen G. Corraini
		 	Title: General Counsel and Corporate Secretary

  

	Cc:	Xenon Pharmaceuticals Inc., 200 - 3650 Gilmore Way, Burnaby, BC, Canada 

 Attention: General Counsel and Corporate Secretary. Facsimile: 604-484-3450 

  
 Teva Pharmaceutical
Industries Ltd. 
 Tel: +972.3.9267267     Fax. +972.3.9267425.     5 Basel Street, Petach Tikva,
Israel. 49131 
 [†] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED
SEPARATELY WITH THE COMMISSION 
 Page 2 of 2Prepared by R.R. Donnelley Financial -- EX-10.5

 Exhibit 10.5 
 LICENSE AGREEMENT 
 BETWEEN: 

THE UNIVERSITY OF BRITISH COLUMBIA, a corporation
continued under the University Act of British Columbia and having its administrative offices at 2075 Wesbrook Mall, in the City of Vancouver, in the Province of British Columbia, V6T 1W5 

(the “University”) 
 AND: 
 XENON GENETICS
INC., a corporation continued under the laws of Canada, and having its administrative offices at Suite 100—2386 East Mall, Vancouver, British Columbia, V6T 1Z3 

(the “Licensee”) 
 WHEREAS: 
 A. The University has been engaged in research during the course of which it has
invented, developed and/or acquired certain technology identified in UBC Invention Disclosure File #UBC 94-061, entitled “Lipolipase Mutation 291, Implication for Coronary Artery Disease”, and File #UBC 91-003, entitled
“Mutation in Human Lipoprotein Lipase Gene which causes Type 1 Hyperlipoproteinemia”; 
 B. [†] has invented,
developed and/or acquired certain technology which may have common subject matter with certain technology invented, developed and/or acquired by the University, and identified in UBC Invention Disclosure File # UBC 99-082, entitled
“Recombinant Viruses Preparation and use thereof in Gene Therapy; 
 C. The University has been jointly engaged in research with the
Academic Hospital at the University of Amsterdam (“AMC”) during the course of which they have jointly invented, developed and/or acquired certain technology identified in UBC Invention Disclosure File # UBC 00039, entitled
“Mutation 447”; 
 D. The research done at the University with respect to the above referenced technologies was undertaken by
Dr. Michael Hayden who is an employee of the University engaged in a number of research projects and a founder and chief scientific officer of the Licensee; 
 E. [†] 
 F. The University is desirous of entering into this agreement (the
“Agreement’) with the objective of furthering society’s use of its advanced technology, and to generate further research in a manner consistent with its status as a non-profit, tax exempt educational institution; and

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

 G. Subject to the terms and conditions hereinafter set out, the Licensee is desirous of the University
granting a license to the Licensee to use or cause to be used the University’s interest in such technology to manufacture, distribute, market, sell and/or license or sublicense products and services derived or developed from such technology.

 NOW THEREFORE THIS AGREEMENT WITNESSETH that in consideration of the premises and of the mutual covenants herein set forth,
the parties hereto have covenanted and agreed as follows: 
 1.0 DEFINITIONS: 

1.1 In this Agreement, unless a contrary intention appears, the following words and phrases shall mean: 

 

	 	(a)	“Accounting”: an accounting statement setting out in detail how the amount of Revenue was determined; 

 

	 	(b)	“Affiliated Company” or “Affiliated Companies”: two or more corporations where the
relationship between them is one in which one of them is a subsidiary of the other, or both are subsidiaries of the same corporation, or fifty percent (50%) or more of the voting shares of each of them is owned or controlled by the same person,
corporation or other legal entity; 

  

	 	(c)	“Collaborative Research Agreement”: the Collaborative Research Agreement dated August 1, 2000 between the University and the Licensee,
which contemplates the performance of a research project entitled “LPL Gene Therapy for LPL Deficiency”, 

  

	 	(d)	“Confidential Information”: any part of the Information which is designated by either party (the “Disclosing
Party”) as confidential, whether orally or in writing but excluding any part of the Information: 

  

	 	(i)	possessed by the receiving party prior to receipt from the Disclosing Party, other than through prior disclosure by the Disclosing Party, as evidenced by the receiving
party’s business records; 

  

	 	(ii)	published or available to the general public otherwise than through a breach of this Agreement; 

 

	 	(iii)	obtained by the receiving party from a third party with a valid right to disclose it, provided that said third party is not under a confidentiality obligation to the
Disclosing Party; or 

  

	 	(iv)	independently developed by employees, agents or consultants of the receiving party who had no knowledge of or access to the Disclosing Party’s Information as
evidenced by the receiving party’s business records; 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

-2- 

	 	(e)	“Date of Commencement” or “Commencement Date”: this Agreement will be deemed to have come
into force on the Date of Commencement which shall be August 1, 2000, and shall be read and construed accordingly; 

  

	 	(f)	“Effective Date of Termination”: the date on which this Agreement is terminated pursuant to Article 18; 

 

	 	(g)	“Field of Use”: gene therapy being [†]. 

 

	 	(h)	“Xenon Improvements”: improvements, variations, updates, modifications, and enhancements which relate to the Technology made
solely by the Licensee or any sublicensees of the Licensee at any time after the Commencement Date that cannot be practised without infringing the claims of the Patents; 

 

	 	(i)	“UBC Improvements”: improvements, variations, updates, modifications, and enhancements which relate to the Technology made solely
by the University at any time after the Commencement Date that cannot be practised without infringing the claims of the Patents; 

  

	 	(j)	“Joint Improvements”: improvements, variations, updates, modifications, and enhancements which relate to the Technology made
jointly by the University and the Licensee or the University and any sublicensees of the Licensee at any time after the Commencement Date that cannot be practised without infringing the claims of the Patents; 

 

	 	(k)	“Improvements”: collectively the UBC Improvements, the Xenon Improvements and the Joint Improvements; 

 

	 	(l)	“Information”: any and all Technology and any and all Improvements, the terms and conditions of this Agreement and any and all
oral, written, electronic or other communications and other information disclosed or provided by the parties including any and all analyses or conclusions drawn or derived therefrom regarding this Agreement and information developed or disclosed
hereunder, or any party’s raw materials, processes, formulations, analytical procedures, methodologies, products, samples and specimens or functions; 

  

	 	(m)	“Patents”: collectively the patents listed in Schedule “A”, including any patents or patent
applications that may be added to Schedule “A” from time to time, and any counterparts, Continuation-ln-Part, renewals, divisionals, reissues, corresponding international patent applications, continuations and any
patents resulting therefrom. For greater certainty the Patents and Patent applications as herein defined shall include, any and all Patents or Patent Applications arising from, or relating to Improvements, including Improvements that result from the
Collaborative Research Agreement between the parties, which Patents or Patent applications shall be added to Schedule “A”; 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

-3- 

	 	(n)	“Product(s)”: goods manufactured in connection with the use of all or some of the Technology and/or any Improvements;

  

	 	(o)	“Revenue”: [†], less the following deductions to the extent included in the amounts invoiced and thereafter actually allowed
and taken: 

  

	 	(i)	[†] 

  

	 	(ii)	[†] 

  

	 	(iii)	[†] 

  

	 	(iv)	[†], and 

  

	 	(v)	[†] 

 Where any Revenue is
derived from a country other than Canada it shall be converted to the equivalent in Canadian dollars on the date the Licensee is deemed to have received such Revenue pursuant to the terms hereof at the rate of exchange set by the Bank of Montreal
for buying such currency. The amount of Canadian dollars pursuant to such conversion shall be included in the Revenue; 
  

	 	(p)	“Royalty Due Dates”: the last working day of March, June, September and December of each and every year during which this
Agreement remains in full force and effect; 

  

	 	(q)	“Sublicensing Revenue”: [†], but excluding: 

 

	 	(i)	[†]; 

  

	 	(ii)	[†]; 

  

	 	(iii)	research fees received by the Licensee in reimbursement for the actual costs of research and development undertaken by the Licensee pursuant to a written research plan.

 Where any Sublicensing Revenue is derived from a country other than Canada it shall be converted to the
equivalent in Canadian dollars on the date the Licensee is deemed to have received such Sublicensing Revenue pursuant to the terms hereof at the rate of exchange set by the Bank of Montreal for buying such currency. The amount of Canadian dollars
pursuant to such conversion shall be included in the Sublicensing Revenue; 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

-4- 

	 	(r)	“Technology”: any and all knowledge, know-how and/or technique or techniques invented, developed and/or acquired, prior to the
Date of Commencement by the University relating to, and including the technology described in Schedule “A” hereto, as amended from time to time, including, without limitation the Patents, and collectively the
University’s interest in the UBC Technology, the UBC – [†] Technology and the UBC—Amsterdam Technology (as hereinafter defined in Article 2.1) and all research, data, specifications, instructions, manuals, papers or other
materials of any nature whatsoever, whether written or otherwise, relating to same; and 

  

	 	(s)	“UBC Trade-marks”: any mark, trade-mark, service mark, logo, insignia, seal, design, symbol or device used by the University in
any manner whatsoever. 

 2.0 PROPERTY RIGHTS IN AND
TO THE TECHNOLOGY: 
 2.1 The parties hereto hereby acknowledge and agree
that: 
  

	 	(a)	Dr. Michael Hayden has assigned his rights to the Technology and any Improvements to the University; 

 

	 	(b)	the University owns any and all right, title and interest in and to the technology identified in UBC Invention Disclosure File # UBC 94-061, entitled
“Lipolipase Mutation 291, Implication for Coronary Artery Disease”, and File # UBC 91-003, entitled “Mutation in Human Lipoprotein Lipase Gene which causes Type 1 Hyperlipoproteinemia” as well as any and all
UBC Improvements (the “UBC Technology”); 

  

	 	(c)	[†] has developed or acquired certain technology which has common subject matter with certain technology invented, developed and/or acquired by the University, and
the University and [†] are named as joint owners within the United States of the technology identified in UBC Invention Disclosure File # UBC 99-082, entitled “Recombinant Viruses Preparation and use thereof in Gene Therapy”
(the “UBC – [†] Technology”); 

  

	 	(d)	the University and AMC jointly own the technology identified in UBC Invention Disclosure File # UBC 00-039, entitled “Mutation 447” (the
“UBC—Amsterdam Technology”), 

  

	 	(e)	the University and the Licensee, subject to the terms of this Agreement jointly own all Joint Improvements, and provided that notwithstanding the applicable patent or
other intellectual property laws of any jurisdiction both the University and the Licensee shall only use and commercially exploit any Joint Improvements in accordance with the terms of this Agreement; and 

 

	 	(f)	the Licensee, subject to the terms of this Agreement, owns any all right, title and interest in and to the Xenon Improvements. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

-5- 

 2.2 The Parties shall, on request, enter into such further agreements and execute any and all documents as
may be required to ensure that ownership of the Technology, and any Improvements vest with, or remain with, the parties as set out in Article 2.1. 
 3.0 GRANT OF LICENSE: 

3.1 In consideration of the license fees, milestone payments and royalty payments reserved herein, and the covenants on the part of the Licensee contained
herein, the University hereby grants to the Licensee within the Field of Use: 
  

	 	(a)	a worldwide exclusive license to use and sublicense the UBC Technology, any UBC Improvements or any Joint Improvements, and any Patents related thereto, including the
right to manufacture, distribute, and sell Products and provide services on the terms and conditions hereinafter set forth during the term of this Agreement; 

 

	 	(b)	a license of the University’s rights to the UBC – [†] Technology and any UBC Improvements or Joint Improvements and any Patents related thereto,
including the right to use and sublicense the University’s rights in the UBC – [†] Technology and any UBC Improvements or Joint Improvements thereto, and to manufacture, distribute, and sell Products and provide services on the terms
and conditions hereinafter set forth during the term of this Agreement. The University acknowledges and agrees that it shall not license within the Field of Use any of the University’s rights to the UBC – [†] Technology or any UBC
Improvements or Joint Improvements thereto to any entity other than the Licensee for the duration of the term of this Agreement; 

  

	 	(c)	a worldwide co-exclusive license together with Amsterdam Molecular Therapeutics B.V. (“AMT”) of the University’s rights to
the UBC—Amsterdam Technology and any UBC Improvements or Joint Improvements and any Patents related thereto, including the right to use and sublicense the University’s rights to the UBC -Amsterdam Technology and any UBC Improvements or
Joint Improvements thereto, and to manufacture, distribute, and sell Products and provide services on the terms and conditions hereinafter set forth during the term of this Agreement. The Licensee acknowledges and agrees that AMC has granted a
worldwide co-exclusive license to AMT to use and sublicense the UBC—Amsterdam Technology. The University acknowledges and agrees that it shall not license within the Field of Use any of the University’s rights to the UBC—Amsterdam
Technology or any UBC Improvements or Joint Improvements thereto to any entity other than the Licensee for the duration of the term of this Agreement; 

 3.2 The grant of the license: 
  

	 	(a)	set out in Article 3.1(b) is made expressly subject to all of the rights which [†] has acquired to the UBC – [†] Technology. The Licensee hereby
acknowledges that, the use, practice, exploitation and commercialization of any rights to the UBC – [†] Technology may be subject to the consent of [†], and that it shall be the Licensee’s sole responsibility to obtain such
consent from [†]; 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

-6- 

	 	(b)	set out in Article 3.1(c) is expressly made subject to the conditions precedent that the written consent of AMC be obtained by the University prior to the grant of such
a co-exclusive license to the Licensee. 

 In the event the University is unable to obtain the consent referred to in Article
3.2(b), the grant of license by the University to the Licensee herein shall be limited to the grant of license referred to in Article 3.1(a) and (b). 
 3.3 The licenses granted herein are personal to the Licensee and are not granted to any Affiliated Company or Affiliated Companies, subject to the right of the Licensee to sublicense as set out herein.

 3.4 The Licensee shall not cross-license the Technology or any UBC Improvements or Joint Improvements without the prior written consent of the
University. 
 3.5 Notwithstanding Article 3.1, and subject to Article 10.6 herein, the parties acknowledge and agree that the University may use
the Technology and any Improvements (including UBC Improvements, Joint Improvements and Xenon Improvements) without charge in any manner whatsoever for research, scholarly publication, educational or other non-commercial uses. Except as expressly
provided for above, the University may not use or license any Joint Improvements without the express, prior written consent of the Licensee. 

4.0 SUBLICENSING: 
 4.1 The Licensee shall have the right to grant sublicenses to Affiliated Companies and other third parties with respect to the Technology and any Improvements with the prior written consent of the
University, such consent not to be unreasonably withheld. The Licensee shall not be obligated to obtain the University’s consent to the granting of a sublicense if the proposed sublicensee has a market capitalization in excess of CAN. $[†]
at the time of the granting of the sublicense. Further, the University, subject to a full legal review and approval of the terms of such sublicense agreement and review of the performance terms in accordance with Article 11.3, hereby expressly
consents to the Licensee granting a sublicense to AMT. The Licensee will furnish the University with a copy of each sublicense granted within 30 days after execution. The Licensee shall cause each sublicensee to indemnify the University on the same
terms and conditions as are contained in Article 9.1 and which indemnity shall extend to cover any sub-sublicenses granted by such sublicensee. 

4.2 Except as hereinafter provided, any sublicense granted by the Licensee shall be personal to the sublicensee and shall not be assignable without the
prior written consent of the University, such consent not to be unreasonably withheld. A sublicensee may grant a further sub-sublicense to a third party for the purpose of developing, marketing, selling, manufacturing or distributing Products with
the prior written consent of the University, such consent not to be unreasonably withheld. A sublicensee shall not be obligated to obtain the University’s consent to 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

-7- 

 
the granting of a sub-sublicense if the proposed sub-sublicensee has a market capitalization in excess of CAN. $[†] at the time of the granting of the sub-sublicense. The sublicensee shall
furnish the University with a copy of such sub-sublicense granted within 30 days after execution. A sublicense can be assigned without the consent of the University to an Affiliated Company of the sublicensee or as part of a merger, acquisition or
other business combination in which all or substantially all of the assets of the sublicensee are transferred. All sublicenses and sub-sublicensees shall contain covenants by the sublicensee or sub-sublicensees to observe and perform the terms and
conditions contained in this Agreement, to the extent that the same are applicable. 
 4.3 Upon execution of a sublicense with AMT, AMT may
register such sublicense with the relevant patent authorities, in those jurisdictions in which AMT carries on business and/or has its chief place of business. The University will provide reasonable assistance to AMT with respect to such
registrations, provided that all reasonable costs incurred by the University in association with such registrations, including all legal expenses, shall be paid for by AMT, or the Licensee in the event of any default in payment by AMT. The
University will, on request by the Licensee, endeavour to provide an estimate of such costs. 
 5.0
ROYALTIES: 
 5.1 In consideration of the license granted hereunder, the Licensee
shall pay to the University a royalty comprised of: 
  

	 	(a)	[†]% of the Revenue, and 

  

	 	(b)	[†]% of the Sublicensing Revenue. 

 For
clarification, Sublicensing Revenue shall be exclusive of Revenue, such that in no event shall the Licensee owe royalties to the University under both of Articles 5.1(a) and 5.1(b) in respect of any given amount of revenue. 

5.2 If commercial development by the Licensee of a Product or Products incorporating the Technology or any Improvements is not possible without licensing
other technology from an arms length third party to be used in combination with the Technology or any Improvements, then [†]: 
  

	 	•	 	 [†] and 

  

	 	•	 	 [†] 

 [†]

 5.3 The royalty shall become due and payable within [†] days of each respective Royalty Due Date and shall be calculated with respect to
the Revenue and the Sublicensing Revenue in the three month period immediately preceding the applicable Royalty Due Date. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

-8- 

 5.4 All payments of royalties made by the Licensee to the University hereunder shall be made in Canadian
dollars without any reduction or deduction of any nature or kind whatsoever, except as may be prescribed by Canadian law. 
 5.5 Products shall
be deemed to have been sold by the Licensee and included in the Revenue when invoiced, or if not invoiced, then when delivered, shipped, or paid for, whichever is the first. Sublicensing Revenue shall be deemed to have been received by the Licensee
with respect to each of its sublicensees when such consideration is actually received by the Licensee from its sublicensees. 
 5.6 Any
transaction, disposition, or other dealing involving the Technology or any part thereof between the Licensee and another person that is not made at fair market value shall be deemed to have been made at fair market value, and the fair market value
of that transaction, disposition, or other dealing shall be added to and deemed part of the Revenue or the Sublicensing Revenue, as the case may be, and shall be included in the calculation of royalties under this Agreement. 

6.0 INITIAL LICENSE FEE, ANNUAL MAINTENANCE FEE
AND MINIMUM ANNUAL ROYALTY: 
 6.1 As
part of the consideration for the rights granted by the University to the Licensee hereunder, the Licensee agrees to issue to the University, as an initial license fee the sum of $[†] (Canadian funds) (the “Initial License
Fee”). The said sum shall be paid concurrently with the execution of this Agreement. Neither all nor any portion of the said sum shall be refundable to the Licensee under any circumstances. 

6.2 The Licensee acknowledges and agrees that the University has agreed to accept the Initial License Fee on the condition that [†] 

6.3 In further consideration for the license granted hereunder, the Licensee shall pay to the University, in addition to all other amounts due under this
Agreement, an annual maintenance fee of CAN. $[†] payable on execution of this Agreement and thereafter on or before September 1st of each year during which this Agreement remains in full force and effect (the “Annual Maintenance
Fee”). Neither all nor any part of the Annual Maintenance Fee paid shall be refundable to the Licensee under any circumstances. 

6.4 In addition to all other payments due hereunder, the Licensee shall pay to the University the following milestones, for each product developed by the
Licensee or a sublicensee: 
  

	 	(a)	within [†] days of [†] the sum of CAN. $[†]; 

  

	 	(b)	within [†] days of [†], the sum of CAN. $[†]; and 

  

	 	(c)	within [†] days of [†], the sum of CAN. $[†]. 

 For greater clarity, it is agreed that the foregoing milestone payments shall be due and payable by the Licensee regardless of whether such milestones are achieved by the Licensee or a sublicensee, and
such milestone payments shall in no way effect or diminish the royalties which are due and payable hereunder, and in particular, the calculation of the amount of royalty payable in connection with the Sublicensing Revenue. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

-9- 

 6.5 The Licensee shall pay to the University the milestones due under Article 6.4, in the timeframes
provided under Article 6.4, with the following exceptions: 
  

	 	(a)	[†] 

  

	 	(b)	[†]: 

  

	 	(i)	[†], or 

  

	 	(ii)	[†]; and 

 6.6 For greater certainty, and
notwithstanding any provisions within this Agreement to the contrary, the parties agree that: 
  

	 	(a)	[†]; and 

  

	 	(b)	[†]. 

 7.0
PATENTS: 
 7.1 The Licensee shall have the right to identify any process, use or products arising out
of the Technology and any UBC Improvements or any Joint Improvements that may be patentable including the right to apply for further patents in other jurisdictions, or continuations, continuations-in-part, divisions, reissues, re-examinations or
extensions of the Patents or any further applications made hereunder, and shall take all reasonable steps to apply for such patents in the name of the University or jointly in the names of the University and the Licensee in the case of any patent
relating to a Joint Improvement, provided that the Licensee pays all costs of applying for, registering and maintaining the patent in such jurisdictions as the Licensee may designate. The Licensee shall be responsible for the management, filing,
prosecution and maintenance of such Patents, provided however, that the Licensee will obtain the University’s prior consent, as to any material decision or action taken in the prosecution of such Patents, which consent shall not to be
unreasonably withheld by the University. The Licensee shall also provide the University with copies of all correspondence and documents relating to the filing, prosecution and maintenance of the Patents. In the event that this Agreement is
terminated for any reason whatsoever, the Licensee shall pay all outstanding costs relating to such patent applications to the date of termination and shall direct the patent agents responsible for such patent applications to take all further
instructions, if any, relating to such applications from the University. 
 7.2 On the issuance of a patent in accordance with Article 7.1, the
Licensee shall have the right to become, and shall become, the licensee of the same all pursuant to the terms contained herein. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

-10- 

 7.3 As of April 27, 2001, the University has incurred CAN. $80,091.70 in patenting the Technology. On
execution of this Agreement, the Licensee will pay to the University the sum of CAN. $80,091.70 to reimburse the University for these costs. All further costs with respect to all Patents or Patent Applications relating to the Technology and any UBC
Improvements or Joint Improvements, and all maintenance fees for such patents incurred by the University at any time after April 27, 2001, shall be reimbursed by the Licensee to the University within 30 days of presentation of receipts and/or
invoices by the University to the Licensee. Without limiting the generality of the forgoing the Licensee agrees to pay for all costs with respect to the Patents, patent applications, divisionals, substitutions, continuations, continuations in part,
all claims of foreign patent applications. 
 7.4 Should the Licensee decide to: 

 

	 	(a)	discontinue pursuing patent protection in relation to the Patents, or any continuation, continuation-in-part, division, re-issue, re-examination or extension of the
Patent(s), or 

  

	 	(b)	not pursue patent protection in relation to the Patent(s) in any jurisdiction, or 

 

	 	(c)	discontinue or not pursue patent protection in relation to any further process, use or products arising out of the UBC Improvements or Joint Improvements in any
jurisdiction, 

 then the Licensee shall provide the University with a minimum of [†] days notice of its decision to
discontinue or not to pursue such patent protection in sufficient time for the University to file a patent application, or continue pursuing an existing patent application. During the [†] day transition period the Licensee shall be responsible
for all costs of filing, prosecuting and maintaining the Patents. 
 7.5 The Licensee shall provide to the University [†]. 

7.6 [†]. 
 7.7 The Licensee will ensure
proper patent marking for all Technology, and any UBC Improvements or Joint Improvements licensed hereunder and shall clearly mark the appropriate patent numbers on any Products made using the Technology and any UBC Improvements or Joint
Improvements or any patented processes used to make such Products. 
 8.0 DISCLAIMER OF
WARRANTY: 
 8.1 The University makes no representations, conditions or warranties, either express or
implied, with respect to the Technology or any Improvements or the Products. Without limiting the generality of the foregoing, the University specifically disclaims any implied warranty, condition or representation that the Technology or any
Improvements or the Products: 
  

	 	(a)	shall correspond with a particular description; 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

-11- 

	 	(b)	are of merchantable quality; 

  

	 	(c)	are fit for a particular purpose; or 

  

	 	(d)	are durable for a reasonable period of time. 

The University shall not be liable for any loss, whether direct, consequential, incidental or special, which the Licensee suffers arising from any
defect, error, fault or failure to perform with respect to the Technology or any Improvements or Products, even if the University has been advised of the possibility of such defect, error, fault or failure. The Licensee acknowledges that it has been
advised by the University to undertake its own due diligence with respect to the Technology and any Improvements. 
 8.2 The parties acknowledge
and agree that the International Sale of Goods Contracts Convention Act and the United Nations Convention on Contracts for the International Sale of Goods have no application to this Agreement. 

8.3 Nothing in this Agreement shall be construed as: 
  

	 	(a)	a warranty or representation by the University as to title to the Technology and/or any Improvement or that anything made, used, sold or otherwise disposed of under the
license granted in this. Agreement is or will be free from infringement of patents, copyrights, trade-marks, industrial design or other intellectual property rights; 

 

	 	(b)	an obligation by the University to bring or prosecute or defend actions or suits against third parties for infringement of patents, copyrights, trade-marks, industrial
designs or other intellectual property or contractual rights; or 

  

	 	(c)	the conferring by the University of the right to use in advertising or publicity the name of the University or the UBC Trade-marks. 

8.4 Notwithstanding Article 8.3, in the event of an alleged infringement of the Technology or any UBC Improvements or Joint Improvements or any right
with respect to the Technology or any UBC Improvements or Joint Improvements, the Licensee or a sublicensee shall have, upon receiving the prior written consent of the University, such consent not to be unreasonably withheld, the right but not the
obligation to prosecute litigation designed to enjoin infringers of the Technology or any UBC Improvements or Joint Improvements. The Licensee acknowledges and agrees that the University may require the consent of [†] and/or AMC, as appropriate
(in so far as any UBC – [†] Technology or UBC—Amsterdam Technology is alleged to be infringed), prior to providing such consent. Provided that it has first granted its prior written consent, the University agrees to co-operate to the
extent of executing all necessary documents and to vest in the Licensee or sublicensee the right to institute any such suits, so long as all the direct and indirect costs and expenses of bringing and conducting any such litigation or settlement
shall be borne by the Licensee or sublicensee and in such event all recoveries shall enure to the Licensee or sublicensee. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

-12- 

 8.5 If any complaint alleging infringement or violation of any patent or other proprietary rights is made
against the Licensee or a sublicensee of the Licensee with respect to the use of the Technology or any UBC Improvements or Joint Improvements or the manufacture, use or sale of the Products, the following procedure shall be adopted: 

 

	 	(a)	the Licensee shall promptly notify the University upon receipt of any such complaint and shall keep the University fully informed of the actions and positions taken by
the complainant and taken or proposed to be taken by the Licensee on behalf of itself or a sublicensee; 

  

	 	(b)	except as provided in Article 8.5(d), all costs and expenses incurred by the Licensee or any sublicensee of the Licensee in investigating, resisting, litigating and
settling such a complaint, including the payment of any award of damages and/or costs to any third party, shall be paid by the Licensee or any sublicensee of the Licensee, as the case may be; 

 

	 	(c)	no decision or action concerning or governing any final disposition of the complaint shall be taken without full consultation with and approval by the University;

  

	 	(d)	the University may elect to participate formally in any litigation involving the complaint to the extent that the court may permit, but any additional expenses
generated by such formal participation shall be paid by the University (subject to the possibility of recovery of some or all of such additional expenses from the complainant); 

 

	 	(e)	notwithstanding Article 8.3, if the complainant is willing to accept an offer of settlement and one of the parties to this Agreement is willing to make or accept such
offer and the other is not, then the unwilling party shall conduct all further proceedings at its own expense, and shall be responsible for the full amount of any damages, costs, accounting of profits and settlement costs in excess of those provided
in such offer, but shall be entitled to retain unto itself the benefit of any litigated or settled result entailing a lower payment of costs, damages, accounting of profits and settlement costs than that provided in such offer; and

  

	 	(f)	the royalties payable pursuant to this Agreement shall be paid by the Licensee to the University in trust from the date the complaint is made until such time as a
resolution of the complaint has been finalized. If the complainant prevails in the complaint, then the royalties paid to the University in trust pursuant to this Article shall be returned to the Licensee, provided that the amount returned to the
Licensee hereunder shall not exceed the amount paid by the Licensee to the complainant in the settlement or other disposition of the complaint. If the complainant does not prevail in the complaint, then the University shall be entitled to retain all
royalties paid to it pursuant to this Article. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

-13- 

 9.0 INDEMNITY AND LIMITATION OF
LIABILITY: 
 9.1 The Licensee hereby indemnifies, holds harmless and defends the University, its Board of
Governors, officers, employees, faculty, students, invitees and agents against any and all claims (including all legal fees and disbursements incurred in association therewith) collectively a
“Claim”) arising out of the exercise of any rights under this Agreement including, without limiting the generality of the foregoing, against any damages or losses, consequential or otherwise,
arising from or out of the use of the Technology or Products licensed under this Agreement by the Licensee or its sublicensees, and sub-sublicensees, or their customers or end-users howsoever the same may arise. A condition of this obligation is
that, whenever the University has information from which it may reasonably conclude an incident has occurred which could give rise to a Claim, the University shall promptly give notice to the Licensee of all pertinent data surrounding such incident
and, in the event a Claim is made or suit is brought the University shall assist the Licensee and cooperate in the gathering of information with respect to the time, place and circumstances and in obtaining the names and addresses of any injured
parties and available witnesses. The University shall not voluntarily make any payment or incur any expense in connection with any such Claim without the prior written consent of the Licensee. The Licensee shall have control over the defence and
settlement of any Claim, provided that the Licensee keeps the University informed of all activities in a timely manner. The obligations set forth in this Article 9.1 shall survive the expiration or termination of this Agreement. 

9.2 Subject to Article 9.3, the University’s total liability, whether under the express or implied terms of this Agreement, in tort (including
negligence), or at common law, for any loss or damage suffered by the Licensee, whether direct, indirect or special, or any other similar or like damage that may arise or does arise from any breaches of this Agreement by the University, its Board of
Governors, officers, employees, faculty, students or agents, shall be limited to the amount of the Initial License Fee paid pursuant to Article 6.1. 
 9.3 In no event shall the University be liable for consequential or incidental damages arising from any breach or breaches of this Agreement. 
 9.4 No action, whether in contract or tort (including negligence), or otherwise arising out of or in connection with this Agreement, may be brought by the Licensee more than six months after the cause of
action has occurred. 
 10.0 PUBLICATION AND CONFIDENTIALITY:

 10.1 The Information provided by the University shall be developed, received and used by the Licensee solely in furtherance of the
purposes set forth in this Agreement subject to the terms and conditions set forth in this Article 10. 
 10.2 Each party hereto covenants and
agrees that it will initiate and maintain an appropriate internal program limiting the internal distribution of the other party’s Confidential Information to only those officers, employees and professional advisors who require said Confidential
Information in performing their obligations under this Agreement and who have signed confidentiality and non-disclosure agreements in a form approved by the Licensee’s Board of Directors in the case of the Licensee and in a form consistent with
the terms of this Agreement in the case of the University. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

-14- 

 10.3 Subject to Article 10.8, the Licensee and the University shall not use, either directly or indirectly,
any Confidential Information of the other party for any purpose other than as set forth herein without the other party’s prior written consent. 
 10.4 If the Licensee or the University are required by judicial or administrative process to disclose any or all of the other party’s Confidential Information, they shall promptly notify the other
party and allow the other party reasonable time to oppose such process before disclosing any such Confidential Information. 
 10.5
Notwithstanding any termination or expiration of this Agreement, the obligations created in this Article 10 shall survive and be binding upon the Licensee and the University, and their successors and assigns. 

10.6 The University shall not be restricted from presenting at symposia, national or regional professional meetings, or from publishing in journals or
other publications, accounts of its research relating to the Information, provided that with respect to Confidential Information only, the Licensee shall have been furnished copies of the disclosure proposed therefor at least [†] days in
advance of the presentation or publication date and does not within [†] days after receipt of the proposed disclosure object to such presentation or publication. Any objection to a proposed presentation or publication shall specify the portions
of the presentation or publication considered objectionable (the “Objectionable Material”). Upon receipt of notification from the Licensee that any proposed publication or disclosure contains
Objectionable Material, the University and the Licensee shall work together to revise the proposed publication or presentation to remove or alter the Objectionable Material in a manner acceptable to the Licensee, in which case the Licensee shall
withdraw its objection. If an objection is made, disclosure of the Objectionable Material shall not be made for a period of [†] months after the date the Licensee has received the proposed publication or presentation relating to the
Objectionable Material. The University shall co-operate in all reasonable respects in making revisions to any proposed disclosures if considered by the Licensee to contain Objectionable Material. The University shall not be restricted from
publishing or presenting the proposed disclosure as long as the Objectionable Material has been removed. After the 6 month period has elapsed the University shall be free to present and/or publish the proposed publication or presentation whether or
not it contains Objectionable Material. 
 10.7 Subject to Article 10.8, the Licensee requires of the University, and the University agrees
insofar as it may be permitted to do so at law, that this Agreement, and each part of it, is confidential and shall not be disclosed to third parties, as the Licensee claims that such disclosure would or could reveal commercial, scientific or
technical information and would significantly harm the Licensee’s competitive position and/or interfere with the Licensee’s negotiations with prospective sublicensees. Notwithstanding anything contained in this Article, the parties hereto
acknowledge and agree that the University may identify the title of this Agreement, the parties to this Agreement and the names of the inventors of the Technology and any Improvements. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

-15- 

 10.8 Notwithstanding the forgoing, the parties acknowledge and agree that the University and the Licensee
may provide a copy of this Agreement to AMC, AMT and [†], and the University must provide certain reports and information to its Board of Governors, the Province of British Columbia and the government of Canada which may inter alia, include a
summary of the terms of this Agreement and the activities thereunder. 
 11.0 PRODUCTION AND
MARKETING: 
 11.1 The Licensee shall not use any of the UBC Trade-marks or make
reference to the University or its name in any advertising or publicity whatsoever, without the prior written consent of the University, except as required by law and except that the Licensee and any of its sublicensees may disclose the existence
and nature of this Agreement and (subject to the confidentiality provisions of Article 10) the nature of the technology being licensed without the need for the University’s consent. Without limiting the generality of the foregoing, the Licensee
shall not issue a press release with respect to this Agreement or any activity contemplated herein without the prior review and approval of same by the University, which approval shall not be unreasonably withheld, except as required by law. If the
Licensee is required by law to act in contravention of this Article, to the extent permissible by law, the Licensee shall provide the University with sufficient advance notice in writing to permit the University to bring an application or other
proceeding to contest the requirement. 
 11.2 The Licensee will not register or use any UBC Trade-marks in association with the Products without
the prior written consent of the University. 
 11.3 The Licensee shall use its commercially reasonable efforts to [†]. The University
acknowledges and agrees that subject to the University’s prior review and approval of the terms in the contemplated sublicense between the Licensee and AMT pursuant to Article 4.1, the granting of such a sublicense by the Licensee to AMT will
meet the forgoing obligation of the Licensee. Without limiting the generality of the foregoing, the Licensee covenants and agrees that it shall provide to the University, on each of the first five anniversaries of the Commencement Date of the
License Agreement or the date of an amendment to the License Agreement, a written report (the “Status Report”) summarizing the Licensee’s development activities relating to the Technology and
any Improvements that sets out all of the following information: 
  

	 	(a)	a summary of the research and development activities that the Licensee has undertaken in the course of the preceding 12 months to develop and commercialize the
Technology and any Improvements; 

  

	 	(b)	a detailed summary of any and all improvements, variations, updates, modifications and enhancements to the Technology and any Improvements which the Licensee has
developed and/or acquired in the course of the preceding 12 months, including any improvements, variations, updates, modifications and enhancements to the Technology or any Improvements of which the Licensee has been advised by any sublicensee, or
sub-sublicensee of the Licensee; and 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

-16- 

	 	(c)	any and all corporate alliances formed by the Licensee related to the Technology or any Improvements in the course of the preceding 12 months, including any such
corporate alliances of which the Licensee has been advised by a sublicensee or sub-sublicensee of the Licensee. 

 11.4 If the
University is of the view that the Licensee is in material breach of Article 11.3, then the University shall notify the Licensee and the parties hereto shall appoint a mutually acceptable person as an independent evaluator (the
“Evaluator”) to conduct the evaluation set forth in Article 11.3. If that the parties cannot agree on such an Evaluator, the appointing authority shall be the British Columbia International
Commercial Arbitration Centre. 
 11.5 Unless the Parties mutually agree otherwise, the following rules and procedures shall govern the conduct
of the parties and the Evaluator before and during the investigation by the Evaluator: 
  

	 	(a)	within [†] days of the appointment of the Evaluator each party shall provide to the Evaluator and the other party copies of all documents, statements and records
on which the party intends to rely in presenting its position to the Evaluator; 

  

	 	(b)	within [†] days of the appointment of the Evaluator the Licensee shall provide to the Evaluator and the University a written summary of its position. On receipt of
the Licensee’s summary the University shall have 15 days to prepare and submit to the Licensee and the Evaluator its own summary in reply to the summary submitted by the Licensee; 

 

	 	(c)	on receipt of the documents, statements, records and summaries submitted by the parties the Evaluator shall have [†] days within which to conduct such further
inquiries as he or she may deem necessary for the purpose of reviewing the efforts made by the Licensee with respect to the promotion, marketing and sale of the Products and the Technology and any Improvements in compliance with the requirements of
Article 11.3. For the purpose of conducting such an inquiry, the Evaluator shall have the right to: 

  

	 	(i)	require either party to disclose any further documents or records which the Evaluator considers to be relevant; 

 

	 	(ii)	interview or question either orally (or by way of written questions) one or more representatives of either party on issues deemed to be relevant by the Evaluator;

  

	 	(iii)	make an “on site” inspection of the Licensee’s facilities; 

 

	 	(iv)	obtain if necessary, the assistance of an independent expert to provide technical information with respect to any area in which the Evaluator does not have a specific
expertise; 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

-17- 

	 	(d)	On completion of the Inquiry described in Article 11.5(c) the Evaluator shall within [†] days prepare a report setting out his or her findings and conclusions as
to whether or not the Licensee has committed a breach of Article 11.3. If the Evaluator has determined that the Licensee has committed a breach of Article 11.3, then the Evaluator shall also set out in the report his or her conclusions as to
whether such breach: 

  

	 	(i)	was substantially due to external market conditions not within the control of the Licensee, or 

 

	 	(ii)	was substantially due to the Licensee’s failure to use its commercially reasonable efforts to comply with the requirements of Article 11.3.

  

	 	(e)	The report and conclusions of the Evaluator shall be delivered to the Licensee and the University, and shall be accepted by both parties as final and binding.

 11.6 If the Evaluator concludes: 
  

	 	(a)	pursuant to Article 11.5(d)(i) that the Licensee’s material breach was substantially due to external market conditions and not due to any omission or failure on
the part of the Licensee, then the License granted hereunder shall continue in good standing, 

  

	 	(b)	pursuant to Article 11.5(d)(ii) that the Licensee’s material breach was substantially due to the Licensee’s failure to use commercially reasonable efforts
then the University shall at its option have the right to terminate this Agreement as provided in Article 18, or 

  

	 	(c)	pursuant to Article 11.5(d) that the Licensee is not in material breach of Article 11.3, then the University shall not terminate this Agreement for breach of Article
11.3, nor shall it change the nature of the license granted hereunder. 

 11.7 The University may not call for more than one
evaluation pursuant to Article 11.4 in each calendar year. The cost of an evaluation hereunder shall be borne [†]. 
 12.0
ACCOUNTING RECORDS: 
 12.1 The Licensee shall maintain at its principal place of
business, or such other place as may be most convenient, separate accounts and records of all Revenues, sublicenses and Sublicensing Revenues, and all business done pursuant to this Agreement, such accounts and records to be in sufficient detail to
enable proper returns to be made under this Agreement, and the Licensee shall cause its sublicensees to keep similar accounts and records. 

12.2 The Licensee shall deliver to the University on the date [†] days after each and every Royalty Due Date, together with the royalty payable
thereunder, the Accounting and a report on all Sublicensing activity, including an accounting statement setting out in detail how the amount of Sublicensing Revenue was determined and identifying each sublicensee and the location of the business of
each sublicensee. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

-18- 

 12.3 The calculation of royalties shall be carried out in accordance with generally accepted Canadian
accounting principles (“GAP”), or the standards and principles adopted by the U.S. Financial Accounting Standards Board (“FASB”) applied on a
consistent basis. 
 12.4 The Licensee shall retain the accounts and records referred to in Article 12.1 above for at least [†] years after
the date upon which they were made and shall permit any duly authorized representative of the University to inspect such accounts and records during normal business hours of the Licensee at the University’s expense. The Licensee shall furnish
such reasonable evidence as such representative will deem necessary to verify the Accounting and will permit such representative to make copies of or extracts from such accounts, records and agreements at the University’s expense. If an
inspection of the Licensee’s records by the University shows an under-reporting or underpayment by the Licensee of any amount to the University, in excess of [†]% for any [†] month period, then the Licensee shall reimburse the
University for the cost of the inspection as well as pay to the University any amount found due (including any late payment charges or interest) within [†] days of notice by the University to the Licensee. 

12.5 During the term of this Agreement, and thereafter, [†]. 
 13.0 INSURANCE: 
 13.1 Unless satisfactory arrangements
are made between the Licensee and the University with respect to a self-insurance program or the requirement for insurance hereunder is waived by the University [†] days prior to the commencement of any human clinical trials or other Product
testing involving human subjects by the Licensee or any sublicensee, then the Licensee shall procure and maintain, during the term of this Agreement, the insurance outlined in Articles 13.2 and 13.3 and otherwise comply with the insurance provisions
contained in Articles 13.2 and 13.3. 
 13.2 The Licensee shall give written notice to the University: 

 

	 	(a)	[†] days prior to the commencement of any human clinical trials or other Product testing involving human subjects by the Licensee or any sublicensee,
(“Human Clinical Trials”); and 

  

	 	(b)	[†] days prior to the first sale of any Product by the Licensee or any sublicensee, 

 of the terms and amount of the appropriate public liability, product liability and errors and omissions insurance which it has placed. Such insurance shall in no case be less than the insurance which a
reasonable and prudent businessperson carrying on a similar line of business would acquire. This insurance shall be placed with a reputable and financially secure insurance carrier, shall include the University, its Board of Governors, faculty,
officers, employees, students, and agents as additional insureds, and shall provide primary coverage with respect to the activities contemplated by this Agreement. Such policy shall include severability of interest and cross-liability clauses and
shall provide that the policy shall not be cancelled or materially altered except upon at least [†] days’ 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

-19- 

 
written notice to the University. The University shall have the right to require reasonable amendments to the terms or the amount of coverage contained in the policy. Failing the parties agreeing
on the appropriate terms or the amount of coverage, then the matter shall be determined by arbitration. The Licensee shall provide the University with certificates of insurance evidencing such coverage [†] days before commencement of Human
Clinical Trials and [†] days prior to the sales of any Product and the Licensee covenants not to start Human Clinical Trials, or sell any Product before such certificate is provided and approved by the University, or to sell any Product at any
time unless the insurance outlined in this Article 13.2 is in effect. 
 13.3 The Licensee shall require that each sublicensee under this
Agreement shall procure and maintain, during the term of the sublicense, public liability, product liability and errors and omissions insurance in reasonable amounts, with a reputable and financially secure insurance carrier or provide satisfactory
arrangements through an appropriate self-insurance program. The Licensee shall use its best efforts to ensure that any and all such policies of insurance required pursuant to this Article shall contain a waiver of subrogation against the University,
its Board of Governors, faculty, officers, employees, students, and agents. 
 14.0 ASSIGNMENT:

 14.1 Except as hereinafter provided, the Licensee will not assign, transfer, mortgage, charge or otherwise dispose of any or all of the
rights, duties or obligations to it under this Agreement without the prior written consent of the University, (subject to the Licensee’s right to sublicense without the prior written consent of the University pursuant to Article 4.1), such
consent not to be unreasonably withheld. The Licensee may assign this license without the consent of the University as part of a merger, acquisition or other business combination in which all or substantially all of the assets of the Licensee are
transferred. 
 14.2 The University shall have the right to assign its rights, duties and obligations under this Agreement to a company or
society of which it is the sole shareholder, in the case of a company, or of which it controls the membership, in the case of a society. In the event of such an assignment, the Licensee will release, remise and forever discharge the University from
any and all obligations or covenants, provided however that such company or society, as the case may be, executes a written agreement which provides that such company or society shall assume all such obligations or covenants from the University and
that the Licensee shall retain all rights granted to the Licensee pursuant to this Agreement. 
 15.0 GOVERNING
LAW 
 15.1 This Agreement shall be governed by and construed in accordance with the laws of the Province
of British Columbia and the laws of Canada in force therein without regard to its conflict of law rules. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

-20- 

 16.0 NOTICES: 

16.1 All payments, reports and notices or other documents that any of the parties hereto are required or may desire to deliver to any other party hereto
may be delivered only by personal delivery or by registered or certified mail, telex or fax, all postage and other charges prepaid, at the address for such party set forth below or at such other address as any party may hereinafter designate in
writing to the others. Any notice personally delivered or sent by telex or fax shall be deemed to have been given or received at the time of delivery, telexing or faxing. Any notice mailed as aforesaid shall be deemed to have been received on the
expiration of five days after it is posted, provided that if there shall be at the time of mailing or between the time of mailing and the actual receipt of the notice a mail strike, slow down or labour dispute which might affect the delivery of the
notice by the mails, then the notice shall only be effected if actually received. 
  

			
	 If to the University:
	  	
		
	 If to the Licensee:
	  	 The Managing Director

		  	 University—Industry Liaison Office

		  	 University of British Columbia

		  	 IRC 331—2194 Health Sciences Mall

		  	 Vancouver, British Columbia

		  	 V6T 1Z3

		  	
Telephone:                     
(604)822-8580

		  	
Fax:                        
        (604)822-8589

		
	 If to the Licensee:
	  	 The President

		  	 Xenon Genetics Inc.

		  	 Gerald McGavin Building

		  	 Suite 100—2386 East Mall

		  	 Vancouver, British Columbia

		  	 V6T 1Z3

		  	
Telephone:                     
(604)221-8478

		  	
Fax:                        
        (604)221-8423

 17.0 TERM: 
 17.1 This Agreement and the license granted hereunder shall terminate on the expiration of a term of 10 years from the Date of Commencement or the expiration of the last patent obtained pursuant to
Article 7 herein, whichever event shall last occur, unless earlier terminated pursuant to Article 18 herein. 
 18.0
TERMINATION: 
 18.1 This Agreement shall automatically and immediately terminate without notice to the
Licensee if any proceeding under the Bankruptcy and Insolvency Act of Canada, or any other statute of similar purport, is commenced by or against the Licensee provided such proceedings have not been dismissed within [†] days of the date
on which they were commenced. In the event that the sublicense to be entered into between the Licensee and AMT is terminated, the Licensee may terminate this Agreement on [†] days prior written notice to the University, subject to payment of
all amounts owed to the University. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

-21- 

 18.2 The University may, at its option, terminate this Agreement immediately on the happening of any one or
more of the following events by delivering notice in writing to that effect to the Licensee: 
  

	 	(a)	if any resolution is passed or order made or other steps taken for the winding up, liquidation or other termination of the existence of the Licensee;

  

	 	(b)	if the Licensee is more than [†] days in arrears of royalties or other monies that are due to the University under the terms of this Agreement after written
notice; 

  

	 	(c)	if the Technology or any Improvements becomes subject to any security interest, charge or encumbrance in favour of any third party , other than a sublicensee, granted
by the Licensee without prior written consent of the University, not to be unreasonably withheld; 

  

	 	(d)	if the Licensee ceases or threatens to cease to carry on its business; 

  

	 	(e)	if the Licensee undergoes a reorganization or any part of its business relating to this Agreement is transferred to a subsidiary or associated company without the prior
written consent of the University, such consent not to be withheld except as provided in Article 18.3 and to be provided within [†] days of receipt of a written request for the same; 

 

	 	(f)	if the Licensee commits any breach of Articles 4.1, 11.1, 11.2 or 13; 

  

	 	(g)	if it is determined, pursuant to Article 11.5, that the Licensee is in breach of Article 11.3; 

 

	 	(h)	if any sublicensee of the Licensee is in breach of its sublicense agreement with the Licensee and the Licensee does not cause such sublicensee to cure such default
within [†] days of receipt of written notice from the University requiring that the Licensee cause such sublicensee to cure such default, or 

  

	 	(i)	if the Licensee is in breach of the Collaborative Research Agreement dated August 1, 2000, between the Licensee and the University, which breach has not been cured
within the time provided for the curing of such breach under the terms of such other agreement. 

 18.3 The University shall not
withhold its consent pursuant to Article 18.2(e) unless the granting of such consent would result in the University having a contractual relationship with an entity with whom the University is prohibited from contracting with pursuant to its then
existing policies. 
 18.4 Other than as set out in Articles 18.1 and 18.2, if either party shall be in default under or shall fail to comply
with the terms of this Agreement then the non-defaulting party shall have the right to terminate this Agreement by written notice to the other party to that effect if: 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

-22- 

	 	(a)	such default is reasonably curable within [†] days after receipt of notice of such default and such default or failure to comply is not cured within 30 days after
receipt of written notice thereof; or 

  

	 	(b)	such default is not reasonably curable within [†] days after receipt of written notice thereof, and such default or failure to comply is not cured within such
further reasonable period of time as may be necessary for the curing of such default or failure to comply. 

 Any written notice
issued pursuant to this Article 18.4 shall expressly set out the default or defaults with respect to which notice is being given. 
 18.5 If
this Agreement is terminated pursuant to Article 18.1, 18.2, or 18.4, the Licensee shall make royalty payments to the University in the manner specified in Article 5, and 6 and the University may proceed to enforce payment of all outstanding
royalties or other monies owed to the University and to exercise any or all of the rights and remedies contained herein or otherwise available to the University by law or in equity, successively or concurrently, at the option of the University. Upon
any such termination of this Agreement, the ‘Licensee shall forthwith deliver up to the University all Technology and any UBC Improvements in its possession or control and shall have no further right of any nature whatsoever in the Technology
or any UBC Improvements. On the failure of the Licensee to so deliver up the Technology and any UBC Improvements, the University may immediately and without notice enter the Licensee’s premises and take possession of the Technology and any UBC
Improvements. The Licensee will pay all charges or expenses incurred by the University in the enforcement of its rights or remedies against the Licensee including, without limitation, the University’s legal fees and disbursements on an
indemnity basis. 
 18.6 The Licensee shall cease to use the Technology or any UBC Improvements in any manner whatsoever or to manufacture or
sell the Products within five days from the Effective Date of Termination, subject to the expiration or invalidation of any applicable Patents. The Licensee shall then deliver or cause to be delivered to the University an accounting within 30 days
from the Effective Date of Termination. The accounting will specify, in or on such terms as the University may in its sole discretion require, the inventory or stock of Products manufactured and remaining unsold on the Effective Date of Termination.
The University will instruct that the unsold Products be stored, destroyed or sold under its direction, provided this Agreement was terminated by the University pursuant to Article 18.2 or 18.4 and subject to the expiration or invalidation of any
applicable Patents. Without limiting the generality of the foregoing, if this Agreement was terminated pursuant to Article 18.1, the unsold Products will not be sold by any party without the prior written consent of the University. The Licensee will
continue to make royalty payments to the University in the same manner specified in Article 5 and 6 on all unsold Products that are sold in accordance with this Article 18.6, notwithstanding anything contained in or any exercise of rights by the
University under Article 18.5 herein. 
 18.7 Notwithstanding the termination of this Agreement, Article 12 shall remain in full force and
effect until [†] years after 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

-23- 

	 	(a)	all payments of royalty required to be made by the Licensee to the University under this Agreement have been made by the Licensee to the University, and

  

	 	(b)	any other claim or claims of any nature or kind whatsoever of the University against the Licensee has been settled. 

19.0 MISCELLANEOUS COVENANTS OF LICENSEE: 

19.1 The Licensee hereby represents and warrants to the University that the Licensee is a corporation duly organized, existing and in good standing under
the laws of Canada and has the power, authority and capacity to enter into this Agreement and to carry out the transactions contemplated by this Agreement, all of which have been duly and validly authorized by all requisite corporate proceedings.

 19.2 The Licensee represents and warrants that [†]. 
 19.3 The Licensee shall comply with all laws, regulations and ordinances, whether Federal, State, Provincial, County, Municipal or otherwise, with respect to the Technology and any Improvements and/or
this Agreement. 
 19.4 [†] 

19.5 [†] 
 19.6 The Licensee shall pay all
taxes and any related interest or penalty howsoever designated and imposed as a result of the existence or operation of this Agreement, including, but not limited to, tax which the Licensee is required to withhold or deduct from payments to the
University. The Licensee will furnish to the University such evidence as may be required by Canadian authorities to establish that any such tax has been paid. The royalties specified in this Agreement are exclusive of taxes. If the University is
required to collect a tax to be paid by the Licensee or any of its sublicensees, the Licensee shall pay such tax to the University on demand. 

19.7 The obligation of the Licensee to make all payments hereunder will be absolute and unconditional and will not, except as expressly set out in this
Agreement, be affected by any circumstance, including without limitation any set-off, compensation, counterclaim, recoupment, defence or other right which the Licensee may have against the University, or anyone else for any reason whatsoever.

 19.8 All amounts due and owing to the University hereunder but not paid by the Licensee on the due date thereof shall bear interest in
Canadian dollars at the rate of one per cent (1 %) per month. Such interest shall accrue on the balance of unpaid amounts from time to time outstanding from the date on which portions of such amounts become due and owing until payment thereof in
full. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

-24- 

 20.0 GENERAL: 

20.1 Nothing contained herein shall be deemed or construed to create between the parties hereto a partnership or joint venture. No party shall have the
authority to act on behalf of any other party, or to commit any other party in any manner or cause whatsoever or to use any other party’s name in any way not specifically authorized by this Agreement. No party shall be liable for any act,
omission, representation, obligation or debt of any other party, even if informed of such act, omission, representation, obligation or debt. 

20.2 Subject to the limitations hereinbefore expressed, this Agreement shall enure to the benefit of and be binding upon the parties and their respective
successors and permitted assigns. 
 20.3 No condoning, excusing or overlooking by any party of any default, breach or non-observance by any
other party at any time or times in respect of any covenants, provisos or conditions of this Agreement shall operate as a waiver of such party’s rights under this Agreement in respect of any continuing or subsequent default, breach or
non-observance, so as to defeat in any way the rights of such party in respect of any such continuing or subsequent default or breach, and no waiver shall be inferred from or implied by anything done or omitted by such party, save only an express
waiver in writing. 
 20.4 No exercise of a specific right or remedy by any party precludes it from or prejudices it in exercising another right
or pursuing another remedy or maintaining an action to which it may otherwise be entitled either at law or in equity. 
 20.5 Marginal headings
as used in this Agreement are for the convenience of reference only and do not form a part of this Agreement and are not be used in the interpretation hereof. 
 20.6 The terms and provisions, covenants and conditions contained in this Agreement which by the terms hereof require their performance by the parties hereto after the expiration or termination of this
Agreement shall be and remain in force notwithstanding such expiration or other termination of this Agreement for any reason whatsoever. 
 20.7
If any Article, part, section, clause, paragraph or subparagraph of this Agreement shall be held to be indefinite, invalid, illegal or otherwise voidable or unenforceable, the entire Agreement shall not fail on account thereof, and the balance of
this Agreement shall continue in full force and effect. 
 20.8 The parties hereto each acknowledge that the law firm of Richards Buell Sutton
has acted solely for the University in connection with this Agreement and that all other parties hereto have been advised to seek independent legal advice. 
 20.9 This Agreement sets forth the entire understanding between the parties and no modifications hereof shall be binding unless executed in writing by the parties hereto. 

 

	20.10 Time	shall be of the essence of this Agreement. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

-25- 

 20.11 Whenever the singular or masculine or neuter is used throughout this Agreement the same shall be
construed as meaning the plural or feminine or body corporate when the context or the parties hereto may require. 
 20.12 This Agreement may be
executed in any number of counterparts, each of which when delivered will be deemed to be an original, for all purposes and will constitute one and the same instrument, binding on the parties, notwithstanding that all the parties are not signatories
of the same counterpart. 
 20.13 In the event of a conflict arising between the interpretation of this Agreement and the Collaborative Research
Agreement, the terms of this Agreement shall prevail. 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

-26- 

 IN WITNESS WHEREOF the parties hereto have hereunto executed this
Agreement on the 19th day of June, 2001 but effective as
of the Date of Commencement. 
  

							
	 SIGNED FOR AN ON BEHALF of
 THE UNIVERSITY OF BRITISH COLUMBIA
 by its duly authorized
officers:
  
 /s/ David P. Jones

Authorized Signatory
  

Authorized Signatory
	  	 )
 )

)
 )

)
 )

)
 )
	  	 David P. Jones
 Associate Director
 University-Industry Liaison
	  	 
				
	 THE CORPORATE SEAL OF 

XENOX GENETICS INC 
 was hereunto affixed
in the presence of:
  
 /s/ Frank
Holler
 Authorized Signatory
  

Authorized Signatory
	  	 )
 )

)
 )

)
 )

)
 )

)
	  		  	

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

-27- 

 SCHEDULE “A” 

DESCRIPTION OF “TECHNOLOGY” 

 

					
	 UBC File #
	  	 Title
	  	 Patents

			
	 94-061
	  	Lipolipase Mutation 291, Implication for Coronary Artery Disease	  	 U.S.: 5,658,729
 U.S.: SN
08/817,192
 Can.: SN 2,202,477
 EPO: 95
93 75 98.1 (Ger., Fr., U.K., Switz.)

			
	 91-003
	  	Mutation in Human Lipoprotein Lipase Gene which causes Type 1 Hyperlipoproteinemia	  	Can.: SN 2,035,177
			
	 99-082
	  	Recombinant Viruses Preparation and use thereof in Gene Therapy	  	 U.S.: SN 08/737,954
 FR:
94/06759 PCT:
 FR 95/00669
 CIP: SN
09/713,268

			
	 00-039
	  	Mutation 447	  	PCT: CA00/00762

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

-28- 

 This AMENDING AGREEMENT is dated for reference as of the 12th day of July, 2007. 

BETWEEN: 
 XENON
PHARMACEUTICALS INC. (formerly known as Xenon Genetics Inc.), having its head office at 3650 Gilmore Way, Burnaby, British Columbia, V5G 4W8 
 (the “Company”) 
 OF THE FIRST PART; 

AND: 
 THE UNIVERSITY
OF BRITISH COLUMBIA, a corporation 
 continued under the University Act of British Columbia and having its

 administrative offices at 2075 Wesbrook Mall, in the City of 

Vancouver, in the Province of British Columbia, V6T 1W5 
 (the “University”) 
 OF THE SECOND PART. 

WHEREAS: 
 A. The Company and the
Consultant entered into a LPL License Agreement made as of August 1, 2000 (the “LPL License Agreement”); and 
 B. The
parties now wish to make certain amendments to the LPL License Agreement, as detailed here in this Agreement (the “Amending Agreement”). 
 NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by all parties hereto, the Company and the University hereby covenant and agree as
follows: 
 1 Capitalized terms used herein, which are not otherwise defined herein, shall have the meaning ascribed to such terms in the
LPL License Agreement. 
  

	2	Section 6.4 of the LPL License Agreement is hereby amended as follows: 

 

	 	(a)	Subsection 6.4(b) is hereby amended by deleting it in its entirety and substituting the following: 

 

	 	“(b)	within [†] days of the initiation of Phase II Clinical Trials: 

  

	 	(i)	for the first Product, the sum of CAN. $[†]; and/or 

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

			
	  
 Amending Agreement
	  	  
 Page 1 of 2

	 	(ii)	for the second and each subsequent Product (as applicable) that [†], the sum of CAN. $[†].” 

 

	 	(b)	Following subsection 6.4(c), the following new subsection 6.4(d) shall be added: 

 

	 	“(d)	in the event that the Licensee or its sublicensee initiates a combined Phase I/Phase II Clinical Trial for any Product, the milestone payments noted above under
subsections 6.4(a) and (b) shall not be applicable respecting said Product(s), and instead, the Licensee shall pay to the University, within thirty (30) days after the commencement of such combined Phase I/Phase II clinical trial:

  

	 	(i)	for the first Product, the sum of CAN. $[†]; and/or 

  

	 	(ii)	for the second and each subsequent Product (as applicable) that [†], the sum of CAN. $[†].” 

3. Section 1.1(q) and the definition of “UBC License Milestones” is hereby amended to include the combined Phase I/Phase II Clinical
Trial milestone payments under subsection 6.4(d). 
 4. Except as amended herein, the LPL License Agreement remains in full force and
effect, unamended. 
 5. This Agreement may be signed in counterparts, and delivered personally or by courier, mail, facsimile or
electronically, each of which counterparts when executed by any of the signatories hereto shall be deemed to be an original and such counterparts shall together constitute one and the same Agreement. 

IN WITNESS WHEREOF duly authorized signatories of the Company and the University, each after having had the opportunity to discuss this Amending
Agreement with their respective legal advisors, have executed this Agreement on the date(s) indicated below but effective as of the Commencement Date. 
  

							
	XENON PHARMACEUTICALS INC.	  	 	  	UNIVERSITY OF BRITISH COLUMBIA
				
	By:	  	 /s/ Simon N. Pimstone
	  		  	 /s/ J.P. Heale

		  	 Dr. Simon N. Pimstone
 President & CEO
	  		  	 J.P. Heale, Ph.D, MBA

Associate Director

				
	Date:	  	July 17, 2007	  		  	Date: September 14, 2007

  
 [†] DESIGNATES PORTIONS
OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION 

			
	  
 Amending Agreement
	  	  
 Page 2 of 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}]]